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ABSTRACT 
The RASopathies are a collection of developmental diseases caused by 
germline mutations in components of the RAS/MAPK signaling pathway and is one of 
the world’s most common set of genetic diseases. A majority of these mutations 
result in an upregulation of RAS/MAPK signaling and cause a variety of both physical 
and neurological symptoms. Neurodevelopmental symptoms of the RASopathies 
include cognitive and motor delays, learning and intellectual disabilities, and various 
behavioral problems. Recent noninvasive imaging studies have detected widespread 
abnormalities within white matter tracts in the brains of RASopathy patients. These 
abnormalities are believed to be indicative of underlying connectivity deficits and a 
possible source of the behavioral and cognitive deficits. To evaluate these long-range 
connectivity and behavioral issues in a cell-autonomous manner, MEK1 loss- and 
gain-of-function (LoF and GoF) mutations were induced solely in the cortical 
glutamatergic neurons using a Nex:Cre mouse model. Layer autonomous effects of 
the cortex were also tested in the GoF mouse using a layer 5 specific Rbp4:Cre 
mouse. Immunohistochemical analysis showed that activated ERK1/2 (P-ERK1/2) 
was expressed in high levels in the axonal compartments and reduced levels in the 
soma when compared to control mice. Axonal tract tracing using a lipophilic dye and 
an adeno-associated viral (AAV) tract tracing vector, identified significant 
corticospinal tract (CST) elongation deficits in the LoF and GoF Nex:Cre mouse and in 
the GoF Rbp4:Cre mouse. AAV tract tracing was further used to identify significant 
deficits in axonal innervation of the contralateral cortex, the dorsal striatum, and the 
hind brain of the Nex:Cre GoF mouse and the contralateral cortex and dorsal 
striatum of the Rbp4:Cre mouse. Behavioral testing of the Nex:Cre GoF mouse 
indicated deficits in motor learning acquisition while  the Rbp4:Cre GoF mouse 
showed no failure to acquire motor skills as tested. Analysis of the expression levels 
  i 
of the immediate early gene ARC in Nex:Cre and Rbp4:Cre mice showed a specific 
reduction in a cell- and layer-autonomous manner. These findings suggest that 
hyperactivation of the RAS/MAPK pathway in cortical glutamatergic neurons, induces 
changes to the expression patterns of P-ERK1/2, disrupts axonal elongation and 
innervation patterns, and disrupts motor learning abilities. 
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PREFACE 
The research in this dissertation was performed under the supervision of Dr. 
J.M. Newbern in the School of Life Sciences at Arizona State University between 
January 2014 and October 2018. All work herein is to the best of my knowledge 
original except where acknowledgements or references are made to previous works 
or the contributions of others. 
The work presented in this dissertation is composed of research on both gain- 
and loss-of-function mutations in the RAS-RAF-MEK-ERK (RAS/MAPK) cellular 
signaling pathway in the central nervous system (CNS). This work is presented in the 
context of the RASopathies and the genetic germline mutations within the RAS/MAPK 
signaling pathway that are responsible for them. Chapter 1 is a literature review that 
encompasses the individual RASopathies and the germline genetic mutations that 
cause them. This is accompanied by a brief history of the RAS/MAPK signaling 
pathway, the core components and mechanism of the RAS/MAPK signaling pathway, 
and functions of the pathway within the context of the RASopathies and my own 
research.  
Chapter 2 involves a study on the effects of loss-of-function (LoF) of cellular 
RAS/MAPK signaling primarily in cortical glutamatergic neurons. This chapter 
primarily consists of materials published in the journal eLife (Xing et al. 2016) and 
has been edited to highlight my own contributions except where referenced. Chapter 
3 is comprised of a study on the effects of gain-of-function (GoF) RAS/MAPK 
signaling primarily in cortical glutamatergic neurons. This work constitutes materials 
that are currently in revision for publication. Chapter 4 defines the cortical layer 
specificity of the phenotypes involved in the gain-of-function model of RAS/MAPK 
cellular signaling. This work constitutes materials that are currently in revision for 
publication. 
  xiv 
Chapter 5 includes concluding remarks as well as future directions and the 
challenges faced in the field of the RASopathies as well as possible translational 
implications. 
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CHAPTER 1 
INTRODUCTION 
The RASopathies 
Germline genetic mutations within the genes that encode components of the 
RAS-RAF-MEK-ERK (RAS/MAPK) signal transduction pathway cause several human 
genetic syndromes collectively known as RASopathies. These syndromes 
include Noonan syndrome (NS), Noonan syndrome with multiple lentigines (NSML) 
(formerly LEOPARD syndrome), neurofibromatosis type 1 (NF-1), Costello syndrome 
(CS), capillary malformation-arteriovenous malformation syndrome (CM-AVM), 
cardio-facio-cutaneous syndrome (CFC), Legius syndrome, autoimmune 
lymphoproliferative syndrome (ALPS), Hereditary gingival fibromatosis 1 (HGF1), and 
Autosomal dominant intellectual disability type 5 (IDD5) (Tidyman and Rauen 2009; 
Katherine A. Rauen 2013). Caused by germline mutations, the RASopathies are 
classified as developmental disorders that share many overlapping clinical 
characteristics including craniofacial dysmorphologies, cardiovascular abnormalities, 
cutaneous, musculoskeletal, and ocular abnormalities, neurocognitive impairment, 
hypotonia, and an increased risk of cancer (Katherine A. Rauen 2013; Aoki, Niihori, 
S. Inoue, et al. 2016). Individually, there is a wide range of frequencies in the 
RASopathies with some syndromes being quite rare. For example, NS occurs in 
1:1000 to 1:2500 individuals while NSML and ALPS have approximately 200 reported 
cases each worldwide (Gelb and Tartaglia 1993; Autoimmune lymphoproliferative 
syndrome 2018). Regardless of the frequencies of the individual syndromes, as a 
group, the RASopathies constitute one of the largest groups of developmental 
syndromes worldwide (Katherine A. Rauen 2013) (Table 1).  
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In addition to germline mutations of the RAS/MAPK pathway, postzygotic 
genetic mutations cause a mosaic genetic disorder with phenotypes that can be quite 
distinct from the previously defined RASopathies (Hafner and Groesser 2013). The 
mosaic RASopathies include Keratinocytic epidermal nevus (KEN), Keratinocytic 
epidermal nevus syndrome (KENS), Schimmelpenning syndrome (SS),  Sebaceous 
nevus (SN), Mosaic Costello syndrome  (MCS), Segmental neurofibromatosis type I 
(SN1) (Hafner and Groesser 2013). There is a wide range of symptoms for these 
disorders due to their mosaic nature. Symptoms range from cutaneous nevi in KEN 
to hemiparesis, ocular abnormalities and skeletal abnormalities including incomplete 
bone formation, hypertrophy or hypoplasia of bones, bone cysts, kyphoscoliosis, and 
vitamin-D resistant rickets in KENS and SS. Neurological defects reported in KENS 
and SS include seizures, intellectual disability, ventricular abnormalities, cortical 
atrophy, and hemimegalencephaly. Symptoms of MCS and SN1 are largely similar to 
their germline mutation counterparts with some CS and NF1 patients having been 
shown to have mosaic mutations with no significant phenotypic differences from 
those having germline mutations (Colman et al. 1996; Gripp et al. 2006; Hafner and 
Groesser 2013). Frequencies in individual diseases of mosaic RASopathies also have 
a large range. KEN ranges from ~1:333 to 1:1000 while MCS has only two known 
cases reported having been found in the relevant literature (Hafner and Groesser 
2013; EN) (Table 2).  
Diagnosis of the individual RASopathies is generally performed by clinical 
findings of key features and confirmed by genetic testing if necessary (Table 3). In 
some cases, clinical findings may not be sufficient and genetic testing of known 
genetic variants may need to be performed. Management of each syndrome within 
the RASopathies largely falls to surveillance and treatment of the individual 
manifestations (Margaret P Adam et al. 1993-2018). Some syndromes require 
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preventative treatments to avoid primary and secondary complications. To prevent 
primary complications in severe cases of ALPS for example, bone marrow 
transplantation is performed to prevent primary manifestations (Bleesing et al. 
2017).  To prevent secondary manifestations in CS and CFC cases, antibiotic 
prophylaxis is used to avoid bacterial endocarditis due to heart valve defects (Gripp 
2012; Rauen 2016). In general, syndromes associated with developmental 
intellectual disabilities and cognitive impairments can be addressed by early 
intervention and specialized educational programs (Margaret P Adam et al. 1993). 
Precise and early diagnosis using clinical diagnosis and genetic testing is a critical 
part in monitoring and treating those afflicted with RASopathies.  
 
RAS/MAPK Signaling Pathway: Background 
 The discovery of RAS began with the study of oncogenic retroviruses that 
were the cause of sarcomas infecting mice, rats, cats, monkeys, chickens, and 
turkeys in the early 1960s. In 1964 the potent oncogenic Harvey murine sarcoma 
virus (HRAS) was discovered followed by the Kirsten murine sarcoma virus (KRAS) in 
1967 (Harvey 1964; Kirsten and Mayer 1967; Cox and Der 2010). These 
retroviruses, H-ras and K-ras, contained the potently oncogenic genetic elements 
that were later found to comprise the human HRAS and KRAS oncogenes (Cox and 
Der 2010). The link between the H-ras and K-ras retroviruses and human HRAS and 
KRAS oncogenes was discovered by several research groups in 1982 and 1983. At 
this time, it was found that DNA isolated from several different human carcinoma cell 
lines caused morphologic transformations in NIH/3T3 mouse fibroblasts (Der et al. 
1982; Parada et al. 1982; Santos et al. 1982). Researchers discovered that a 
missense mutation in codon 12 of HRAS and KRAS, also found in the viral H-ras and 
K-ras viral genes, was the molecular basis of RAS activation and the basis of RAS 
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oncogenicity (Reddy et al. 1982; Taparowsky et al. 1982; O’Toole et al. 1983; 
Coulier et al. 1989). A third oncogenic RAS gene was soon identified in 
neuroblastoma-derived DNA and labeled NRAS (Hall et al. 1983). The detection of 
mutant RAS genes in patient’s tumors and not in normal tissues provided additional 
proof of the role mutant RAS has in the formation of carcinomas (Santos et al. 1984; 
Cox and Der 2010). 
 It wasn’t until about 10 years later that RAS would be associated with the 
EGFR tyrosine kinase (Cox and Der 2010). An important observation was made that 
the adapter protein growth factor receptor bound protein 2 (GRB2) provided a link 
between EGFR and RAS activation (Lowenstein et al. 1992; Cox and Der 2010). It 
was speculated that the biochemical function of the RAS protein was that of a binary 
switch involved in signal transduction (Hurley et al. 1984; Cox and Der 2010). This 
was due to the fact that RAS was able to bind both guanosine triphosphate (GTP) 
and guanosine diphosphate (GDP) which essentially presented RAS in either an “on” 
state or an “off” state respectively (Scolnick et al. 1979; Hurley et al. 1984; Cox and 
Der 2010).  Downstream of RAS, it was discovered that the kinase RAF would bind 
preferentially to activated Ras-GTP hinting to a role in signal transduction from 
activated RAS (Warne et al. 1993; Zhang et al. 1993; Cox and Der 2010). Around a 
year earlier, it was recognized that there was a Ras- and Raf-dependent activation of 
mitogen activated protein kinases MAPK3 (ERK1) and MAPK1 (ERK2) and that Raf 
had the ability to activate the mitogen activated protein kinase kinases MAP2K1 
(MEK1) and MAPK2K2 (MEK2) (Gallego et al. 1992; Howe et al. 1992; Kyriakis et al. 
1992). Together, these observations defined the basis of the RAS-RAF-MEK-ERK 
cellular signaling pathway from extracellular ligand binding to the final protein 
kinases in the pathway, ERK1 and ERK2. 
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RAS/MAPK Signalling Pathway: Core Pathway 
 The RAS/MAPK signaling pathway relays extracellular cues in the form of 
neurotrophins to affect critical cellular processes. The primary manner of activation 
for the RAS/MAPK pathway is by ligand binding activation of neurotrophic receptor 
tyrosine kinase 2 (NTRK2). There are three related yet distinct NTRK receptors, 
NTRK1, NTRK2, and NTRK3. Each receptor consists of a single transmembrane 
protein with a tyrosine kinase domain on the cytoplasmic side and each NTRK 
receptor has a primary affinity for specific neurotrophins. NTRK1 is primarily a 
receptor for the neurotrophin nerve growth factor (NGF), NTRK2 is primarily a 
receptor for brain derived neurotrophic factor (BDNF) and neurotrophin 4 (NTF4), 
and NTRK3 is primarily a receptor for neurotrophin 3 (NTF3). A large amount of 
structural homology in both the neurotrophins and NTRK receptors can cause cross 
reactivity between the neurotrophins and the receptors. In addition to the RAS/MAPK 
pathway, NTRK receptor signaling activates the phosphatidylinositol-4,5-
bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)/serine/threonine kinase 1 
(AKT1), calcium signaling through the phospholipase C gamma 1 (PLCγ1) (Kanehisa 
et al. 2017). Furthermore, within the RAS/MAPK pathway, RAS signals to additional 
pathways, namely the p38 kinase signaling pathway with additional MAPK signaling 
via the PIK3CA/AKT1 pathway, and the mitogen-activated protein kinase  MAPK7 
(ERK5) kinase signaling pathway (Reichardt 2006; Tidyman and Rauen 2016; 
Kanehisa et al. 2017). In spite of the various signaling and pathway cross-talk 
dynamics, the common features within pathogenesis of the RASopathies are the 
genetic mutations within the core components of the RAS/MAPK and pathway 
activation of ERK1 and ERK2. (Tidyman and Rauen 2009; Katherine A. Rauen 2013; 
Tidyman and Rauen 2016). 
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 RAS/MAPK signaling through NTRK2 begins with receptor activation and the 
phosphorylation of tyrosine residues Tyr 516 and Tyr 817 (Leal et al. 2017; 
The UniProt Consortium 2017). Receptor activation by BDNF/NTF4 binding induces a 
dimerization of the NTRK2 receptors followed by autophosphorylation of the tyrosine 
residues at the active sites (Reichardt 2006; Leal et al. 2017). Transactivation of 
NTRK2 independent of neurotrophin signaling has also been reported to occur 
through zinc-mediated activation of SRC family kinases (SFK) (Huang et al. 2008; 
Leal et al. 2017). Once NTRK2 is activated, phosphorylated Tyr 516 recruits and 
phosphorylates SHC adaptor protein 1 (SHC1) which in turn recruits growth factor 
receptor bound protein 2 (GRB2) and SOS Ras/Rho guanine nucleotide exchange 
factor (GEF) 1 and 2 (SOS1, SOS2) (Reichardt 2006; Leal et al. 2017). Additional 
scaffolding proteins can compete with SHC1 to bind at the phosphorylated Tyr 516 
site on the activated NTRK2 receptor. Dimerized SH2B type 1, 2, or 3, adaptor 
proteins (SH2B1, SH2B2, SH2B3) can bind the phosphorylated Tyr 516 site in place 
of SHC that can provide a link from the activated NTRK2 receptor to GRB2/SOS 
(Qian et al. 1998; Reichardt 2006). The adapter molecule fibroblast growth factor 
receptor substrate 2 (FRS2), also competes for the phosphorylated Tyr 516 site and 
provides phosphorylation recruitment of adapter protein GRB2 independent of SHC 
or SH2B recruitment. FRS2 additionally recruits other signaling proteins including C-
terminal Src kinase (CSK), SRC proto-oncogene, non-receptor tyrosine kinase (SRC), 
protein tyrosine phosphatase, non-receptor type 11 (PTPN11), and CRK proto-
oncogene, adaptor protein (CRK). This mixture of adapter proteins related to the 
activation of NTRK2 and the GRB2/SOS complex is believed to be one way to 
mediate signal strength and duration of signaling through the RAS/MAPK pathway 
(Reichardt 2006; Minichiello 2009) (Figure 1). 
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Figure 1. 
NTRK2 Recruits Various Adapter Proteins. Several adapter proteins compete for 
binding at the activated NTRK2 Tyr 516 recruitment site. When bound to active 
NTRK2, SHC, SH2B2 dimer, and FSR2 become phosphorylated and recruit GRB2 
bound to SOS. CRK recruits C3G to activate MAPK alternatively to GRB/SOS 
recruitment. Phospholipase C gamma 1 (PLCG1) binds to activated NTRK2 Tyr 817 
and activates MAPK through an alternative pathway.   
 
 
 
 
 
 
 
 
 
 
  8 
Activated SOS1 or SOS2 initiates the exchange of GDP for GTP on the 
membrane localized RAS protein. The exchange begins with the release of GDP 
through a quick succession of reactions. Once GDP is released, the series of reactions 
is reversed by the binding of a nucleotide, usually the RAS activating GTP due to 
much higher intracellular concentrations (Vetter 2001). When activated, RAS recruits 
RAF to the cell membrane which begins a series of complex actions to activate RAF. 
These actions include dimerization of RAF proteins, dephosphorylation and 
phosphorylation of different domains of RAF, dissociation from 
phosphatidylethanolamine binding protein 1 (PEBP1), and association with various 
scaffolding proteins. Several RAS GTPase activating proteins (RASGAPs) engage to 
exchange the GTP for GDP to inactivate RAS. These RASGAPs include synaptic Ras 
GTPase activating protein 1 (SYNGAP1), RAS p21 protein activator 1 (RASA1), and 
neurofibromin 1 (NF1), (Reichardt 2006; McCubrey et al. 2007). When activated, 
RAS is then capable of activating c-RAF which in turn phosphorylates MEK1 and/or 
MEK2. ERK1 and/or ERK2 are the specific targets that are then phosphorylated by 
MEK1 and/or MEK2 thus completing the RAS/MAPK core pathway (Figure 2).  
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Figure 2. 
RAS Activation by GEFs and Deactivation by GAPs. RAS acts as a binary 
molecular switch that is either in an off or inactive state when bound by GDP, or in 
an on or active state when bound by GTP. Activation of RAS is performed by the 
exchange of GDP for GTP by an activated GEF (SOS1 / SOS2). In its active state, 
RAS can activate several different pathways including the RAS/MAPK pathway 
implicated in the RASopathies.  
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RAS/MAPK Pathway: Functions 
The well conserved RAS/MAPK signaling pathway is perhaps the most studied 
cellular signaling pathway to date. The RAS/MAPK signaling pathway functions in 
many aspects of cellular mechanics including cell survival, differentiation, and 
proliferation. In the case of neurons, RAS/MAPK signaling pathway functions include 
axonal outgrowth, synaptic plasticity, synapse stabilization and removal, retrograde 
transport processes, and actin cytoskeleton regulation. Much of what has been 
studied and learned about RAS/MAPK signaling comes from cancer research studies 
performed on specific cell types in vitro. Neurons however, consisting of several 
distinct compartments and operating in a more diverse and complex manner, do not 
seem to have experienced that same magnitude of research. This is especially true of 
in vivo pathway functions under physiological or diseased conditions as is seen within 
the RASopathies.  
 
Cell Survival  
Early in vitro studies using PC12 cells revealed that RAS/MAPK signaling and 
ERK activation prevents apoptosis suggesting a means of cell survival through ERK 
activation and the suppression of mitogen-activated protein kinase MAPK8 (JNK) and 
mitogen-activated protein kinase MAPK14 (p38) signaling (Xia et al. 1995). However, 
later experiments deleting B-RAF in vitro and deleting B-RAF or B-RAF and C-RAF in 
vivo showed conflicting results concerning RAS/MAPK mediated cell survival. Using 
cultured embryonic sensory dorsal ganglion (DRG) neurons as well as sympathetic 
and motor neurons, it was demonstrated that B-RAF in vitro was needed and 
sufficient for cell survival (Wiese et al. 2001; Encinas et al. 2008). However, In vivo 
deletion of B-RAF or B-RAF and C-RAF in neurons did not lead to cell death showing 
that RAF signaling does not significantly mediate survival during embryonic 
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development (Chen et al. 2006; Zhong et al. 2007; Galabova-Kovacs et al. 2008; 
Pfeiffer et al. 2013; Zhong 2016). Furthermore, in retinal ganglion cells in vivo, 
RAS/MAPK signaling can be pro-apoptotic upon optic nerve damage or 
neuroprotective under ocular hypertensive conditions (Zhou et al. 2005; Luo et al. 
2007). Interestingly, a prior study found that the deletion of both isoforms of ERK, 
ERK1 and ERK2, in sensory neurons resulted in a significant amount of cell death in 
vivo (O’Brien et al. 2015). An additional recent in vivo study revealed that the 
conditional deletion of RAS/MAPK signaling in cortical glutamatergic neurons resulted 
in the significant death of Layer 5 CTIP2+ neurons. The reported cell death followed 
temporally the failure of corticospinal tract axon elongation (Xing et al. 2016). In 
these cases, it is possible that cell death was primarily due to the loss of axonal 
connectivity and not due directly to the loss of ERK signaling. 
During development and in the presence of NGF, cellular survival functions of 
the RAS/MAPK signaling pathway work through anti-apoptotic actions. RAS activation 
occurs upon TRKA receptor binding by NGF and leads to the activation of the 
PI3K/AKT and RAS/MAPK signaling pathways and inhibition of the JNK -  p53 pro-
apoptotic pathway (Mazzoni et al. 1999; Kaplan and Miller 2000; Kristiansen and 
Ham 2014). These actions prevent the release of cytochrome-c from the 
mitochondria and the subsequent release and cleaving of caspase-3 and have been 
reported both in vitro in sympathetic neurons and in vivo in superior cervical 
ganglion neurons (SCGs) (McCarthy et al. 1997; Martinou et al. 1999; Kristiansen 
and Ham 2014; Alberts 2015)(Kristiansen and Ham 2014; Alberts 2015). PI3K/AKT 
signaling inhibits the transcription factor FOXO3a which in turn inhibits the 
transcription of pro-apoptotic Bcl-2 homology domain 3 (BH3-only) proteins such as 
BCL2 like 11 (BIM) and BCL2 binding component 3 (PUMA) (Gilley et al. 2003; Zhang 
et al. 2011; Kristiansen and Ham 2014). PI3K/Akt signaling also inhibits the function 
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of BCL2 associated agonist of cell death (BAD) by direct phosphorylation which 
inhibits BAD and prevents the release of BAX from a dimer complex with anti-
apoptotic BCL-2 or BCL-XL (Datta et al. 1997; Kristiansen and Ham 2014). 
Interestingly, phosphorylation of RSK through RAS/MAPK-ERK signaling can also 
phosphorylate and inhibit BAD (Bonni et al. 1999). Further pro-survival activity by 
ERK activation of RSK comes via RSK phosphorylation of the transcription factor 
CREB. Upon activation, CREB initiates transcription of several anti-apoptotic factors 
including the BCL2 family of apoptosis regulating proteins (Riccio et al. 1999). 
Activated ERK is also able to directly phosphorylate and inhibit the pro-apoptotic 
BH3-only protein, BIM, which would otherwise bind to and inactivate pro-survival 
proteins BCL-2 or BCL-XL (Gilley et al. 2003; Ley et al. 2003; Zhang et al. 2011).  
 
Embryonic Development 
 Several common or overlapping features of the RASopathies include 
craniofacial dysmorphologies, cardiac malformations, and CNS defects resulting in 
neurocognitive deficits (Katherine A. Rauen 2013). The development and 
morphogenesis of these regions are thought to be highly dependent upon fibroblast 
growth factor (FGF) induced ERK1/2 signaling during neural crest and neural tube 
formation in embryonic development (Corson et al. 2003; Samuels et al. 2009; 
Gilbert and Barresi 2016). Additionally, specific regions of mouse, chick, and 
zebrafish embryos were found to have spatially restricted areas in which ERK1/2 was 
detected during transient and prolonged periods of embryonic development. These 
spatially restricted areas are believed to develop under the influence of FGF as it was 
seen that ERK1/2 activation could be blocked by inhibiting FGF receptor (FGFR) 
function (Shinya et al. 2001; Corson et al. 2003; Lunn et al. 2007; Samuels et al. 
2009). Additionally, further testing by genetic regulation of FGF8 expression in the 
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neural tube and neural crest also aided in defining the critical role FGF induced 
ERK1/2 activation plays in development. It was shown that lowered FGF8 levels was 
followed by the failure to generate a normal complement of neural crest cells. This 
led severe cardiac and craniofacial defects whose severity was directly linked to the 
levels of FGF8 that were shown to be reliant on ERK signaling (Meyers et al. 1998; 
Kawauchi et al. 2005; Samuels et al. 2009). Normal CNS patterning is also disrupted 
when FGF8 is disrupted in the developing neural tube causing the failure to develop a 
cerebellum, olfactory bulb, and a normal cerebral cortex in embryonic mice (Chi et 
al. 2003). Moreover, inactivation of ERK2 in the developing neural crest also results 
in cardiac and craniofacial defects similar to the phenotypes seen in the FGF8 
mutants and humans that are haploinsufficient for the MAPK1 gene that encodes the 
ERK2 protein (Newbern et al. 2008; Samuels et al. 2009). Conditional knockouts of 
Braf, Raf1, and Mek1/2, upstream elements of ERK1/2, and the transcription factor 
SRF which is a downstream target of activated ERK1/2, all resulted in similar 
phenotypes (Newbern et al. 2008). These links of FGF to ERK1/2 activation in vivo 
gave the first evidence of the possibility of a highly selective developmental program 
within specific sets of progenitors (Samuels et al. 2009).  
Neural precursor cells go through mitotic division in the ventricular zone of 
the newly formed neural tube. The precursor cells are attached to the inner luminal 
and outer pial surfaces of the ventricular zone. Progression from G1 to S stages of 
the cell cycle occurs as they migrate from the luminal surface to the pial surface. The 
precursor cells then migrate back to the luminal surface during the G2 stage, lose 
their attachments to the pial surface, and undergo mitosis. Cell division produces 
either precursor cells or postmitotic neuroblasts then exit the cell cycle and begin 
differentiation into neuronal subclasses (Purves 2012; Pillat et al. 2016). The 
RAS/MAPK signaling pathway is a key source of integrating extracellular cues during 
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development to influence the actions of the cell cycle. In PC12 cells ERK activation is 
required for both proliferation and differentiation through stimulation by epithelial 
growth factor (EGF) or (NGF) respectively (Hallberg et al. 1994; Pouysségur et al. 
2002). It has been widely reported that transient ERK activation in the cytoplasm 
caused by EGF stimulation, results in sustained cell cycle activity and proliferation. 
However, sustained ERK activation in the cytoplasm created by NGF stimulation 
causes nuclear re-localization of activated ERK resulting in cell cycle arrest and 
differentiation (Traverse et al. 1992; Vaudry 2002; von Kriegsheim et al. 2009; Pillat 
et al. 2016). The sustained activation of ERK is a result of signaling through RAP1-
BRAF-MEK as well as RAS-RAF-MEK signaling and may include recruitment of PI3K, 
PKC, and the second messenger cAMP (Qui and Green 1992; York et al. 2000; 
Vaudry 2002; Pillat et al. 2016).  
 
Neuron Migration and Axon Growth 
Neuronal migration and axon guidance are two crucial processes in 
development that are highly associated with RAS/MAPK signaling. Involvement in 
these processes by RAS/MAPK is through not only transcriptional control by ERK 
phosphorylation of transcription factors, but also by direct interactions with 
cytoskeletal elements. Cell migration is a crucial and somewhat scheduled event 
during normal development. For example, during neural crest cell migration, 
deviation from a specific path of migration or failure to adapt to the target 
environment leads to elimination (Wakamatsu et al. 1998; Poelmann and 
Gittenberger-de Groot 1999; Cho and Klemke 2000). Work in identifying substrates 
of P-ERK1/2 and their roles in migration found several essential elements used in cell 
motility. Myosin light chain kinase (MYLK) family members involved in cell adhesion 
dynamics and membrane protrusion (Klemke et al. 1997; Huang et al. 2004), paxillin 
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(PXN) and protein tyrosine kinase 2 (PTK2) that complex to help regulate cellular 
adhesion dynamics (Huang et al. 2004; Valiente et al. 2011; Cooper 2013). In 
cortical neuron migration, it was found that hepatocyte growth factor (HGF) signaling 
through MET proto-oncogene, receptor tyrosine kinase (MET), Ras/MAPK, Rac1/p38, 
and PI3K/Akt signaling pathways are all necessary (Segarra et al. 2006). Although 
this study placed the dependence of Rac1/p38 signaling on the activation of Ras or 
PI3K, it was shown that Ras/MAPK and PI3K/Akt signaling were parallel pathways 
and each pathway was required for cell migration (Segarra et al. 2006).  
 A diverse mixture of extracellular cues, both chemical and mechanical, in the 
form of neurotrophins, netrins, semaphorins, cell adhesion molecules (CAMS), and 
ephs and ephrins, for example, work in concert in the execution of axonal outgrowth. 
These signaling molecules and binding receptors are under the developmental control 
of transcription factors that are regulated by the RAS/MAPK and protein kinase C 
(PKC) signaling pathways. Via TRK receptor activation and retrograde signaling, both 
CREB and NFAT transcription factor families are activated to express the genes 
necessary to produce the elements needed at the site of axonal extension and 
pathfinding (Lonze et al. 2002; Graef et al. 2003; Polleux and Snider 2010). In 
cortical spinal motor neurons, both in vitro and in vivo, IGF like family member 1 
receptor (IGFLR1) activation by IGFL1, specifically activated and enhanced axonal 
growth through both the PI3K and RAS/MAPK signaling pathways. This study 
further states that in conjunction with their results and previous studies, that 
BDNF does not play a role in axonal outgrowth (Ozdinler and Macklis 2006). Early 
In vitro studies however using sympathetic neurons found that TRKB activation 
induced local axonal outgrowth and that elongation was dependent upon both PI3K 
and MEK activity (Atwal et al. 2000). The seeming contradiction in these two 
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conclusions only serves to highlight the cell type specific and spatio-temporal 
activities of RAS/MAPK signaling. 
It was suggested by Atwal et al. that regulation of cytoskeletal stability was 
induced through PI3K by regulation of cytoskeletal elements, or by the RAS/MAPK 
and direct interactions of ERK with microtubule and neurofilament proteins (Atwal et 
al. 2000). It was later found that activated ERK did indeed act in the phosphorylation 
of microtubule associated protein 1B (MAP1B) and microtubule associated protein tau 
(TAU). MAP1B is highly enriched and localized in axons during development and has 
both dendritic and axonal functions in adulthood while non-phosphorylated TAU is 
predominately detected in the axons (Dehmelt and Halpain 2005; Ramkumar et al. 
2018). NGF activation of the RAS/MAPK pathway in PC12 cells and primary neurons 
activates cyclin dependent kinase 5 regulatory subunit 1 (CDK5R1) that then forms 
an active complex to phosphorylate MAP1B. Phosphorylated MAP1B has crucial roles 
in microtubule dynamics that affect axonal elongation and growth cone dynamics 
(Harada et al. 2001; Hahn et al. 2005; Yang et al. 2012). TAU has been found to 
have several functions associated with microtubules: Controlling microtubule 
modifications, altering the mechanical properties of microtubules, spacing of 
microtubules, and also regulation of microtubule motor transport (Ramkumar et al. 
2018). Tau is capable of being phosphorylated on 17 different sites by activated 
ERK1/2 resulting in Tau losing its affinity for microtubules substantially (Avila 2008; 
Hanger et al. 2009; Qi et al. 2016). Although ERK mediated phosphorylation of Tau 
results in microtubule instability, there are several different kinases phosphorylating 
Tau that have a stabilizing effect. This dynamic effect of stable and unstable 
phosphorylations could therefore be part of the dynamic assembly / disassembly 
mechanism that occurs during axonal growth. 
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Connectivity in the RASopathies 
 Non-invasive imaging of major white matter tracts within NF1 patients has 
revealed widespread abnormalities in local and global measurements using diffusion 
tensor imaging (DTI). DTI has been widely used to measure changes in white matter 
structure and the relationship to cognitive abilities in different stages of development 
(Assaf and Pasternak 2008; Qiu et al. 2015). DTI takes advantage of the differences 
of water diffusion in different directions. By measuring the extent of diffusion in all 
directions of a three-dimensional space, the anisotropy, or directional dependency, 
can be measured. In comparing this to isotropic diffusion, distinctions can be made 
between the elliptical shapes of oligodentricytic ensheathment of axons and the 
generally spherical shape of cell bodies. Measurements from the tensor model such 
as fractional anisotropy (FA), axial diffusivity (AD), radial diffusivity (RD), and mean 
diffusivity or apparent diffusion coefficient (MD or ADC) are then used to indicate the 
underlying axonal organization and microstructure of the brain. FA values from DTI 
are the main measure of white matter microstructural integrity and also indicate 
increases in overall diffusivity. MD values are an indication of a more diffuse or less 
organized structure in both adults and children with NF1 (Karlsgodt et al. 2012). DTI 
does suffer from some drawbacks however, such as only being able to reveal one 
dominant fiber tract in a given voxel and the inability to distinguish areas between 
tracts. Even with these limitations, DTI does allow for in vivo imaging and is a very 
useful tool for studying brain architecture both during and after development (Assaf 
and Pasternak 2008; Qiu et al. 2015). 
 NF1 patients with megalencephaly and general learning disabilities are 
thought to have a possible generalized alteration of the microstructure of the brain. 
DTI studies have defined these significant microstructural changes in the major white 
matter tracts in NF1 patients in measurements of FA and MD. DTI analysis of the 
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corpus callosum of children with NF1, aged 3-17, indicated significantly lower FA 
values compared to control patients. Measurements of whole brain histograms in 
these children showed an overall significant increase in MD (Filippi, Watts, Lindsay A. 
N. Duy, et al. 2013). Another study in adolescent NF1 patients, aged 9-18, also 
detected significantly lower FA values and significantly higher MD values within the 
cingulate bundle, superior longitudinal fasciculus, and the anterior thalamic radiation 
compared to controls. This study also reported widespread local and global 
abnormalities in white matter tracts (Koini et al. 2017). Significant decreases in FA 
and significant increases in MD of the corpus callosum, caudate nucleus, frontal 
white matter, parietooccipital white matter, thalamus, pons, and other select areas 
of adults with NF1 (S. L. Zamboni et al. 2007). In the first brain-wide DTI study of 
white matter microstructure, significant reductions in FA and overall increases of MD 
across the brain of adults with NF1. These results were explained that diffusion was 
not globally increased but was less constrained along the axonal tracts indicating 
decreased organization of tracts, decrease of myelination, or increased axonal 
spacing along the tracts (Karlsgodt et al. 2012). Regulation of RAS/MAPK as well as 
Akt and FAK by NF1 has been shown to impact cell adhesion, cell survival, and 
cellular migration. The findings of these DTI studies have some consistencies with a 
loss of fasciculation and possibly pathfinding abilities of growing axons during 
development (Karlsgodt et al. 2012). To find a link with these findings, further work 
is needed. 
Resting state functional connectivity MRI (rs-fcMRI) in NF1 adults found 
significantly reduced anterior-posterior connectivity compared to controls. Comparing 
edge (link between two nodes that have correlated activity) distribution in NF-1 and 
control patients, results suggested a pattern of long-range connectivity in the control 
group that was absent in the NF-1 group. The authors theorized that since these 
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connectivity differences in network structures were found in the resting state, it may 
predispose NF-1 patients to additional difficulties when task requirements are 
presented (Friston 2011; Tomson et al. 2015a). In a task-related fMRI study, key 
components of working memory circuits were found to be significantly hypo-
activated in NF-1 patients verses healthy control subjects. A Variety of additional 
differential patterns of connectivity were found to be present in the NF-1 patients in 
direct comparison to the control group. Overall findings of this study could be 
speculated to show that the NF-1 patients have a less efficient pattern of neural 
activity (Amira F. A. Ibrahim et al. 2017).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
 
Immediate Early Gene ARC – Memory and Learning 
 Cognitive, learning, and memory deficits are reported in many cases of 
RASopathy syndromes and vary widely between disorders. Cognitive impairments 
are reported in up to 80% of NF1 patients while approximately 25% of Noonan 
syndrome patients are reported to have learning disabilities (Allanson and Roberts 
1993; Plasschaert et al. 2015). Learning and long-term memory formation relies on 
newly transcribed and translated proteins to stabilize synaptic changes. One of the 
most defined immediate early genes (IEG) is activity regulated cytoskeleton 
associated protein (Arc). Changes in the expression of ARC in regions associated with 
memory, learning, and plasticity are used as a widespread readout of activity in 
these processes (Guzowski et al. 1999; Gallo et al. 2018). The Arc gene encodes an 
mRNA transcript that is translocated from the nucleus to the cytosol then transported 
to the post-synaptic dendrites (Steward and Worley 2001). Upon synaptic activity, 
Arc mRNA is transported to and stabilized at active synapses indicating local 
translation of ARC at those sites (Steward et al. 1998; Epstein and Finkbeiner 2018). 
Shortly after translation, ARC is transported to the nucleus where it accumulates as 
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seen in neurons of the hippocampus and somatosensory cortex (Korb et al. 2013; 
Epstein and Finkbeiner 2018). Arc is known to play a crucial role in synaptic plasticity 
leading to learning and memory consolidation that when disrupted can lead to major 
behavioral abnormalities (Korb and Finkbeiner 2011; Shepherd and Bear 2011; Gallo 
et al. 2018). 
 Transcription of Arc is induced by a variety of signaling cascades upon 
neuronal activity. Calcium influx through glutamate binding of the N-methyl-D-
aspartate receptor (NMDAR), glutamate metabotropic receptor 1 (GRM1) or α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR), BDNF stimulation 
of NTRK2, and voltage gated calcium channels (VGCC) can each stimulate Arc 
transcription through the RAS/MAPK pathway (Epstein and Finkbeiner 2018). 
Stimulation of the AMPAR also leads to inhibition of Arc transcription through a G 
protein coupled mechanism (Rao et al. 2006; Epstein and Finkbeiner 2018). In turn, 
ERK itself directly phosphorylates ARC leading to the nuclear localization and the 
inhibition of glutamate ionotropic receptor AMPA type subunit 1 (GRIA1) (Korb et al. 
2013; Nikolaienko et al. 2017; Epstein and Finkbeiner 2018). These inhibitory 
mechanisms lead to homeostatic scaling of synaptic activity that when dysregulated 
can lead to a brain that is poorly suited to form memories (Epstein and Finkbeiner 
2018). 
 
Summary 
 The term RASopathies was coined to encapsulate the collection of syndromes 
caused by germline genetic mutations specifically within the RAS/MAPK signaling 
pathway. The mechanisms and interactions of this pathway have been exhaustively 
studied and pieced together from many different cell types mainly in in vitro studies. 
The signaling mechanisms however are extremely specific to various factors 
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including cell type, environmental, temporal, signal context and duration, and spatial 
characteristics. The central nervous contains a very heterogenous mixture of cells 
and numerous brain structures. Recent data has implicated aberrant connectivity 
issues to be involved in the neurological and behavioral issues within patients with 
NF1. However, little is known about cell-specific and structural specific contributions 
within the physiological setting of the RASopathy pathologies. 
To address the aberrant RAS/MAPK signaling functions in the context of 
connectivity, we employed an in vivo conditional RAS/MAPK signaling (MEK1) loss- 
and gain-of-function model to specifically target long-range cortical neurons. This 
allowed the determination of cell-type autonomous effects on the connectivity issues 
reported in the RASopathies. This conditional genetics approach was additionally 
used to determine the presence of any cortical layer autonomous effects in the MEK1 
gain-of-function mouse. Behavioral analysis was performed using this approach to 
address cell-type and layer autonomous effects in motor learning acquisition. 
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Abstract 
Aberrant signaling through the Raf/MEK/ERK (ERK/MAPK) pathway causes pathology 
in a family of neurodevelopmental disorders known as “RASopathies” and is 
implicated in autism pathogenesis. Here, we have determined the functions of 
ERK/MAPK signaling in developing neocortical excitatory neurons. Our data reveal a 
critical requirement for ERK/MAPK signaling in the morphological development and 
survival of large Ctip2+ neurons in layer 5. Loss of Mek1/2 led to deficits in 
corticospinal tract formation and subsequent corticospinal neuron apoptosis. 
ERK/MAPK hyperactivation also led to reduced corticospinal axon elongation but was 
associated with enhanced arborization. ERK/MAPK signaling was dispensable for 
axonal outgrowth of layer 2/3 callosal neurons. However, Mek1/2 deletion led to 
reduced expression of Arc and enhanced intrinsic excitability in both layers 2/3 and 
5, in addition to imbalanced synaptic excitation and inhibition. These data 
demonstrate selective requirements for ERK/MAPK signaling in layer 5 circuit 
development and general effects on cortical pyramidal neuron excitability. 
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Introduction 
The canonical Ras/Raf/MEK/ERK (ERK/MAPK) signaling pathway is a key 
intracellular signaling cascade downstream of cell surface receptors critical for brain 
development (Samuels et al. 2009). In the developing cortex, the ERK/MAPK 
pathway is thought to be particularly important for neuronal responses to 
neurotransmitters and receptor tyrosine kinase (RTK) ligands, such as FGFs and 
neurotrophins. In the mature brain, it is well established that ERK/MAPK plays a 
central role in the activity-dependent plasticity of neural circuits (Thomas and 
Huganir 2004; Shilyansky et al. 2010).  
Importantly, a number of human neurodevelopmental syndromes have been 
linked to aberrant ERK/MAPK activity. This related group of human syndromes, 
increasingly referred to as RASopathies, are caused by genetic mutations in core 
components or regulators of the ERK/MAPK signaling cascade (Rauen 2013). 
Macrocephaly, neurodevelopmental delay, cognitive impairment, and epilepsy are 
frequently observed in RASopathy patients with clinical manifestations being 
dependent on the precise causative mutation (Rauen 2013). RASopathies are most 
often associated with hyperactive ERK/MAPK signaling (e.g. Neurofibromatosis type 1 
(NF1), Noonan, Costello, and Cardiofaciocutaneous (CFC) syndromes) (Rauen 2013); 
however, mutations that lead to diminished ERK/MAPK activation have been 
identified in a subset of LEOPARD and CFC syndrome patients (Kontaridis et al. 
2006; Nowaczyk et al. 2014). Abnormal Ras/MAPK signaling has also been observed 
in models of other monogenic neurodevelopmental disorders, including Fragile X 
syndrome and Tuberous Sclerosis (Chévere-Torres et al. 2012; Osterweil et al. 2013; 
Faridar et al. 2014; Zhang et al. 2014). Recent exciting work has shown that 
pharmacological normalization of pathological Ras/MAPK activity is sufficient for 
correcting select cellular and behavioral abnormalities in Fragile X, Tuberous 
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Sclerosis, NF1, Noonan, and Costello syndrome mutant mice (Li et al. 2005; Cui et 
al. 2008; Wang et al. 2012; Osterweil et al. 2013; Lee et al. 2014; Zhang et al. 
2014). However, our understanding of these disorders remains rudimentary as there 
is limited information on brain cell type-specific consequences of either loss- or gain-
of-function through this pathway. 
Accumulating evidence also suggests that pathological ERK/MAPK signaling 
contributes to certain forms of autism. Altered Ras/MAPK signaling has been 
identified as a common downstream mediator of divergent genetic mutations linked 
to autism, and Erk1/MAPK3 is present in a region of 16p11.2 mutated in ~1% of 
cases of autism (Kumar et al. 2007; Eichler and Zimmerman 2008; Weiss et al. 
2008; Pinto et al. 2010; Gilman et al. 2011; Gilman et al. 2012; Pucilowska et al. 
2015). Little is known about how ERK/MAPK signaling might relate to the 
pathogenesis of autism. An important current research theme is that the behavioral 
manifestations of autism spectrum disorders (ASDs) may be linked to both functional 
hypo- and hyper-connectivity between distinct brain regions (Geschwind and Levitt 
2007; Just et al. 2007; Keown et al. 2013; Supekar et al. 2013). Furthermore, 
recent work in postmortem brains of autistic patients suggests that local patches of 
disorganization, in which cortical layers 4-5 are particularly affected, play an 
important role in disease pathogenesis (Stoner et al. 2014). In one study, co-
expression network analyses of autism-linked genetic mutations suggested that layer 
5 in prefrontal and sensorimotor cortex is a key site of convergence for pathogenesis 
(Willsey et al. 2013). Whether aberrant ERK/MAPK signaling might result in cortical 
layer disorganization and defective long-range connectivity is unknown.  
To address questions of cell type specificity and consequences for circuit 
formation, we have defined the effects of ERK/MAPK loss- and gain-of-function on 
the development of cortical pyramidal neurons.  Pyramidal neuron-specific functions 
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of ERK/MAPK signaling were assessed by deleting the upstream kinases 
Mek1/MAP2K1 and Mek2/MAP2K2 (Mek1/2) or overexpressing hyperactive Mek1. 
Conditional deletion of Mek1/2 led to major disruption of layer 5 with noticeably 
fewer Ctip2-expressing large neurons compared to controls. Further, long range axon 
extension of layer 5 corticospinal projection neurons during early development was 
markedly impaired. Subsequent to delayed entry of axons into the cervical spinal 
cord, many layer 5 projection neurons in sensorimotor cortices underwent apoptosis. 
Gain-of-function ERK/MAPK signaling also affected layer 5 CST neurons with a 
resultant decrease in axon elongation and associated increase in axon branching.  
The morphological requirement for ERK/MAPK signaling was specific for layer 5, as 
layer 2/3 was not disrupted and callosal projection neurons in upper cortical layers 
do not exhibit overt changes in axon extension or targeting following Mek1/2 
deletion. In contrast to the layer-specific functions of ERK/MAPK on axonal 
development, we found that ERK/MAPK was required for the expression of ARC and 
other plasticity-associated genes across all cortical lamina. Further, loss of 
ERK/MAPK signaling in pyramidal neurons disrupted excitatory and inhibitory 
neurotransmission and altered intrinsic excitability in both layers 2/3 and 5. Our data 
reveal unexpectedly specific requirements for ERK/MAPK signaling in layer 5 circuit 
development and general effects on the excitability of cortical pyramidal neurons in 
multiple layers. 
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Materials and Methods 
Transgenic Mice 
 Animal experiments were performed in accordance with established protocols 
approved by the Institutional Animal Care and Use Committee at the University of 
North Carolina–Chapel Hill and Arizona State University and NIH guidelines for the 
use and care of laboratory animals.  All mice were housed in standard conditions 
with food and water provided ad libitum and maintained on a 12-hr. dark/light cycle.  
Experiments were replicated a minimum of three times with mice derived from 
independent litters. Nex:Cre expression alone did not have a detectable effect on the 
phenotypes described in this manuscript. Thus, Cre-expressing or Cre-negative 
littermates were utilized as controls unless indicated otherwise. Mek1loxp/loxp mice 
possess a loxp flanked exon 3 while Mek2-/- mice contain a neo insertion in exons 4-
6, which encodes the kinase domain (Bélanger et al. 2003; Bissonauth et al. 2006). 
Mek2-/- mice are viable and breed normally. Loxp-STOP-loxp-caMEK1 mice were 
kindly provided by Dr. Maike Krenz and Dr. Jeffrey Robbins (Krenz et al. 2008); the 
IGF1Rloxp/loxp were kindly provided by Dr. Ping Ye (Liu et al. 2009); the Nex:Cre mice 
were kindly provided by Dr. Klaus Nave and Dr. Sandra Goebbels (Goebbels et al. 
2006); and the Emx1:Cre mice were kindly provided by Dr. Franck Polleux (Gorski et 
al. 2002). “Ai3” mice were purchased from Jackson laboratories (Madisen et al. 
2010). All mice in this study were of mixed genetic background. 
Genomic DNA extracted from tail or toe samples was utilized for mouse 
genotyping by PCR using standard techniques.  Primers for gene amplification are as 
follows (listed  5’-3’): Cre - TTCGCAAGAACCTGATGGAC and 
CATTGCTGTCACTTGGTCGT amplify a 266 bp Cre allele; Mek1 –
CAGAAGTTCCCACGACACTA, CTGAAGAGGAGTTTACGTCC, and 
GTCTGTCACTTGTCTTCTGG amplifies a 372 bp wild type and a 682 bp floxed allele; 
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Mek2 – CTGACCTTCCTGTAGGTG, ACTCACGGACATGTAGGA, and 
AGTCATAGCCGAATAGCCTC amplify a 293 bp wild-type allele and a 450 bp knockout 
allele; caMEK1  -GTACCAGCTCGGCGGAGACCAA and TTGATCACAGCAATGCTAACTTTC 
amplify a 600 bp mutant allele; Ai3 – AAGGGAGCTGCAGTGGAGTA, 
CCGAAAATCTGTGGGAAGTC, ACATGGTCCTGCTGGAGTTC, and 
GGCATTAAAGCAGCGTATCC amplify a 297 bp wild-type allele and a 212 bp Ai3 allele; 
IGF1R-CTTCCCAGCTTGCTACTCTAGG and CAGGCTTGCAATGAGACATGGG amply a 
124 and a 220 bp band for wild-type and floxed alleles. 
 
Viral and DiI Injections 
P0-P5 litters were removed as a group, cryo-anesthetized on wet-ice for 3-5 
min, and immediately injected with 50-500nl of solution using a 5 uL Hamilton 
syringe fitted with a 32-gauge beveled needle mounted to a stereotaxic arm. For 
viral labeling, the AAV5-CAG-FLEX-tdTomato vector was prepared by the UNC Viral 
Vector Core and diluted in sterile PBS, 5% sorbitol, and 0.1% Fast Green to allow for 
visualization prior to injection. For DiI tracing, a 10% DiI solution (Life Technologies) 
was prepared in DMSO and injected into the primary motor cortex or the cervical 
spinal cord. Upon completion of the injection, pups recovered on a heating pad and 
were returned as a group to the home cage.  
 
Tissue Preparation  
Mice of the appropriate age were anesthetized and perfused transcardially 
with 4% paraformaldehyde/PBS. For cryoprotection, sub dissected samples were 
incubated in a graded series of 10%, 20%, and 30% sucrose/PBS at 4˚C before 
embedding in O.C.T. compound and freezing. Cryostat sections were collected on 
Fisherbrand Superfrost/Plus slides (Fisher Scientific) and air-dried prior to staining. 
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For some experiments, brains were dissected, post fixed, and mounted in agarose 
prior to vibratome sectioning. 
 
Immunolabeling 
For immunofluorescent staining, sections were rinsed in PBS and blocked with 
5% normal serum/0.1% Triton X-100/PBS at room temperature.  Primary antibodies 
were diluted in blocking solution and incubated 1-2 days at 4˚C with gentle 
agitation.  The antibodies utilized were; rabbit anti-Parvalbumin (Swant), chicken 
anti-GFP (Aves Labs), rat anti-Ctip2 (Abcam), rabbit anti-Satb2 (Abcam), rabbit anti-
Cux1 (Santa Cruz), mouse anti-NeuN (Chemicon), rabbit anti-Cleaved Caspase-3 
(Cell Signaling Technology), rabbit anti-Iba1 (Wako), goat anti-IGF1 (R&D 
Research), rabbit anti-PKCγ (Santa Cruz), rabbit anti-MEK1/2 (Abcam), rabbit anti-P-
ERK1/2 (Cell Signaling Technology) and rabbit anti-IGF1Rβ (Cell signaling 
Technology).  After rinsing in PBS/T, the secondary antibody was diluted in blocking 
solution and added overnight at 4˚C. Secondary antibodies included Alexa Fluor 488, 
546 or 568, and 647 conjugated anti-rabbit, anti-mouse, anti-rat, or anti-goat IgG 
(Invitrogen).  For some experiments, slides were then incubated in Hoechst or DAPI 
for nuclear labeling, rinsed, and mounted. Images were collected with a Zeiss LSM 
710, 780, or Leica SP5 laser scanning confocal microscope. 
 
Image Analysis and Quantitation 
Confocal images of regions of interest were collected from individual brain 
sections for each animal. For assessment of relative neocortical volume, cortical area 
was measured in five anatomically matched coronal sections along the rostro-caudal 
axis, averaged, and normalized against the control brain. For assessment of Ctip2, 
Cux1, Satb2, and NeuN expressing cells, regions of primary sensory, motor, and 
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visual cortex from at least three anatomically matched sections of mutant and 
control cortices were defined using morphological and anatomical features described 
in Paxinos and Franklin 2001 (Franklin and Paxinos 2013). Radial columns were 
outlined within the cortical region of interest and measured. The total sampled area 
from a specific region of cortex of a single brain ranged from 1-3 mm2. Individual 
layer boundaries were determined by the changes in density and appearance of 
NeuN labeling. Images were then transferred into ImageJ, a pixel intensity threshold 
was set manually by an observer blind to the genotype, and watershed segmentation 
was performed. The binary image mask was then analyzed using the particle analysis 
tool to count the number of events with a min-max size cutoff of 50-600 µm2 for 
NeuN labeling and 30-300 µm2 for Ctip2+, Cux1+, or Satb2+ labeled nuclei.  For NeuN 
density determination, the total number of NeuN+ cells within a radial column was 
divided by the area of the column and averaged across at least three separate 
columns within the cortical region of interest. For determination of the relative 
proportion of Ctip2+ or Satb2+ cells in layer 5 or Cux1+ cells in layers 2-4, the 
number of each labeled cell within specific laminar boundaries was divided by the 
total NeuN count within the entire radial column to determine the proportion of each 
neuronal subtype per radial column. Results from this analysis were averaged across 
three individual radial columns per cortical region and normalized against the 
littermate control analyzed in parallel for each mutant. These images were also 
utilized for determination of the cross-sectional area of neuronal soma. Randomly 
selected, well-labeled NeuN expressing neurons that included a DAPI labeled nucleus 
were outlined manually in Photoshop and measured.  
For analysis of axonal innervation, a modification of the cell counting 
procedure described above was utilized where images of the region of axonal 
innervation from at least three anatomically matched sections were collected, 
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manually thresholded in ImageJ, and the number of labeled pixels was measured.  
Representative images have been cropped and adjusted for brightness and 
contrast in Photoshop for presentation. Student's t-test was used for statistical 
analysis. 
 
Western Blotting 
Sensorimotor cortices were dissected from both mutant and litter mate control mice 
and lysed in RIPA buffer (0.05M Tris-HCl, pH 7.4, 0.5M NaCl, 0.25% deoxycholic 
acid, 1% NP-40, and 1mM EDTA, Millipore) supplemented with 0.1% SDS, protease 
inhibitor cocktail (Sigma) and phosphatase inhibitor cocktail II and III (Sigma). 
Lysates were cleared by centrifugation and protein concentration was 
determined using the Bio-Rad protein assay (Bio-Rad) using BSA as a standard. 
Equal amounts of protein were denatured in reducing sample buffer, separated by 
SDS-PAGE gels, and blotted to PVDF membranes (Bio-Rad). Blots were blocked with 
5% BSA in TBS containing 0.5% Tween 20 (TBS-T) for 1 h at room temperature, 
then incubated overnight at 4°C with primary antibodies. The primary antibodies 
used were rabbit anti-phospho Erk1/2 (Thr202/Tyr204) (Cell Signaling Technology, 
Inc), rabbit anti-Erk1/2 (CST), rabbit anti-phospho-p90RSK (Thr573)  (Cell Signaling 
Technology, Inc.), rabbit anti-RSK (Cell Signaling Technology, Inc.), rabbit anti-
MSK1(Ser360) (Abcam), rabbit anti-MSK1 (Cell Signaling Technology, Inc.), rabbit 
anti-Mek1/2 (Cell Signaling Technology, Inc.), rabbit anti-Arc (Synaptic System) and 
anti-GAPDH (Cell Signaling Technology, Inc.). After washing with TBS-T, 
membranes were incubated with HRP-conjugated secondary antibodies in 5% milk in 
TBS-T for 2 h at room temperature.  Blots were washed with TBS-T and detection 
was performed with SuperSignal West Pico chemiluminescent substrate (Thermo 
Scientific). 
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 Results 
Excitatory neuron-specific modification of ERK/MAPK activity 
Previous work has shown that ERK1/2 is activated in embryonic cortical 
neurons, albeit at much lower levels than in the ventricular zone (Faedo et al. 2010; 
Toyoda et al. 2010; Pucilowska et al. 2012; Li et al. 2014). In western blots of 
sensorimotor cortical lysates from P1, 2, 7, 14, and 21-day old mice, it was shown 
that levels of pan-ERK1/2 and pan-MEK1/2 exhibit a steady but evident increase 
from a relatively lower level at birth. Phosphorylated-ERK1/2 and phosphorylated-
MEK1/2 levels were also relatively low at birth but increased noticeably by P7 and 
peaked at P14  (Oliveira et al. 2008). The expression of phosphorylated ERK1/2 at 
P3 did not exhibit any clear-cut laminar specificity. These findings indicate that 
ERK/MAPK signaling is activated in the developing cortex, peaking during the second 
postnatal week (Xing et al. 2016). 
We generated a mouse model to test the direct, neuron-autonomous role of 
ERK/MAPK signaling by inactivating Mek1/2 specifically in immature mouse cortical 
excitatory neurons. We conditionally deleted Mek1/2 with a Cre-dependent Mek1 
allele, a germ-line Mek2 deletion allele, and Cre-recombinase under the control of 
the Nex/NeuroD6 promoter (Mek1loxp/loxp Mek2-/- Nex:Cre, referred to hereafter as 
Mek1/2CKO(Nex)) (Goebbels et al.). As expected, Nex:Cre activated reporter-gene 
expression in the Cre-dependent EYFP mouse line, Ai3, in excitatory, but not 
inhibitory, neurons in the neocortex (Figure 3B-C) (Madisen et al. 2010). Cre-
mediated reporter gene expression was apparent by mid-embryogenesis (data not 
shown). Western blotting of neocortical lysates and immunolabeling show that 
Mek1/2CKO(Nex) mice exhibit significantly reduced MEK1 levels by birth and reduced 
phosphorylation of ERK/MAPK substrates, RSK, and MSK (Figure 3A). Complete loss 
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of MEK1 protein would not be expected in whole cortical lysates due to MEK1 
expression in inhibitory interneurons and non-neuronal cell types. These data show 
that the Nex:Cre-mediated genetic targeting strategy is effective at inducing loss of 
ERK/MAPK signaling in developing cortical excitatory neurons. Mek1/2CKO(Nex) pups 
were born at normal Mendelian ratios without overt differences from littermate 
controls. However, a delay in overall growth could be detected by the end of the first 
postnatal week. At P14 Mek1/2CKO(Nex) mice exhibited an average reduction in body 
weight of 37.1 ±11.3% and neocortical volume was reduced by 23.2 ±6.4% (mean 
±SEM, n=7, p<0.0001).  Behaviorally, P14 Mek1/2CKO(Nex) mice exhibited 
spontaneous and persistent hindlimb clasping when lifted by the tail (data not 
shown), an indicator of neurological impairment. Lethality was invariably observed in 
the third to fourth postnatal week. A qualitatively similar effect on growth, 
neurological function, and viability was also observed in Erk1-/- Erk2loxp/loxp Nex:Cre 
mice (data not shown), demonstrating that phenotypes are conserved following 
deletion of different core components of the ERK/MAPK cascade (Xing et al. 2016).  
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Figure 3 
 
 
 
 
 
Mek1/2CKO(Nex) Cortical Excitatory Neurons Specific Recombination. (E) P1 
and P14 Map2k1/2; Neurod6-Cre cortices show pronounced loss of MAP2K1 
expression and reduced phosphorylation of ERK/MAPK pathway substrates, RSK and 
MSK (n=5). (F-G) Representative confocal images of P14 control mouse brains show 
that cortical excitatory neurons in the cortex and hippocampus exhibit a high level of 
MAP2K1 immunolabeling (E). MAP2K1 levels are profoundly reduced in the cortex 
(yellow arrows) and hippocampal subfields CA1-CA3 (blue arrow) in P14 Map2k1/2; 
Neurod6-Cre mice (G) (n=6, scale bar=2 mm).  
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 Disruption of layer 5 and reduced number of Ctip2+ neurons after ERK/MAPK 
inactivation 
 Comprehensive analyses of layer 5 neurons have identified specific gene 
expression patterns, morphologies, and electrophysiological characteristics for this 
neuronal subtype (Leone et al. 2008; Kwan et al. 2012; Custo Greig et al. 2013). We 
analyzed the expression pattern of a critical transcription factor for layer 5 
development, Ctip2, in control and mutant cortices (Figure 4A-B) (Arlotta et al. 
2005). The appearance of co-labeled Ctip2+/NeuN+ neurons in layer 5 appeared 
disrupted in rostral P14 Mek1/2CKO(Nex) cortices compared to controls (Figure 4B, 
yellow arrows).   
Ctip2+ layer 5 neurons are a small percentage of the total cortical neuron 
population. In the sensory cortex of control mice, we found that Ctip2+ layer 5 
neurons represent only 9.61 ±0.84% (mean ±SEM, n=5) of all NeuN+ neurons within 
a radial column. Thus, our previous global NeuN estimates across an entire cortical 
column were not sensitive enough for detecting changes confined to sparse neuronal 
subtypes. To quantify the number of Ctip2+ neurons, we determined the relative 
proportion of cells in layer 5 that express Ctip2+ as a percentage of NeuN+ cells 
across all lamina in a radial cortical column. This measurement was performed in 
motor, sensory, and visual cortices. Indeed, we found that P14 Mek1/2CKO(Nex) 
primary motor and sensory cortices exhibit a clear decrease in the relative proportion 
of Ctip2+ neurons in layer 5 (Figure 5A-F, G). Qualitatively similar results were 
observed in P14 Mek1/2CKO(Emx1) cortices (Data not shown). The relative proportion of 
Ctip2+ neurons in visual cortices (Figure 5E-F, G) was not significantly diminished in 
Mek1/2CKO(Nex) mutants, suggesting the effect in sensory and motor cortex was due 
to loss of the cell type and not a result of ERK/MAPK regulation of global Ctip2 
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expression levels (Xing et al. 2016).   
Figure 4.  
 
 
Loss of ERK/MAPK signaling leads to a reduction in the number of Ctip+ 
layer 5 neurons. Immunostaining of P14 control (A) and Mek1/2CKO(Nex) (B) sagittal 
forebrain sections for all neurons, callosal projection neurons, and subcortical 
projection neurons with NeuN, Satb2, and Ctip2, respectively, revealed an aberrant 
pattern of Ctip2 expression in layer 5 of mutant sensorimotor cortices (yellow 
arrows) (n=6, scale bar = 100µm).  
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Figure 5.  
 
 
 
Loss of ERK/MAPK signaling leads to a reduction in the number of Ctip+ 
layer 5 neurons. Representative confocal images of Ctip2 immunolabeling in radial 
columns of primary motor (D-E), sensory (F-G), and visual (H-I) cortex from P14 
control (D, F, H) and Mek1/2CKO(Nex) (E, G, I) brains (scale bar = 30µm). 
Quantification of the relative number of layer 5 Ctip2+ neurons as a proportion of the 
total number of NeuN+ neurons in a cortical column revealed a substantial decrease 
in motor and sensory, but not visual, cortices in P14 mutant mice (J) (n=4, mean 
±SEM, * = p < 0.05). 
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Failure of CST development neurons in layer 5 
Layer 5 neurons are morphologically heterogeneous with distinct 
subpopulations that can be differentiated by cortico-cortical or subcortical axonal 
projections. We examined layer 5 projections in the hindbrain corticobulbar tract 
(CBT) and spinal cord corticospinal tract (CST) of P14 Mek1/2 mutant mice. 
Immunostaining for a well-established marker of corticospinal projections, PKCγ, and 
genetic labeling with Ai3 revealed a profound decrease in the size of the CBT in P14 
Mek1/2CKO(Nex) hindbrains (Figure 6A-B). CST labeling was also strikingly reduced in 
the cervical spinal cord (data not shown) and essentially absent in the lumbar spinal 
cord in both Mek1/2CKO(Nex) (Figure 6C-D) and Mek1/2CKO(Emx1) mutants (Figure 6E-F). 
Analysis of rare Mek1/2 mutants that survived as late as P24 revealed that no CST 
axons were present in lumbar spinal cords (data not shown). These data provide 
further evidence of an overt loss of corticospinal neurons by the second postnatal 
week (Xing et al. 2016). 
Corticospinal neurons represent a subset of the entire Ctip2+ population in 
sensorimotor layer 5 (Arlotta et al. 2005). The lack of layer 5 neuron loss in the 
Mek1/2CKO(Nex) visual cortex suggests that ERK/MAPK signaling is dispensable for the 
development of projection neurons targeting structures other than the spinal cord. 
Past work has shown that callosally projecting layer 5 neurons have significantly 
shorter and less complex apical dendritic arbors than subcortical projection neurons 
(Molnár and Cheung 2006; Larsen et al. 2007). To determine which of these classes 
was affected by Mek1/2 deletion, a Thy1-based reporter, YFP-16, that fluorescently 
labels a small proportion of layer 5 neurons in sensorimotor cortex, was bred with 
Mek1/2CKO(Nex) mice (Feng et al. 2000).  
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These mutants clearly show that the fluorescently labeled layer 5 neurons in P14-P21 
Mek1/2CKO(Nex) YFP-16 sensorimotor cortices have substantially shorter apical 
dendrites than in controls (Data not shown). The reduction in large, tufted neurons in 
layer 5 of mutant mice provide further evidence for a deficit in the development of 
corticospinal projection neurons (Xing et al. 2016). 
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Figure 6.  
 
 
 
Corticospinal tract defects in the Mek1/2CKO (Nex) mice. To further evaluate 
the loss of layer 5 projection neurons, we examined the expression of a well-
established corticospinal tract marker, PKCγ. Compared to control hindbrains (A) and 
spinal cords (C), a profound decrease in corticospinal tract labeling was observed in 
the Mek1/2CKO (Nex) hindbrain (B-yellow arrows, scale bar = 200 µm) and spinal 
cord (D), consistent with the reduced number of Ctip2+ layer 5 neurons (df=dorsal 
funiculus, n=3, scale bar = 50 µm). 
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ERK/MAPK signaling is necessary for corticospinal axon extension 
The loss of layer 5 neurons following deletion of Mek1/2 could be due to an 
early disruption in the initial specification of this neuronal subtype.  During layer 5 
neuron development, Nex:Cre is not expressed until neurons are post-mitotic (Wu et 
al. 2005; Goebbels et al.). However, it remained possible that post-mitotic stages of 
embryonic layer 5 neuron specification were altered during embryogenesis. In 
newborn mutant pups, we found that the expression and number of Ctip2+ neurons 
in presumptive layer 5 was not diminished following Mek1/2 deletion (Figure 7A-C). 
Thus, ERK/MAPK signaling is not required for the initial establishment of the correct 
numbers of the Ctip2+ deep-layer neuron population. 
By P3 in wild-type neonates, corticospinal axons have projected through the 
ventral hindbrain, crossed the midline at the medullary/spinal cord boundary, and 
are extending into cervical spinal cord through the dorsal funiculus (Schreyer and 
Jones 1982). We asked whether ERK/MAPK signaling was required for the initial 
outgrowth of corticospinal projections in vivo. In vivo DiI injections into the motor 
cortex of P0.5 neonates were performed to assess subcortical axon growth, 
especially into the spinal cord (Figure 8A). Strikingly, analysis of anterogradely 
labeled axonal projections at P3-4 revealed a highly significant decrease in the 
extension of corticospinal axons into the lower cervical/upper thoracic segments of 
spinal cord (Figure 7D-E). Moreover, a profound decrease in the caudal extension of 
descending corticospinal axons into the spinal cord of P2 Mek1/2CKO(Emx1) Ai3 mice 
was also observed (Data no shown). DiI labeling of subcortical projections in 
Mek1/2CKO(Nex) mice revealed that layer 5 neuron growth into the tectum and 
pons/medulla was not significantly decreased (Figure 8B). These data demonstrate 
that the initial growth of corticospinal axons to the level of the hindbrain is not 
significantly disrupted in Mek1/2 mutants, however, ERK/MAPK signaling is clearly 
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necessary for corticospinal axon elongation into the spinal cord. 
In vitro studies have demonstrated that IGF1 signaling acting via PI3K and 
ERK/MAPK promotes corticospinal axon outgrowth in vitro (Ozdinler and Macklis 
2006). IGF1 is also focally and intensely expressed in the medulla in the presumptive 
inferior olivary nucleus during the precise developmental time frame (P1 – P2) that 
CST axons normally enter the spinal cord (Data not shown). IGF-1 expression is 
temporally regulated, being present by E18 and much diminished by P14 (data not 
shown). Mek1/2 deletion in CST axons does not affect IGF1 expression by these cells 
(Data not shown). Thus, IGF-1 may act via ERK/MAPK within corticospinal neurons to 
regulate corticospinal outgrowth (Xing et al. 2016). 
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Figure 7.  
 
 
 
 
Layer 5 neuron corticospinal axon outgrowth requires ERK/MAPK signaling 
in vivo. Expression of a well-known master transcription factor for layer 5 neurons, 
Ctip2, was intact in cortical layer 5 as shown in representative confocal images of 
newborn control (A) and Mek1/2CKO(Nex) (B) sensorimotor cortices (scale bar = 50 
µm). Quantitation of the number of Ctip2-expressing nuclei in cortical layer 5 did not 
reveal a significant difference in Ctip2+ neuron density between control and mutant 
neonates (C) (n=3, mean ± SEM, p = 0.89). In vivo DiI injections into the 
sensorimotor cortex of P0.5 control and Mek1/2CKO(Nex) neonates were performed and 
mice were collected three days after injection. The extent of anterograde DiI labeling 
was analyzed in coronal sections through the spinal cord (D). We observed a 
significant decrease in the extent of corticospinal (cst) elongation in mutant mice, 
especially in the lower cervical/thoracic spinal cord segments (yellow arrows in D) 
(n=3, scale bar = 100 µm).  Quantitation of CST length relative to the medullary 
decussation revealed a significant decrease in corticospinal axon growth in mutant 
spinal cords (E) (n=3, mean ± SEM, * p = 0.02).  
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Figure 8.  
 
 
 
The rostro caudal elongation of layer 5 axons in the spinal cord requires 
ERK/MAPK. A-B.  In vivo DiI injections into the sensorimotor cortex were 
performed in P0.5 control and Mek1/2CKO(Nex) neonates to label subcortical projection 
neuron afferents (A).  Mice were collected three days after injection and the extent 
of DiI labeling in multiple subcortical targets was analyzed in coronal sections 
through the brain (B).  A substantial difference in the innervation of the thalamus 
(th), cerebral peduncle (cp), superior colliculus (sc), or pons (po) was not detected in 
mutants (B) (n=3, scale bar=100 µm).  
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Caspase-3 activation in Layer 5 neurons after ERK/MAPK deletion 
By P3 we noted a dramatic increase in the number of activated caspase-3 
labeled neurons in layer 5 in Mek1/2CKO(Nex) mutants when compared to controls 
(Figure 9A-B, E). Modest caspase-3 activation was also observed in layer 6, but not 
in upper layers 1-4 (Figure 9E). In line with the elevation of caspase-3 activity, we 
observed Iba1+ microglia in P3 Mek1/2CKO(Nex) cortices with a ramified morphology 
that appeared to be engulfing Ctip2+ neurons (Figure 9C-D). To further confirm the 
absence of corticospinal neurons, we retrogradely labeled corticospinal projection 
neurons by injecting DiI into the cervical spinal cord in Mek1/2CKO(Nex) neonates at P3, 
the time point when dying cells could initially be detected in the cortex.  Analysis of 
retrogradely labeled corticospinal neurons in the primary motor cortex at P7 revealed 
a significantly reduced number of DiI labeled cells consistent with the death of these 
neurons during this time period (Data not shown). Interestingly, retrograde DiI 
labeling of P5 layer 5 neurons that project into the contralateral hemisphere did not 
reveal a substantial decrease in P9 mutants relative to controls (Data not shown). 
These data indicate that loss of Mek1/2 results in overt caspase-3 activation and 
corticospinal neuron death that can be first detected at P3-4. 
We examined the possibility that transformation of Ctip2+ corticospinal 
neurons into an alternative phenotype during the neonatal period contributes to the 
reduction in Ctip2+ layer 5 neuron number observed at P14. We tested whether 
Ctip2+ layer 5 neurons might be transforming into a callosal phenotype by 
quantifying the proportion of cortical neurons that express Satb2, an important 
transcription factor for the differentiation of callosal neurons (Alcamo et al. 2008; 
Britanova et al. 2008). Since Satb2 is co-expressed by a minority of Ctip2+ neurons 
and Satb2 plays a transient role in corticospinal differentiation, we only assayed 
Satb2+ layer 5 neurons that were Ctip2- (Leone et al. 2015; McKenna et al. 2015). A 
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significant decrease in the proportion of Satb2+/Ctip2- neurons in layer 5 could be 
detected in motor cortex, but not sensory cortex, in P14 Mek1/2CKO(Nex) mice when 
compared to controls (Figure 9F).  These findings demonstrate that the reduced 
number of Ctip2+ neurons in layer 5 does not coincide with a compensatory increase 
in the proportion of Satb2+/Ctip2-, presumably callosal, layer 5 neurons. 
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Figure 9.  
 
Initiation of layer 5 neuron death by P3 in Mek1/2CKO(Nex) mutants. 
Representative confocal images of immunolabeling for cleaved activated caspase-
3, a well-known marker of neuronal apoptosis in P3 control (A) and 
Mek1/2CKO(Nex) (B) sensorimotor cortices. Note the extensive increase in the 
number of activated caspase-3+ cells co-labeled with Ctip2 in layer 5 of mutant 
cortices (B, yellow arrows) (n=4, scale bar = 50 µm). Quantification of activated 
caspase-3+ cells in upper layers (layer 1-4), layer 5 (Ctip2+) and layer 6 revealed 
a pronounced elevation in the number of apoptotic cells in layer 5 in P3 
Mek1/2CKO (Nex) mice relative to controls (E). The numbers of activated 
caspase-3+ cells are comparable in upper layers and doubled in layer 6 relative to 
controls (E) (n=4, mean ± SEM, * p<0.05). Quantification of the relative number 
of layer 5 Satb2+/Ctip2- neurons as a proportion of the total number of NeuN+ 
neurons in a cortical column revealed a substantial decrease in motor, but not 
sensory, cortices in mutant mice (F) (n=3, mean ±SEM, * p=0.003). Relative to 
controls many microglia (Iba1+) were observed with processes surrounding Ctip2 
labeled neurons in Layer 5 of mutant cortices (C-D) (n=3, scale bar=5 µm). 
E F 
C D 
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Gain-of-function ERK/MAPK signaling reduces CST elongation, but enhances 
branching  
 Many neurodevelopmental syndromes that involve mutations in canonical 
members of the ERK/MAPK cascade exhibit enhanced ERK/MAPK activity (Rauen 
2013). Thus, we assessed effects of hyper-activation of the ERK/MAPK pathway on 
developing cortical excitatory circuits. A Cre-dependent constitutively-active 
Mek1S217/222Q (caMEK1) overexpressing line was crossed with Nex:Cre (caMEK1(Nex)) 
and Emx1:Cre (caMEK1(Emx1)) mice to induce gain-of-function ERK/MAPK signaling 
(Krenz et al. 2008). Immunolabeling for MEK1 confirmed overexpression of the 
caMEK1 allele in the caMEK1(Nex) cortex (Figure 10). In contrast to the loss-of-
function mutants, caMEK1(Nex) mice are viable and able to breed but are reduced in 
weight. Adult male control mice weighed 41.01±1.17g while mutants were 
27.68±0.67g (mean ±SEM, n=14 controls, 11 mutants). CaMEK1(Emx1) are viable and 
grossly normal, but exhibit lethality between 6 and 10 weeks of age.  
 We first asked whether ERK/MAPK hyperactivation led to defects in 
lamination, particularly in layer 5. Ctip2 labeling of mature sensorimotor cortices 
showed no overt defects in the specification or number of layer 5 neurons in 
caMEK1(Nex) mice (Figure 11 A-C). Based on our previous results, we hypothesized 
that hyperactivation of ERK/MAPK would lead to enhanced corticospinal axon growth 
into the spinal cord. In vivo DiI injections of P0.5 motor cortices were performed to 
assess the extent and pattern of layer 5 subcortical axon outgrowth. Innervation of 
the thalamus and medulla appeared normal in P3.5 gain of function mutants (Data 
not shown). Surprisingly, we detected a marked decrease in the initial extension of 
DiI labeled corticospinal afferents into the spinal cord in P3-4 caMEK1(Nex) mutants 
(Figure 12 A-B). Further, genetic labeling of corticospinal projections revealed a 
significantly diminished CST size in the spinal cord dorsal funiculus of both 
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caMEK1(Emx1) and caMEK1(Nex) mutants (Data not shown). These data show that 
enhanced ERK/MAPK signaling results in a decrease in the elongation of corticospinal 
axons into the spinal cord that persists into adulthood. 
We tested whether the final pattern of axonal elongation and arborization was 
altered in caMEK1(Nex) mutants using a Cre-dependent, tdTomato-expressing viral 
vector (AAV5-CAG-FLEX-tdTomato).  Following unilateral injection of AAV into 
primary motor cortex at P1, the extent of axonal labeling was assessed in the white 
matter tract and grey matter in hindbrain (Figure 13, A-F) and spinal cord (Figure 
14, G-J) sections.  To determine the amount of axonal elongation that occurred 
between the hindbrain and the spinal cord, high resolution confocal imaging and 
measurement of axonal RFP labeling in the white matter of the hindbrain 
corticobulbar tract (CBT) (Figure 13, C-D) and cervical spinal cord CST (Figure 14, I-
J) was performed. We then calculated the amount of RFP labeling in the spinal cord 
white matter tract relative to the amount of labeling in the hindbrain white matter 
tract within individual mice to provide a measure of axonal elongation. While control 
mice showed little reduction in the extent of labeling in the spinal cord white matter 
tract relative to the hindbrain, caMEK1(Nex) mutant mice exhibited a significant 
60.14±8.3% reduction in labeling in the spinal cord CST relative to the hindbrain 
(Figure 14, M). These findings provide further support for a substantial and 
persistent decrease in the elongation of corticospinal axons following hyperactivation 
of ERK/MAPK.   
In striking contrast to the decreased axonal elongation into the spinal cord, 
we noted a significant increase in the density of axonal labeling in the hindbrain grey 
matter of caMEK1(Nex) mutants (Figure 13, A-B, E-F). The hindbrain reticular nucleus 
is known to receive input from the primary motor cortex (Esposito et al. 2014). The 
ratio of axonal labeling in the hindbrain grey matter relative to labeling in the 
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hindbrain white matter (CBT) provided quantitative evidence of enhanced axonal 
arborization in the caMEK1(Nex) mutants (Figure 14, N). We also tested whether 
increased arborization could be detected in the spinal cord.  The absolute level of 
axonal labeling density in the spinal cord grey matter was reduced in mutant mice 
(Figure 14, I and K, J and L).  However, a comparison of the ratio of axonal labeling 
in the spinal cord grey matter relative to axonal labeling in the spinal cord white 
matter tract suggests that CST axon arborization is increased per axon (Figure 14, 
N). A similar result was also observed in the spinal cord of showncaMEK1(Emx1) Ai3 
mutants (Data not shown). In sum, our findings show that ERK/MAPK 
hyperactivation reduces the number of axons that extend longitudinally down the 
spinal cord, but the extent of arborizing axonal outgrowth into the hindbrain and 
spinal cord grey matter is enhanced. 
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Figure 10.  
 
 
 
Mouse model for excitatory neuron specific gain-of-ERK/MAPK signaling in 
the cortex. Representative confocal images of forebrain sections from controls (A) 
and caMEK1(Nex) mutants (B) demonstrate that the expression of MEK1 is 
substantially higher in excitatory neurons across all layers of the cortex, but not in 
the striatum (n=4, scale bar = 100 µm). 
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Figure 11.  
 
 
 
No overt defects in the specification or number of layer 5 neurons in 
caMEK1(Nex) mice detected. Representative confocal images of sensory cortices 
show that the expression and distribution of the callosal projection neuron marker, 
Satb2, and subcerebral projection neuron marker, Ctip2, in caMEK1(Nex) forebrains 
(B) appears normal when compared to littermate controls (A) (n=4, scale 
bar=100µm).  The relative proportion of Ctip2+ layer 5 neurons as a percentage of 
NeuN+ neurons within a radial unit did not show a significant difference between 
adult mutant and control motor cortices (C) (n=3, mean ± SEM, p=0.2).  
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Figure 12.  
 
 
 
 
Gain of function ERK/MAPK signaling in caMEK1(Nex) mice decreases 
corticospinal extension into the spinal cord.  In vivo DiI injections into P0 
neonates were performed to label corticospinal axons during initial stages of 
elongation into the spinal cord (D). Analysis of DiI labeling in the spinal cord dorsal 
funiculus at P3 revealed a significant decrease in the extent of axonal elongation in 
mutant spinal cords relative to controls (E) (n=3, mean ± SEM, * p = 0.033, scale 
bar = 100 µm).   
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Figure 13. 
 
 
 
Hyperactivation of ERK/MAPK enhances axonal branching in the hindbrain 
and spinal cord. AAV5-FLEX-tdTomato injections into control (Nex:Cre) and 
caMEK1(Nex) motor cortices at P1 (inset in A-B) results in labeling of subcerebral axon 
projections in P30 hindbrains (A-F). The extent of axonal branching was measured by 
comparing the amount of axonal labeling in the hindbrain (A-B, zoom in E-F), to the 
amount of axonal labeling in the corresponding white matter tract, the CBT (C-D), 
respectively. We observed a significant increase in the relative ratio of grey/white 
matter labeling in caMEK1(Nex) mutant hindbrains (n=4, mean ± SEM, * p < 0.05) 
when compared to controls (Figure 10b, N). 
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Figure 14. 
 
 
 
Hyperactivation of ERK/MAPK enhances axonal branching in the hindbrain 
and spinal cord. AAV5-FLEX-tdTomato injections into control (Nex:Cre) and 
caMEK1(Nex) motor cortices at P1 (inset in Figure 10a, A-B) spinal cords (G-L).  To 
measure axonal elongation from the hindbrain to spinal cord, high resolution confocal 
images of the extent of axonal labeling in sections of the hindbrain corticobulbar 
tract (cbt, C-D) and brachial spinal cord corticospinal tract (cst, I-J) were collected 
and compared. The ratio of corticospinal to corticobulbar tract axonal labeling was 
significantly decreased in caMEK1(Nex) mutants (M), providing further evidence for a 
reduction in corticospinal axon elongation at P30 (n=3, mean ± SEM, * p < 0.01, 
scale bar = 500 µm). 
The extent of axonal branching was measured by comparing the amount of axonal 
labeling in the spinal cord grey matter (zoom in K-L), to the amount of axonal 
labeling in the corresponding white matter tract, CST (I-J). We observed a significant 
increase in the relative ratio of grey/white matter labeling in caMEK1(Nex) mutant 
spinal cords (n=3, mean ± SEM, * p < 0.05) when compared to controls (N). 
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Discussion 
The pathogenesis of neurological deficits in neurodevelopmental syndromes 
associated with altered ERK/MAPK signaling is poorly understood, due to the lack of 
knowledge regarding cell-type specific effects of loss and gain of function through the 
ERK/MAPK pathway. Here, we have identified a striking dependence on levels of 
ERK/MAPK signaling for the development of large Ctip2+ neurons in layer 5. Both 
high and low levels of ERK/MAPK signaling disrupted corticospinal axon projections. 
Interestingly, ERK/MAPK signaling does not appear to be a key regulator of 
projections for all excitatory neuron subtypes as axons of callosally projecting layer 
2/3 neurons extend and target normally in the absence of ERK/MAPK signaling. In 
contrast to the neuronal subtype-specific effects on axonal outgrowth, the expression 
of plasticity associated proteins and neuronal intrinsic excitability were dependent on 
ERK/MAPK signaling in multiple cortical layers.  
 
Specific regulation of layer 5 CST neuron morphology 
In vitro analyses have suggested that ERK/MAPK signaling acts as an 
important regulator of cortical neuron dendritic and axonal morphogenesis 
(Dijkhuizen and Ghosh 2005; Kumar et al. 2005; Wu et al. 2005). However, our in 
vivo data reveal a remarkably specific requirement for the ERK/MAPK pathway in the 
morphological development of layer 5 long range projection neurons.  ERK/MAPK 
signaling is dispensable for the early phases of CST neuronal differentiation, axon 
growth all the way to the medulla, and even responsiveness to midline guidance 
cues.  However, a drastic delay in corticospinal axon growth was observed in Mek1/2 
mutants between P2-4 when CST axons in control mice start to invade the spinal 
cord. By P14 in controls, CST axons have reached the lumbar spinal cord. In P14 
mutant mice, only a few corticospinal axons were present in the cervical spinal cord 
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and no axons reached lumbar segments.  
Trophic cues linked to ERK/MAPK activation, specifically, BDNF, IGF1, IGF2, 
GDNF, and pleiotrophin, have been shown to regulate developing corticospinal 
neuron growth (Giehl et al. 1998; Ozdinler and Macklis 2006; Dugas et al. 2008; 
Ueno et al. 2013). IGF1 has been described as a particularly potent growth factor for 
CST development both in vitro and in vivo (Ozdinler and Macklis 2006).  IGF1 protein 
levels are higher in the spinal cord than the brain in the early postnatal stage 
(Rotwein et al. 1988) and we identified a focal pattern of IGF1 protein expression in 
the ventral medulla near the location where developing corticospinal axons enter the 
cervical spinal cord. However, we quite surprisingly found that deletion of IGF1R in 
long-range projection neurons did not lead to the predicted failure of CST 
development. Our results suggest that CST axon growth in the spinal cord may be 
orchestrated by multiple growth factors or via non-neuronal actions of IGF1. For 
example, vascular endothelial cells also express IGF1R and endothelial cell-derived 
trophic cues are potent regulators of corticospinal neuron survival and outgrowth in 
vitro (Dugas et al. 2008). Overall our data support the view that multiple cues 
converge upon ERK/MAPK to regulate transcriptional and cell biological processes 
required for extension of long axons. 
Following the delayed entry of axons into the spinal cord in Mek1/2 mutants, 
we detected layer 5 neurons undergoing apoptosis in a restricted time frame during 
the first postnatal week.  Counts revealed loss of roughly half of the Ctip2-expressing 
layer 5 neurons, which reflects a substantial proportion of the CST population. The 
reduced number of CST neurons in ERK/MAPK mutants is reminiscent of the loss of 
CST neurons after lesions to developing corticospinal projections in the neonatal 
period (Tolbert and Der 1987; Merline and Kalil 1990).  Loss of trophic support from 
the spinal cord could plausibly account for these findings; an effect that might be 
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exacerbated by known consequences of ERK/MAPK disruption on retrograde 
transport of growth factor signaling components including signaling endosomes 
(Mitchell et al. 2012). We cannot completely exclude that the reduced number of 
Ctip2+ neurons in layer 5 results, in part, from conversion into an alternative 
neuronal type.  For example, loss of Fezf2 results in conversion of corticospinal 
neurons into a callosal fate (B. Chen et al. 2005; J.-G. Chen et al. 2005; Molyneaux 
et al. 2007). Our assessment of Satb2+/Ctip2- layer 5 neurons did not reveal a 
coincident increase in the number of presumed callosally fated layer 5 neurons in 
Mek1/2CKO(Nex) mice. Interestingly we did not find similar layer 5 apoptosis occurring 
in conditional IGF1R mutants, placing our results at odds with a recent study 
suggesting that microglia-derived IGF1 is required for the survival of layer 5 long 
range projection neurons (Ueno et al. 2013). Whatever the mechanism, our data 
show that layer 5 corticospinal neurons are remarkably vulnerable to loss of 
ERK/MAPK signaling during the neonatal period and our results may be relevant to 
motor system dysfunction in RASopathy patients and layer 5 disorganization 
observed in ASDs. 
Perhaps surprisingly, rostro caudal corticospinal axon extension was also 
highly diminished in the setting of enhanced ERK/MAPK signaling. At every stage 
examined from P3 onward, the number of CST axons in the dorsal funiculus in 
response to gain of ERK/MAPK signaling was reduced. A distinct feature of axon 
growth in gain of function mutants was enhanced axonal branching in the hindbrain. 
Normally, over the first two postnatal weeks, ERK/MAPK activation is upregulated, 
coincident with increased BDNF/TrkB expression (Maisonpierre et al. 1990; Timmusk 
et al. 1994). BDNF/TrkB signaling has been shown to promote corticospinal axon 
branching in vitro (Ozdinler and Macklis 2006). We suggest that hyperactivation of 
ERK/MAPK triggers mechanisms normally associated with BDNF induced corticospinal 
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branching, possibly resulting in premature closure of the period of rostro caudal axon 
elongation. Reduced axon extension of layer 5 projection neurons in the setting 
ERK/MAPK hyperactivation would likely have major implications for cortical circuit 
development in the human brain where distances are vastly longer than in rodents.  
 
Global regulation of neuronal excitability 
In addition to effects on axonal connectivity, dysregulated ERK/MAPK 
signaling is likely to disrupt glutamatergic signaling  (Di Cristo et al. 2001; Thomas 
and Huganir 2004). Studies have demonstrated that mature RASopathy mouse 
models exhibit reduced hippocampal LTP and spatial memory impairment (Costa et 
al. 2002; Cui et al. 2008; Lee et al. 2014).  Our findings provide genetic confirmation 
for prior work using pharmacological inhibitors demonstrating ERK/MAPK regulation 
of plasticity-associated genes induced by excitatory activity, including Arc, Egr2, and 
Fos (Waltereit et al. 2001; Majdan and Shatz 2006; Tropea et al. 2006; Panja et al. 
2009). Further, we establish a link between ERK/MAPK and expression of Npas4, 
Nrn1/Cpg16, and Nptx2/Narp in vivo (Coba et al. 2008). Unexpectedly, hyper-
activation of ERK/MAPK signaling with the caMEK1S217/221Q mutation had little effect 
on the expression of these same plasticity associated genes. These findings are  in 
line with a past study of hippocampal gene expression in a different caMEK1 mouse 
mutant (Nateri et al. 2007). The severity of effects on expression of plasticity 
associated genes is likely correlated with the magnitude of ERK/MAPK hypo- or 
hyper-activity in response to specific mutations. 
Since ERK/MAPK dependent changes in plasticity associated gene expression 
were widespread, we asked whether ERK/MAPK has general or layer-specific effects 
on developing projection neuron excitability and synaptic transmission. Our work 
demonstrates that complete loss of ERK/MAPK signaling leads to increased intrinsic 
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excitability of both layer 2/3 and layer 5 pyramidal neurons. Further, we show that 
Mek1/2 deleted layer 2/3 neurons exhibited increased excitatory synaptic strength. 
We conclude that ERK/MAPK signaling contributes to excitatory/inhibitory balance 
during the early postnatal period by reducing the excitability of cortical excitatory 
neurons. Changes in excitatory drive in a subset of layer 2/3 neurons have been 
shown to trigger a compensatory homeostatic increase in inhibitory drive, thus 
maintaining a stable synaptic excitatory/inhibitory ratio (Xue et al. 2014). 
Remarkably, layer 2/3 pyramidal neurons lacking Mek1/2 exhibit reduced inhibitory 
synaptic input in the absence of a fully compensatory change in excitation.  Loss of 
ERK/MAPK activity in cortical pyramidal neurons may disrupt the homeostatic 
balance between synaptic excitation and inhibition, a mechanism hypothesized to 
form the neurological basis of autism (Rubenstein and Merzenich 2003). ERK/MAPK 
may also regulate the release of BDNF from excitatory neurons, a well-known 
regulator of inhibitory synapse formation (Huang et al. 1999; Kohara et al. 2007; 
Porcher et al. 2011). 
During postnatal cortical pyramidal neuron development, input resistance 
decreases and the frequency of GABAergic and amplitude of glutamatergic 
spontaneous neurotransmission increase (Desai et al. 2002; Morales et al. 2002). 
Our findings are consistent with pyramidal neurons lacking Mek1/2 failing to undergo 
these developmental alterations and further suggest that loss of ERK/MAPK signaling 
may arrest normal physiological development. Importantly, the alterations in action 
potential threshold in neurons lacking Mek1/2 may secondarily result from increased 
sodium channel density due to the smaller neuronal size or the observed increase in 
membrane resistance, which may also influence quantal amplitude measurements. 
Our observations that disruption of ERK/MAPK signaling alters excitatory/inhibitory 
balance and the expression of select plasticity associated genes, coupled with known 
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effects on Hebbian forms of synaptic plasticity (Thomas and Huganir 2004), suggest 
that alterations in ERK/MAPK signaling are likely to dramatically disrupt network 
activity and cortical re-wiring.  
 
Circuit abnormalities in RASopathies 
Hypotonia, muscle weakness, and delay in motor milestones are often observed in 
RASopathy patients (Dileone et al. 2010; Mejias et al. 2011; Tidyman et al. 2011; 
Oberman et al. 2012; Stevenson et al. 2012). Although some of these symptoms 
may be due to alterations in muscle development, we have shown here that upper 
motor neuron and corticospinal tract development are especially sensitive to both 
gain and loss of ERK/MAPK activity. Thus, deficits in motor function or motor learning 
in Ras/MAPK Syndromes may be explained, in part, by altered corticospinal 
connectivity. Importantly, our data point to distinct effects in gain vs loss of function 
mutants. Our results therefore argue for a mutation-specific approach to correct 
neurological dysfunction within the RASopathy spectrum. Aberrant long-range circuit 
development has also been proposed as a defining feature of ASD pathogenesis and 
that layer 5 may be a focal point (Stoner et al. 2014; Willsey et al. 2013). An 
interesting possibility is that altered activation of ERK/MAPK at early developmental 
stages in response to certain ASD linked mutations (Fmr1, Mecp2, Tsc1/2) and 
environmental insults (hypoxia, inflammation, etc.) might contribute to select cortical 
circuit abnormalities, especially for neurons projecting over long distances. 
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CHAPTER 3 
LONG-RANGE AXONAL DEVELOPMENT IN A GAIN-OF-FUNCTION  
CAMEK MOUSE MODEL 
 
 
 
 
Hyperactivation of MEK1 in cortical glutamatergic neurons results  
in projection axon deficits and aberrant motor  
learning in a layer autonomous manner 
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Abstract         
Germline mutations within the components of the RAS-RAF-MEK-ERK 
(RAS/MAPK) pathway form a group of neurodevelopmental disorders collectively 
known as RASopathies. A large portion of these mutations result in an upregulation 
of signaling. Here, we used cre-loxp technologies to hyperactivate the RAS/MAPK 
pathway in cortical glutamatergic neurons to determine developmental effects on 
long-range axonal projections by inserting a constitutively active MEK1 construct. In 
hyperactive mutants, cortical glutamatergic neurons displayed an increased level of 
activated ERK1/2 in axons, but a surprising reduction in the cell body. The 
expression of RAS/MAPK substrates in the soma important for plasticity, such as 
ARC, were also reduced in the neurons. We further identified significant deficits in 
corticocortical and corticostriatal axonal innervation and branching and a significant 
reduction of corticospinal tract elongation. In addition to the connectivity issues, 
hyperactivation of RAS/MAPK signaling also led to motor learning acquisition deficits 
in an accelerating rotarod test and a fine reaching and grasping task. These data 
suggest that the pathogenesis of cognitive deficits in RASopathies involves changes 
in the development of neuronal connectivity and the expression of plasticity 
associated genes at an early stage of cortical formation and subsequent 
developmental stages. 
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Introduction 
The RAS-RAF-MEK-ERK (RAS/MAPK) signaling pathway plays a crucial role in 
the development and maintenance of the central nervous system. Extracellular cues 
in the form of neurotrophins are transmitted through the pathway to activate a 
variety of transcription factors and influence cellular processes in the cytoplasm 
(Mebratu and Tesfaigzi 2009). Several cellular processes that rely on the RAS/MAPK 
pathway include; cellular proliferation and differentiation, cell growth and survival, 
axon growth and pathfinding, neurite arborization, and dendritic spine formation 
(Jeanneteau et al., 2010; Kalil and Dent, 2014; Mebratu and Tesfaigzi, 2009; 
Nowaczyk et al., 2013; Polleux and Snider, 2010). Additionally, RAS/MAPK signaling 
in the mature brain is essential for activity-dependent plasticity and associative 
learning and consolidation (Atkins et al., 1998; Thomas and Huganir, 2004; Gómez-
Palacio-Schjetnan and Escobar, 2013). 
Several germline mutations found in the RAS/MAPK signaling pathway are the 
source of many well-defined genetic syndromes collectively referred to as 
RASopathies (Rauen, 2012). Many of these syndromes such as Noonan Syndrome 
(NS), Legius Syndrome (formally known as NF1-like syndrome), Costello Syndrome 
(CS), Neurofibramatosis type 1 (NF1), Capillary Malformation-Arteriovenous 
Malformation (CM_AVM), and Cardio-facio-cutaneous (CFC), result in hyperactivity of 
the RAS/MAPK signaling pathway (Rauen, 2012). Mutations that lead to 
downregulation of the RAS/MAPK pathway include subsets of Noonan Syndrome with 
Multiple Lentigines (formerly referred to as LEOPARD syndrome) (NSML), and CFC 
syndrome (Nowaczyck et al., 2013; Rauen, 2012). While some of these syndromes 
such as CS and CFC are quite rare, up to 1:810,000 and 1:380,000 respectively 
(Allanson and Roberts, 1993; Gripp and Lin, 2012), others, such as NS and NF1, are 
more prevalent and affect ~1:1000 - 1:2500 and ~1:2500 - 1:3000 individuals 
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worldwide respectively (Rauen, 2012; Williams et al., 2009). Specific genetic 
mutations in the individual components of the signaling pathway are found in          
upstream elements of MAPK3/MAPK1 (ERK1/2) (Rauen, 2012). Additional monogenic 
neurodevelopmental disorders that ultimately lead to activation of MAPK signaling 
includes Fragile X syndrome, Tuberous Sclerosis and 16p11.2 deletion syndrome 
(Subramanian et al., 2015). The result of these syndromic genetic mutations are 
several neurodevelopmental disorders that include macrocephaly, 
neurodevelopmental and intellectual disabilities, neurocognitive impairment and 
delay, motor delay, seizures, learning disabilities and an increasing association with 
Autism spectrum disorders (ASD) (Axelrad et al., 2011; Jozwiak et al., 2008; Rauen, 
2012; Subramanian et al., 2015).  
Current evidence indicates widespread abnormal structural changes in the 
white matter tracts of NF1 patients. Diffusion tensor imaging (DTI) studies in 
children with NF1, have detected these abnormal structural changes in the corpus 
callosum and in the brains microstructures (S L Zamboni et al. 2007; Filippi, Watts, 
Lindsay A.N. Duy, et al. 2013; Aydin et al. 2016). DTI analysis of select brain regions 
in mature NF1 patients, indicate basic and diffuse changes in cerebral microstructure 
in the caudate and lentiform nuclei, thalamus, pons, frontal and parietooccipital 
white matter, and the corpus callosum (S L Zamboni et al. 2007). Functional 
magnetic resonance imaging (fMRI) and functional connectivity magnetic resonance 
imaging (fcMRI) studies in subjects with NF1 indicated altered neural activity and 
network connectivity (Tomson et al. 2015b; Amira F.A. Ibrahim et al. 2017). DTI 
analysis in mouse models of NF1, revealed significant differences in three main 
structures of interest, prefrontal cortex, caudate putamen, and the hippocampus. 
Additionally, widespread cortical and subcortical changes in white matter diffusivity 
patterns with no major disruption or disorganization of axons is also reported in the 
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DTI study of this mouse model (Fame et al. 2011). These imaging techniques have 
provided a wide view of global differences in major white and gray matter areas. 
However, very little is known of the specific effects of RAS/MAPK signaling 
misregulation on system wide connectivity and long-range axonal circuit formation 
during and after development. Furthermore, DTI imaging gives a broad view of 
structural anomalies in relation to white matter tracts (oligodendrocytes/myelination) 
but does not directly address any underlying axonal contribution to these anomalies. 
This is especially true of cell and circuit specific effects during and after development. 
Previously, we reported a critical requirement for RAS/MAPK signaling in loss- 
and gain-of-function as it applies specifically to cortical pyramidal neurons (Xing et 
al., 2016). Deletion of Map2k1/2 (Mek1/2) in cortical glutamatergic neurons resulted 
in the absence of large CTIP2+ neurons in cortical layer 5 and the impairment of 
corticospinal tract (CST) axonal extension in the dorsal funiculus of the cervical and 
lumbar spinal cord (Xing et al., 2016). Up-regulation of ERK/MAPK signaling in 
cortical glutamatergic neurons also decreased CST axonal elongation but markedly 
increased axonal branching in the gray matter of the spinal cord and the gray matter 
of the hind brain (Xing et al., 2016). Nonetheless, further research is needed to 
assess aberrant RAS/MAPK signaling on cortical glutamatergic neuronal projections in 
the forebrain and sub-cortical projections, cortical layer specific effects, activated 
ERK1/2 levels and localization patterns, or behavior and learning phenotypes.  
To address these issues, we created mouse models with a constitutively 
active Mek1 (caMek1) gene construct driven by CRE to hyperactivate MEK1 in 
cortical glutamatergic neurons. Our connectivity and innervation analysis focused on 
all cortical layers of the primary motor cortex to address the learning disabilities 
associated with motor function and motor delay. Furthermore, we were able to 
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analyze subcortical projections to lower motor and CST extension that could further 
lead to the neurodevelopmental phenotypes seen in human RASopathy patients. 
We first analyzed the developmental and mature levels of activated ERK1/2 
(P-ERK1/2) and localization pattern. MEK1 hyperactivation led to a succinct 
localization of P-ERK1/2 in the axonal projections of post-mitotic glutamatergic 
neurons in embryonic tissue that persisted in adult mice. Analysis of contralateral 
cortical projections and cortico-striatal projections revealed a significant decrease in 
axonal innervation and branching. Behavioral testing in the open-field, rotarod, and 
reaching and grasping task revealed no overt motor control deficiencies but did show 
a significant impairment in motor control learning. Analysis of activity dependent 
gene expression showed a surprisingly low level of expression of gene products that 
are highly dependent on the activation the RAS/MAPK pathway. The use of these 
conditional genetic tools allowed the analysis of cell specific effects and contributions 
to the pathologies reported in RASopathy patients. 
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Materials and Methods 
Transgenic Mice 
All animal experiments were performed in accordance with established 
procedures approved by the Institutional Animal Care and Use Committee of Arizona 
State University and NIH guidelines for the use and care of laboratory animals. Mice 
used in this work were of a mixed genetic background and housed in standard 
conditions. The mice were kept on a 12-hour light/dark cycle with food and water 
provided ad libitum. Each experiment was replicated a minimum of three times using 
littermates or mice from independent litters. No detectable effects on the phenotypes 
described in this manuscript were observed from Cre expression alone. Therefore, 
Cre-expressing or Cre-negative mice were used as controls. Map2k1s217/222 mice were 
furnished by Dr. Maike Krenz and Dr. Jeffrey Robbins (Krenz et al., 2008). NeuroD6-
Cre mice were provided by Dr. Klaus Nave and Dr. Sandra Goebbels (Goebbels et al., 
2006). Rbp4:Cre mice were purchased from the Mutant Mouse Resource & Research 
Centers (RRID:MMRRC_036400-UCD).  
 
Tissue Preparation 
Transcardial perfusions were performed on mice using a 4% 
paraformaldehyde/PBS solution with dissected brains being post-fixed in the same 
solution overnight at 4°C. Dissected brains were then serially incubated in 15% and 
30% sucrose/PBS solutions prior to embedding in Tissue-Tek O.C.T. (Tissue-Tek 
4583) and freezing. Cryostat sectioning was performed with sections being collected 
on Fisherbrand Superfrost/Plus slides (Fisher Scientific 12-550-15) and air-dried 
prior to staining. Alternatively, cryostat sections were collected in well plates with 
cold PBS for free-floating staining as appropriate. For some experiments, brains were 
mounted in agarose after post-fixation in preparation for vibratome sectioning. 
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 Viral Injections 
P1 pups were removed from their home cage as a group and were individually 
cryo-anesthetized on ice for 4-6 minutes. Viral injections were then performed 
immediately with 50-80nl of solution using a 32-gauge beveled needle fitted to a 
Hamilton 5µl neuros syringe mounted on a stereotaxic arm. After injections, pups 
were placed on a 37°C heated surface for recovery and returned to their home cage 
as a group. Adeno Associated Viral vectors, RAAV9/AAV-Flex-tdTomato and 
RAAV8/CAG-Flex-tdTomato were purchased from the UNC Viral Vector Core and used 
for all viral tracing experiments. 
 
Behavioral Assays 
A single-pellet reaching and grasping task test was performed using both 
male and female Nex:Cre/caMek1 mice and male RBP4:Cre/caMek1 mice. Mice were 
mildly food restricted throughout training to maintain at least 90% of their baseline 
weight which amounted to free feeding between 2 and 6 hours daily. Sucrose pellets 
(TestDiet 1811555) were used for this test and the mice were acclimated to the 
pellets in their home cages. After pellet acclimation, mice were then placed in the 
testing chamber, an acrylic chamber 15cm X 10cm X 20cm, with pellets either singly 
or in pairs depending on their housing for further acclimation. After acclimation, 
forelimb dominance was determined by placing a single pellet on the food platform 
(10cm high) outside a single slit (5cm wide) in one end of the test chamber. Once a 
mouse has conducted at least 20 reaching attempts within 20 mins with at least 70% 
of those reaches made with one hand, that mouse was moved on to testing. Testing 
consisted of placing a single pellet on the food platform in front of the slit, right or 
left, corresponding with the preferred paw. Testing was performed for 10 minutes 
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daily for 5 days. Scoring was performed as follows; Success: if the mouse reached 
with its preferred paw, retrieved the pellet, and fed the pellet into its mouth. Drop: If 
the mouse grasped the pellet but drops it before reaching its mouth. Fail: If the 
mouse reached for the pellet but failed to grasp it or knocked it out of position. Mice 
were scored on the rate (metric/attempts) for each of these metrics. 
Open field testing was performed in an open top opaque plexiglass box 
measuring 38cm X 38cm X 30cm. The area within the box is illuminated by a single 
40-watt spotlight approximately 2 meters overhead and centered within the area. 
Recording of mouse movements is done using a Microsoft LifeCam or Logitech HD 
Webcam and VirtualDub video capture software. Open field quantitation was 
performed using the MouseMove (Samson et al. 2015) plugin for ImageJ (Schindelin 
et al. 2012). 
Rotarod analysis for the NexCre/caMek1 mice was performed on a Ugo Basile 
(Stoelting Co.) accelerating rotarod. Animals were given three trials in the first test 
session, with 45 seconds between each trial. Two additional trials (Test 2) were 
given 48 hours later. RPMs (revolutions per minute) increased from 3 to 30 RPMS 
over the 5-minute trial period. Measures were taken for latency to fall from the top 
of the rotating barrel. Nine to ten weeks following the first two tests, a subset of 
mice were given an additional two trials (Test 3). In the last test (Test 4), mice were 
given 2 trials using a reversed-rotation procedure, in which the direction of the barrel 
rotation was periodically altered. 
In the elevated plus maze task, mice were given one five-minute trial on the 
plus maze which had two walled arms (the closed arms, 20 cm in height) and two 
open arms. The maze was elevated 50 cm from the floor, and the arms were 30 cm 
long. Animals were placed on the center section (8 cm x 8 cm) and allowed to freely 
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explore the maze. Measures were taken of time on, and number of entries into, the 
open arms of the maze. 
The Morris water maze task consisted of a large circular pool (diameter = 122 
cm) partially filled with water (45 cm deep, 24-26°C), located in a room with 
numerous visual cues. The procedure involved three different phases: a visual cue 
test with a visible platform, acquisition in the hidden platform task, and a test for 
reversal learning. Only mice that performed well in the visual cue test were further 
evaluated in the acquisition and reversal tests. Three to four days following the 
visible platform task, mice were tested for their ability to find a submerged, hidden 
escape platform (diameter = 12 cm). Each animal was given 4 trials per day, with 1 
minute per trial, to swim to the hidden platform. Mice were tested until the group 
reached learning criterion, with a maximum of 9 days of testing. When criterion was 
reached, mice were given a one-minute probe trial in the pool with the platform 
removed. Selective quadrant search was evaluated by measuring the percent of time 
spent in the target (platform quadrant) and opposite quadrants. Following the 
acquisition phase, mice were tested for reversal learning, using the same procedure 
as described above except the hidden platform was re-located to the opposite 
quadrant in the pool. As before, measures were taken of swim distance to find the 
platform. Once the criterion for learning was met, the platform was removed from 
the pool, and the group was given a probe trial to evaluate reversal learning as 
previously described. 
 
Immunohistochemistry 
Tissue sections were rinsed with PBS/0.1% Triton X-100 (PBST) and blocked with 
5% normal donkey serum in PBST at room temperature for ~1 hour. Primary 
antibodies were diluted in PBST/5%NDS and incubated overnight at 4°C with gentle 
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shaking. Primary antibodies used were; rabbit anti-MEK1 (Abcam ab32091), rabbit 
anti-phosph-p44/42 MAPK (ERK1/2) (Thr202/Tyr204) (Cell Signalling 4370), rabbit 
anti-ERK2 (Abcam ab32081), rabbit anti-ARC (Synaptic Systems 156 003), mouse 
anti-β 3 Tubulin (TUBB3) (Bioloegend 801202), rabbit anti-RFP (Rockland 600-901-
379), chicken anti-RFP (Rockland 600-401-379), mouse anti-neun (Millipore Sigma 
MAB377), and DAPI (Sigma Aldrich 10236276001). After rinsing in PBST 3X, 
secondary antibodies diluted in PBST/5%NDS were added and incubated overnight at 
4°C with gentle shaking. Secondary antibodies included Alexa Fluor 488, 546 or 568, 
and 647 conjugated anti-rabbit, anti-mouse, or anti-goat IgG (Invitrogen). Imaging 
was performed using a Zeiss LSM 800 laser scanning confocal microscope (LSCM), or 
a Leica SP5 LSCM.  
 
Western Blotting 
Cortices were collected from mutant and control mice and lysed in a buffer 
containing 50mM Tris-CL, 150mM NaCl, 0.1%triton x-100, Protease Inhibitor 
(Sigma-Aldrich P2714), and Phosphatase Inhibitor (Sigma-Aldrich P5726) either by 
sonication or with a syringe. Lysates were then cleared by centrifugation and total 
soluble protein concentrations determined by Bradford Assay using a Peirce Protein 
Assay Kit (Thermo Scientific 23200). Proteins were denatured in equal amounts of 
2X Laemmli sample buffer (BioRad 161-0737), separated by SDS-PAGE using either 
10% or 4-20% Mini-PROTEAN TGX precast gels (BioRad 456-1035 and 456-8095), 
then transferred to PVDF membranes (BioRad 162-0177). Membranes were blocked 
with 5% non-fat dry milk (NFDM) in TBS with 0.5% Tween (TBST) for 1 hour at room 
temperature followed by overnight incubation at 4°C with primary antibodies in 5% 
bovine serum albumin. Primary antibodies used were; rabbit anti-MEK1 (Abcam 
ab32091), rabbit anti-phosph-p44/42 MAPK (ERK1/2) (Thr202/Tyr204) (Cell 
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Signalling 4370), rabbit anti-ERK2 (Abcam ab32081), rabbit anti-ARC (Synaptic 
Systems 156 003), rabbit anti-GAPDH (Cell Signalling 2118), goat anti β-Actin (Cell 
Signaling 8457), and rabbit anti-β actin (Cell Signalling 8457). Secondary antibodies 
used were anti-rabbit HRP and anti-goat HRP (Jackson Immunoresearch 711-035-
152 and 705-035-147). Membranes were then washed in TBST and incubated with 
HRP-conjugated secondary antibodies in 5% NFDM/PBST for 1 hour at room 
temperature. Membranes were washed in TBST, developed with Pierce ECL Western 
Blotting Substrate (Thermo Scientific 32106), and exposed to radiographic film 
(Thermo Scientific 34089). 
 Quantification of Western Blots was performed using a high-resolution 
scanned image of the exposed radiographic film in a grayscale TIFF file format. The 
file was then transferred to Imagej were a region of interest was created to 
encompass individual bands for all mutant, control and loading control samples. The 
mean gray value of each band was then recorded along with a background 
measurement for each band. All values were inverted (subtracted from 255) and the 
background values were subtracted from the band values. The net band values were 
then reported as a ratio of net band value over net loading control value.  
 
Image Analysis and Quantitation 
For quantitation of axonal innervation and branching in the cortex and 
striatum, a radial section of the cortex encompassing all layers within the primary 
motor cortex was used. A minimum of 4 sections from each mutant and control 
animal centered about the rostral-caudal area of the injection site was analyzed. The 
area in µm2 of this region was measured in Photoshop and the image was then 
transferred to Imagej. Once in Imagej, pixel intensities were adjusted using the Otsu 
Auto Threshold component, total pixels counted, and multiplied by the images pixel 
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size to obtain the total µm2 of pixels in the ROI. The total µm2 was then divided by 
the number of transfected cells that were manually counted in an identical ROI in the 
ipsilateral (RFP injected) cortical hemisphere to obtain the axonal labeling per 
transduced cell. Spinal cord arborization was measured in the same manner except 
the µm2 of pixels was normalized to the CST to obtain a spinal cord arborization 
ratio. 
The CBT was measured using at least three anatomically matched hind brain 
sections from each mutant and control animal. The CBT was outlined using the 
difference of appearance in NEUN or DAPI and the image was transferred to Imagej. 
A pixel intensity threshold was manually set by an observer blinded to the genotype. 
The number of labeled pixels was then measured and multiplied by the images pixel 
size to obtain the µm2 of pixels in the CBT. The µm2 of pixels was then normalized to 
the number of transfected cells in the injection site ROI to obtain the CBT axonal 
labeling per transduced cell. The CST in the dorsal funiculus was measured in the 
same manner except the µm2 of pixels was normalized to the CBT to obtain the CST 
elongation ratio. 
Representative images have been cropped and adjusted for brightness and 
contrast in Photoshop for presentation. All images used for comparison analysis 
where collected using the same microscope settings and all adjustments made were 
done equally between images. 
 
Statistical Analysis 
Data analysis was performed using SPSS software (IBM Analytics). Statistical 
methods used included Student’s t-test (unpaired, two-tailed), ANOVA, repeated 
measures ANOVA, and multivariate ANOVA. F-test results, p-values, and tests used 
are reported where appropriate.  
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 Results 
MEK1 hyperactivation results in increased levels of P-ERK in the axons of cortical 
excitatory neurons 
To evaluate the effects of up-regulation of the RAS/MAPK pathway in cortical 
excitatory neurons and long-range axonal projections, we generated an ERK/MAPK 
gain-of-function mouse by crossing a Map2k1S217/222 (caMek1)(Krenz et al., 2008) 
mouse with a NeuroD6-Cre (NexCre) (Goebbels et al., 2006) mouse. The resulting 
mouse line, NexCre/caMek1, is designed to express a constitutively active MEK1 
construct primarily in cortical glutamatergic neurons. Nex promoter activity is 
detected as early as E11.5 in the telencephalon with prominent levels of CRE 
recombinase being produced at around E13.5 (Goebbels et al., 2006). Western Blot 
analysis of cortical lysates from E 14.5 NexCre/caMek1 embryos confirmed highly 
elevated levels of MEK1 with a fold change of +14.99 ± 2.00 when compared to 
controls (Mean ± SEM, GAPDH normalized, p=0.002, n=5, Student’s t-test) (Figure 
15A). Immunohistochemical (IHC) analysis of MEK1 expression in cortical samples of 
E14.5 embryos confirmed a robust level of MEK1 in cortical glutamatergic neurons in 
the cortical plate and axonal processes in the intermediate zone (Figures 16A-F) 
(n=5).  
Having verified a strong presence of MEK1 in E14.5 embryos, we next 
examined the NexCre/caMek1 embryos at E14.5 for activated ERK1/2 (P-ERK1/2). At 
this time-point in development, layer VI corticothalamic projection neurons (CThPN) 
and layer V subcerebral projection neurons (SCPN) will have been generated in the 
cortex along with a portion of layer II/III callosal projection neurons (Greig et al., 
2013). Western Blot analysis confirmed significantly elevated levels of P-ERK1/2 with 
a fold change of +1.47 ± 0.20 over controls (Mean ± SEM, ERK2 normalized, 
p=0.043, n=5, Student’s t-test) (Figures 15C-D). ERK2 Western Blotting showed no 
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significant difference between the NexCre/caMek1 and control mice (controls = 1.00 
± 0.00 SEM, mutants = 1.06 ± 0.05 SEM, p=0.245, n=5) (Figure 15C). 
Histochemical analysis revealed a pattern of P-ERK1/2 localized to the intermediate 
zone, a region in the embryonic cortex that contains the axonal processes of cortical 
glutamatergic neurons (n=5) (Figures 15E-L). 
Adult NexCre/caMek1 cortical lysate Western Blotting revealed a significant 
fold change of +1.61 ± 0.20 of MEK1 detection over controls (Mean ± SEM, GAPDH 
normalized, p=0.041, n=3, Student’s t-test) (Figures 17A-B). IHC analysis confirmed 
the specificity and increased levels of MEK1 expression in NexCre/caMek1 cortical 
glutamatergic neurons (Figures 17E-H) (n=3). No significant difference was found in 
P-ERK1/2 levels between adult NexCre/caMek1 and control mice (controls = 1.00 ± 
0.00 SEM, mutants = 0.95 ± 0.21 SEM, p=0.832, n=3, Student’s t-test) when 
normalized to ERK2 levels (controls = 1.00 ± 0.00 SEM, mutants = 1.07 ± 0.08 
SEM, β-actin normalized, p=0.389, n=3, Student’s t-test) (Figures 17C-D). IHC 
analysis of the adult NexCre/caMek1 however revealed distinctly lower levels of P-
ERK1/2 in the neuronal cell bodies through all layers of the cortex when compared to 
controls (n=3) (Figures 17I-L and 18Q, R). Importantly, white matter tracts in the 
adults showed the same P-ERK1/2 localization that was seen in the E14.5 samples 
(n=3) (Figures 17I-L and 2b, M-P). High resolution confocal imaging of white matter 
tracts showed a pattern of P-ERK1/2 co-localizing with the neuron specific class III β-
tubulin, TUJ1 (n=3) (Figures 18M-P).  
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Additional white matter tracts that showed comparable localization of P-ERK1/2 
included the anterior commissure and hippocampal commissure tracts, and the 
cerebral peduncle and corticospinal tracts in the midbrain (n=3) (Figure 19A-D and 
20E-H). These data indicate that hyperactivation of MEK1 in cortical glutamatergic 
neurons results in a significant change in the compartmental localization of P-ERK1/2 
that is evident in both embryonic and adult mice. 
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Figure 15.  
 
 
 
 
MEK1 hyperactivation results in increased levels of P-ERK1/2 in the axons 
of cortical excitatory neurons. Western Blot analysis of E14.5 cortical lysates 
showed a MEK1 fold increase in the NexCre/caMek1 mice when compared to controls 
of +14.99 ± 2.00 (Mean ± SEM, GAPDH normalized, p=0.002, n=5, Student’s t-test) 
(A-B). P-ERK1/2 levels in the E14.5 cortical lysates revealed a MEK1 fold change in 
the NexCre/caMek1 mice when compared to controls of +1.47 ± 0.20 (Mean ± SEM, 
p=0.043, n=5, Student’s t-test). No significant change in protein expression levels of 
ERK2 was detected (controls = 1.00 ± 0.00 SEM, mutants = 1.06 ± 0.05 SEM, 
p=0.245, n=5, Student’s t-test) (C-D). Immunohistochemical (IHC) analysis of E14.5 
NexCre/caMek1 cortical samples (G-L, H,L yellow arrows) exhibits a P-ERK1/2 
localization in the region of the embryonic cortex that contains axonal projections of 
cortical glutamatergic neurons that was not detected in control mice (E-K) (IZ = 
Intermediate zone, VZ = ventricular zone, n=5, scale bars: 1E through 1H = 200µm, 
1I through 1L = 50µm).  
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Figure 16.  
 
 
 
 
Enhanced MEK1 expression is detected in the somatosensory cortex of 
embryonic NexCre/caMek1 mice. Immunostaining of E14.5 somatosensory cortex 
reveals a substantial up-regulation of MEK1 expression in the intermediate zone 
(white matter tracts) and the cortical plate (glutamatergic neuronal bodies) of the 
NexCre/caMek1 (D-F) when compared to controls (A-C) (IZ = Intermediate zone, VZ 
= ventricular zone, cp = cortical plate, n=5, scale bars: A, D = 200 µm, B,C,E,F = 
50µm).  
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Figure 17. 
 
 
Increased levels of P-ERK1/2 in the axons and reduced somal detection of 
P-ERK1/2 persists in adult NexCre/caMek1 mice. Western Blots of adult cortical 
lysates revealed a MEK1 fold increase in the NexCre/caMek1 when compared to 
control mice of +1.61 ± 0.20 (Mean ± SEM, GAPDH normalized, p=0.041, n=3, 
Student’s t-test) (A-B). No significant differences in P-ERK1/2 expression levels 
between the NexCre/caMek1 and control mice were detected (controls = 1.00 ± 0.00 
SEM, mutants = 0.95 ± 0.21 SEM, p=0.832, n=3, Student’s t-test) when normalized 
to ERK2 levels (controls = 1.00 ± 0.00 SEM, mutants = 1.07 ± 0.08 SEM, β-actin 
normalized, p=0.389, n=3, Student’s t-test) (C-D). IHC analysis of MEK1 shows the 
increased expression in the targeted cortical glutamatergic neurons of the 
NexCre/caMek1 mice (G-H) when compared to controls (E-F) (M1 = primary motor 
cortex, cc = corpus callosum, st = striatum, n=3, scale bars = 500µm). P-ERK1/2 
localization to white matter tracts as described in the embryonic NexCre/caMek1 
(Fig. 1) persists in the adult NexCre/caMek1 (K-L) when compared to control mice (I-
J). Additionally, a reduction of somal P-ERK1/2 was detected throughout all cortical 
layers of the NexCre/caMek1 when compared to controls (I-L) (M1 = primary motor 
cortex, cc = corpus callosum, st = striatum, n=3, scale bars = 500µm). 
Adult Cortex 
A C D 
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Figure 18. 
 
 
 
 
Increased levels of P-ERK1/2 in the axons and reduced somal detection of 
P-ERK1/2 persists in adult NexCre/caMek1 mice. High resolution confocal 
imaging of the corpus callosum revealed an increased level of punctate patterned P-
ERK1/2 co-localizing with axonal TUJ1 in the NexCre/caMek1 (O-P, yellow arrows) 
when compared to controls (M-N) (Scale bars, M, O = 10 µm, N, P = 2.5µm, n = 3). 
High resolution confocal images of neuronal bodies in the cortex showed the 
punctate pattern of P-ERK1/2 immunolabeling in the soma with a marked reduction 
of the number of somas expressing P-ERK1/2 in the NexCre/caMek1 mice (R, yellow 
arrows) when compared to controls (Q) (Scale bars = 10µm, n = 3).  
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Figure 19.  
 
 
 
 
P-ERK1/2 localizes to white matter tracts in NexCre/caMek1 mice when 
compared to controls. Additional white matter tracks in the forebrain of the 
NexCre/caMek1 (C-D) that exhibit increased levels of P-ERK1/2 when compared to 
controls (A-B) include the anterior commissure and the hippocampal commissure 
(scale bars = 100µm, n=3, ac = anterior commissure, bst = bed nuclei of the stria 
terminalis, hpc = hippocampal commissure). 
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Figure 20.  
 
 
 
 
P-ERK1/2 localizes to white matter tracts in NexCre/caMek1 mice when 
compared to controls. Subcortical CST projections of the NexCre/caMek1 (G-H) 
mice in the cerebral peduncle also exhibit increased levels P-ERK1/2 when compared 
to control mice (E-F) (scale bars=250µm, n=3, cst = corticospinal tract). 
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Corticocortical and corticostriatal innervation and branching patterns are disrupted 
by constitutively active MEK1 
The current findings regarding the localization patterns of P-ERK1/2, led us to 
question what effect MEK1 glutamatergic hyperactivation has on corticocortical and 
corticostriatal axonal branching and innervation. We had previously reported a 
reduction of corticospinal tract (CST) elongation in the NexCre/caMek1 mice. 
Additionally, we also found enhanced branching and innervation of CST axons in the 
gray matter of the spinal cord and the hind brain when compared to control mice 
(Xing et al., 2016). Axonal targets of the projection neurons of the mouse cortex 
have been established to be primarily layer specific. The deficits found in the CST, 
spinal cord, and hind brain in our previous study, predominately originate from 
cortical layer V (Fame et al. 2011). A smaller number of layer V neurons, ~20%, also 
project to the contralateral cortex (Sohur et al. 2014). Corticostriatal projection 
neurons (CStrPNs) that innervate the contralateral dorsolateral striatum, mainly 
originate from layers II/III and V with a smaller portion occupying layer VI (Sohur et 
al. 2014). Due to the detected abnormalities in long-range cortical projection axons 
in the spinal cord and hind-brain, and the increased levels of P-ERK1/2 detected in 
the axonal compartments, we hypothesized that there would also be an increased or 
hyperactivated branching pattern in the contralateral cortex and contralateral dorsal 
striatum.  
To investigate this hypothesis, we utilized an anterograde tracing approach to 
transfect the glutamatergic neurons of the primary motor cortex of one cortical 
hemisphere, with an Adeno Associated Virus that expresses a CRE dependent td-
Tomato vector (AAV:CAG-FLEX-tdTomato). Then, using high resolution confocal 
images, we measured the axonal innervation of the contralateral cortical hemisphere 
and the contralateral dorsal striatum. Corticocortical axonal projections of the 
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glutamatergic neurons in motor and somatosensory cortices are homotopic and 
therefore innervate corresponding areas in the contralateral cortical hemisphere (Lee 
et al. 2005; Katherine A Rauen 2013; Aoki, Niihori, S.I. Inoue, et al. 2016). 
Additionally, corticostriatal axonal projections from these neurons innervate the 
dorsal medial-lateral striatum both contralaterally and ipsilaterally (Jindal et al. 
2015). Accordingly, we used similar areas in the primary motor cortex and the dorsal 
medial to dorsal lateral striatum to measure specific differences in the amount of 
axonal innervation in the NexCre/caMek1 and control mice. The raw axonal pixilation 
was then normalized to the number of transfected cells in the comparable site from 
the injection hemisphere for each of the serial slices measured. 
The AAV:CAG-FLEX-tdTomato injections were done in the primary motor 
cortex of P1 NexCre/caMek1 and control mice. Analysis of contralateral cortical and 
dorsal striatum axonal innervation was performed at P30 in serial sections of mouse 
cortex (Figure 21A). Cell counts in the injection hemispheres revealed no significant 
difference between the NexCre/caMek1 and control mice (NexCre/caMek1 = 224.73 
± 26.73 SEM, control =189.96 ± 14.20 SEM, n=5, p=0.284, Student’s t-test) 
(Figure 21B-D). Measurements of axonal density in the contralateral cortex revealed 
a significant reduction in axonal branching and innervation. Axonal innervation and 
branching measured 631.68 ± 27.51 SEM pixels2/transfected cell in the 
NexCre/caMek1 mice and 791.79 ± 42.88 SEM pixels2/transfected cell in the control 
mice. This translated to a 19.57% ± 4.30 reduction in the NexCre/caMek1 mice 
when compared to the controls (Mean ± SEM, p=0.014, n=5, Student’s t-test) 
(Figures 22E, F, H, I, K). Contralateral dorsal striatal innervation was also 
significantly reduced in the NexCre/caMek1 mice measuring 155.44 ± 21.18 SEM 
pixels2/transfected cell (n=5) and controls measuring 255.67 ± 23.64 SEM 
pixels2/transfected. This translated to a 37.50% ± 9.14 reduction in axonal 
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innervation in the NexCre/caMek1 mice when compared to controls (Mean ± SEM, 
p=0.013, n=5, Student’s t-test) (Figure 3b, E, G, H, J, L). 
These results indicate that MEK1 hyperactivation not only affects extreme 
long-range cortical axonal projections in the hindbrain and CST, as found in our 
previous study, but also affects the innervation of relatively close targets innervated 
by corticocortical and corticostriatal projections. Additionally, these deficits in axonal 
projections coupled with the results indicating the localization of P-ERK1/2 in the 
axonal compartments, provides evidence that excess P-ERK1/2 disrupts the normal 
development of axonal innervation and branching. 
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Figure 21. 
 
  
 
 
Corticocortical and corticostriatal innervation and branching patterns are 
disrupted by hyperactivated MEK1. Adeno associated viral vector AAV:CAG-Flex-
tdTomato was injected in the primary motor cortex of P1 mice followed by analysis of 
contralateral cortical and dorsal striatum axonal innervation and branching at P30. 
Axonal innervation and branching in the contralateral primary motor cortex and 
dorsal striatum was measured and normalized to the number of transfected cells in 
the injection site. Serial section images of the AAV:CAG-Flex-tdTomato injection site 
showing both rostral-caudal and medial-lateral positions of the AAV-tdTomato 
labeled cells (A). Representative images of the AAV injection site in the primary 
motor cortex of the NexCre/caMek1 (C) and control (B) contralateral to cortical 
hemispheres used for the axonal innervation analysis. Viral-labeled cells were 
counted in the primary motor region of each section used for contralateral 
innervation analysis. No significant differences in labeled cell counts between 
NexCre/caMek1 and control mice were detected (NexCre/caMek1 = 224.73 ± 26.73 
SEM, control =189.96 ± 14.20 SEM, n=5, p-value ≤ 0.2839, Student’s t-test) (D). 
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Figure 22.  
 
 
 
Corticocortical and corticostriatal innervation and branching patterns are 
disrupted by hyperactivated MEK1. Representative images of contralateral axonal 
innervation and branching in the cortex and dorsal striatum of the NexCre/caMek1 
(H-I) and control mice (E-F). Contralateral cortical axonal innervation measured 
631.68 ± 27.51 SEM pixels2/labeled neuron in the NexCre/caMek1 mice (n=5) and 
791.79 ± 42.88 SEM pixels2/labeled neuron in the control mice (n=5). This 
translated to a 19.57% ± 4.30 reduction in axonal innervation in the NexCre/caMek1 
contralateral primary motor cortex when compared to control mice (Mean ± SEM, 
p=0.014, n=5, Student’s t-test) (K). Contralateral axonal innervation of the dorsal 
striatal measured 155.44 ± 21.18 SEM pixels2/labeled neuron in the NexCre/caMek1 
mice (n=5) and 255.67 ± 23.64 SEM pixels2/labeled neuron in the control mice 
(n=5). This translated to a 37.50% ± 9.14 reduction in axonal innervation in the 
NexCre/caMek1 contralateral dorsal striatum when compared to control mice (Mean 
± SEM, p=0.013, n=5, Student’s t-test) (L). (M1 = primary motor cortex, st = 
striatum, scale bars: A, B-D, G = 500µm, E, F-H, I = 100µm). 
ARC protein levels are negatively affected by MEK1 hyperactivation                                    
  90 
It is well established that ERK/MAPK is a major factor in regulating neuronal 
activity and synaptic plasticity (Impey et al., 1999; Thomas and Huganir, 2004), and 
that the transcriptional activity of these processes are regulated or targeted by the 
ERK/MAPK pathway and other pathways (Bramham et al. 2010). ARC is an 
immediate early gene (IEG) whose transcription is controlled by ERK/MAPK and the 
activation of the glutamate receptor N-methyl-D aspartate following LTP induction 
(NMDAR) (Cao et al. 2015). ARC is also identified as a crucial part of learning 
consolidation in motor cortex required learning paradigms, specifically, secondary 
motor cortex (M2) requirements for motor learning in the rotarod task (Petrella et al. 
2016). Motor and learning delays and cognitive impairments reported in RASopathy 
patients in conjunction with our findings on the axonal localization of P-ERK1/2, led 
us to hypothesize that there would be a disruption in the amount of ARC protein 
being produced. 
When measured in the basal state, Western Blots of whole cortical lysates 
revealed a significant decrease of ARC expression in the NexCre/caMek1 mice 
(control = 1.00 ± 0.00 SEM, n=3, NexCre/caMek1 = 0.22 ± 0.02 SEM, n=3, 
p<0.005, Student’s t-test) (Figure 23A-B). Immunostaining of cortical samples 
confirmed the substantial decrease of cortical ARC expression (n=4) (Figures 23C-F).  
Having detected these significantly reduced amounts of ARC protein levels in 
the basal state, we tested to determine if expression and translation levels of ARC 
would be detected at a normal or hyperactivated level in stimulated mice. To test 
this, we examined cortical samples of NexCre/caMek1 and control mice by IHC in the 
stimulated state 2 hours after performance on the rotarod. These samples also 
revealed a marked reduction of ARC expression in the NexCre/caMek1 mice when 
compared to control mice (Figure 24G-4J). 
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These findings revealed that hyperactivation of the ERK/MAPK pathway may 
disrupt an internal pathway equilibrium that results in the downregulation of 
transcription or translation of ARC mRNA or ARC protein in both the basal and 
stimulated states. 
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Figure 23.  
 
 
 
ARC protein levels are negatively affected by MEK1 hyperactivation. Western 
Blot analysis of whole cortical lysates showed a significant reduction in 
NexCre/caMek1 ARC levels when compared to control mice (control = 1.00 ± 0.00 
SEM, n=3, NexCre/caMek1 = 0.22 ± 0.02 SEM, p<0.005, n=3, Student’s t-test) (A-
B). Immunolabeling showed substantial reduction of ARC throughout all layers of the 
NexCre/caMek1 cortex (E-F) in the basal state when compared to controls (C-D) 
(n=4, scale bars = 250µm). 
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Figure 24.  
 
 
 
 
ARC protein levels are negatively affected by MEK1 hyperactivation. 
Immunolabeling of ARC expression after rotarod stimulation also showed a marked 
reduction in the NexCre/caMek1 cortices (I-J) when compared to controls (G-H) 
(n=5, scale bars = 250µm). 
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Motor learning and motor skill acquisition is disrupted by MEK1 hyperactivation in 
cortical glutamatergic neurons  
Having identified deficiencies in long range axonal projections originating in cortical 
glutamatergic neurons and the decrease of ARC detection in the cortex, we next 
questioned if these findings would impair motor function or motor learning 
acquisition. Impairments in motor coordination and motor learning, motor delays, 
and learning disabilities are common elements in the RASopathies (Davis et al. 2000; 
Monje et al. 2005; Blüthgen et al. 2017). These issues have also been identified in 
mouse models created to study the effects of disease subsets within the RASopathies 
(Greig et al. 2013). Therefore, we hypothesized that the NexCre/caMek1 mice would 
show significant deficits in these areas. To analyze this, we employed the open field 
test for gross locomotor function and movement, the accelerating rotarod test for 
locomotor function and motor learning acquisition, and a fine reaching and grasping 
task for fine locomotor function and motor learning acquisition. Additionally, to test 
the for anxiolytic phenotypes, we used the open arm maze and measure of center 
time in the open field test.  
The NexCre/caMek1 mice display no obvious physical defects other than a 
slightly smaller size and ~28% less weight. Our first step however was to assess the 
gross locomotor functions of the mutant mice visually and in an open field test 
(Crawley, 1999). Open field testing revealed no significant difference in total distance 
traveled between the NexCre/caMek1 and control mice (controls = 1834.88cms ± 
172.29cms SEM n=12, NexCre/caMek1 = 2162.80cms ± 218.72cms SEM n=12, 
p=0.252, Student’s t-test) (Figure 25A). Measurements of percent center time also 
showed no significant differences between the NexCre/caMek1 and control mice (% 
center time, controls = 32.40% ± 3.75% SEM, n=12, NexCre/caMek1 = 26.50% ± 
2.56% SEM, p=0.208, n=12, Student’s t-test) (Figure 25A). Results of the open field 
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test and visual observation of the NexCre/caMek1 mice indicated no gross motor or 
locomotion defects that would hinder their physical performance in subsequent 
testing. 
NexCre/caMek1 and control mice were then tested for motor coordination and 
learning on an accelerating rotarod. During Test 1, the NexCre/caMek1 mice showed 
significantly better motor coordination than the control mice (main effect of 
genotype, [F(1,22)=5.85, p=0.0243], n=12) (Figure 25B).  
To test for any anxiety-like effects, we used an elevated plus maze to test the 
NexCre/caMek1 and control mice. In the elevated plus maze, the NexCre/caMek1 
had similar levels of activity to the control but showed a decrease in anxiety-like 
behavior for both percent of open arm time (genotype, [F(1,23)=8.57, p=0.008] 
n=13 controls, n=11 mutants) and percent open arm entries [F(1,23)=5.91, 
p=0.023] n=13 controls, n=11 mutants) (Figure 25C).  
Additional testing of motor skill learning acquisition was performed using a 
skilled reaching and grasping task. This test was designed and used to assay fine 
motor skills and motor learning acquisition of the NexCre/caMek1 and control mice. 
Additionally, the use of this test will serve to assess learning acquisition independent 
of the size differences in the mice. The first days testing showed that both the 
mutants and controls had approximately the same level of skill and ability in base 
performance of this test (Figure 25D). Over the course of the five-day trial however, 
the control mice showed significant improvements in their ability to successfully 
grasp and retrieve the pellet starting with 12.39 ± 4.50 successful attempts on day 
one and increasing to 27.06 ± 5.11 successes on day five (mean, ± SEM, 
[F(1,10)=5.531, p=0.041 Wilks’ Λ=0.644, partial η2=0.644], n=11) (Figures 25D - 
E). The NexCre/caMek1 mice made no improvements over the trial period starting 
with 11.70 ± 5.32 successful grabs on day one and ending with 8.88 ± 3.44 on day 
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five (mean, ± SEM, [F(1,7)=0.450, p=0.524 Wilks’ Λ=0.940, partial η2=0.060], 
n=8) (Figures 25D - E). A significant effect of genotype was also detected between 
the NexCre/caMek1 and control mice (genotype, [F(5,12)=3.165, p=0.047, Wilks’ 
Λ=0.431, partial η2=0.569], n=11 controls, n=7 mutants). These results indicate 
that the NexCre/caMek1 mice exhibit an impairment in motor learning acquisition 
when compared to control mice.  
To test the question of motor coordination and motor learning acquisition 
effects due to hyperactivation of MEK1 in lower motor neurons (LMNs), we used a 
ChAT-IRES-Cre mouse bred with a caMEK1 mouse (ChAT:Cre) to express the 
constitutively active MEK1 construct in the cholinergic LMNs of the hind brain spinal 
cord (Rossi et al., 2100, Krenz et al., 2008). The ChAT:Cre and control mice were 
then subjected to open field and accelerating rotarod testing. When compared to 
control mice, the ChAT:Cre mice showed a significantly lowered difference in total 
distance traveled (control = 2262.4cms ± 143.96cms SEM, n=9, ChAT:Cre = 
1779.32cms ± 93.31cms SEM, n=14, p=0.008, Student’s t-test) and no difference in 
percent center time (control = 40.79% ± 2.21% SEM, n=9, ChAT:Cre = 41.06% ± 
5.45% SEM, n=14, p=0.969 Student’s t-test) (Figure 26F). The Results of rotarod 
testing showed that both the ChAT:Cre and control mice groups were able to 
significantly improve in performance over the five-day testing period. The ChAT:Cre 
mice improved their latency to fall from 65.67secs ± 3.96 to 136.95secs ± 4.18 
(latency to fall, [F(4,52)=15.238, p<0.005, repeated measures ANOVA], n=42) 
(Figure 26G) and the control group improved their latency to fall from 78.15secs ± 
6.01 to 130.18secs ± 6.02 (latency to fall, [F(4,36)=11.208, p<0.005, repeated 
measures ANOVA], n=30) (Figure 26G).  
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No significant effect of genotype between the ChAT:Cre and control group was 
detected (genotype x latency to fall, [F(4,88)=0.673, p=0.613, repeated measures 
ANOVA]). The data from these tests demonstrate that hyperactivation of MEK1 in the 
LMNs had some effect on voluntary locomotor activity but no direct effect on motor 
coordination or motor skill learning. 
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Figure 25.  
 
 
 
Motor learning and motor skill acquisition is disrupted by MEK1 
hyperactivation in cortical glutamatergic neurons. Open field testing of the 
NexCre/caMek1 and control mice revealed no significant difference in distance 
traveled over the testing period indicating an intact motor system in the 
NexCre/caMek1 mice (controls = 1834.88cm ± 172.29 SEM, n=12, NexCre/caMek1 
= 2162.80cm ± 218.72 SEM, p=0.252, n=12, Student’s t-test) (A). Center time 
measurements also revealed no significant differences between NexCre/caMek1 and 
control mice (% center time, controls = 32.40% ± 3.75% SEM, n=12, 
NexCre/caMek1 = 26.50% ± 2.56% SEM, p=0.208, n=12, Student’s t-test). 
Accelerating rotarod testing revealed inconsistent results possibly due to size 
differences in the mutant and control mice. (B). In the elevated plus maze, the 
NexCre/caMek1 had similar levels of activity to the control but showed a decrease in 
anxiety-like behavior for both percent of open arm time (genotype, [F(1,23)=8.57, 
p=0.008] n=13 controls, n=11 mutants) and percent open arm entries 
[F(1,23)=5.91, p=0.023] n=13 controls, n=11 mutants). C). In a single pellet 
reaching and grasping task, the control group significantly improved over the course 
of the trial increasing from 12.39 ± 4.50 to 27.06 ± 5.11 successful attempts (mean, 
± SEM, [F(1,10)=5.531, p=0.041 Wilks’ Λ=0.644, partial η2=0.644], n=11). The 
NexCre/caMek1 however made no improvements over the trial period starting with 
11.70 ± 5.32 and ending with 8.88 ± 3.44 successful attempts (mean, ± SEM, 
[F(1,7)=0.450, p=0.524 Wilks’ Λ=0.940, partial η2=0.060], n=7) (D-E). A significant 
effect of genotype was also detected between the NexCre/caMek1 and control mice 
(genotype, [F(5,12)=3.165, p=0.047, Wilks’ Λ=0.431, partial η2=0.569], n=11 
controls, n=7 mutants) (D-E). 
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Figure 26.  
 
 
 
Motor learning and motor skill acquisition is disrupted by MEK1 
hyperactivation in cortical glutamatergic neurons. Open field testing of 
ChAT:Cre and control mice groups showed a significant difference in total distance 
traveled (control = 2262.4cms ± 143.96cms SEM, n=9, ChAT:Cre = 1779.32cms ± 
93.31cms SEM, n=14, p=0.008, Student’s t-test) and no difference in percent center 
time (control = 40.79% ± 2.21% SEM, n=9, ChAT:Cre = 41.06% ± 5.45% SEM, 
n=14, p=0.969 Student’s t-test) (F). Rotarod testing showed that both the ChAT:Cre 
and control mice groups were able to significantly improve in performance over the 
five-day testing period. The ChAT:Cre mice improved their latency to fall from 
65.67secs ± 3.96secs to 136.95secs ± 4.18secs ([F(4,52)=15.238, p<0.005, 
repeated measures ANOVA], n=42) and the control group improved from 78.15secs 
± 6.01secs to 130.18secs ± 6.02secs ([F(4,36)=11.208, p<0.005, repeated 
measures ANOVA], n=30) (G). No significant effect of genotype between the 
ChAT:Cre and control group was detected (genotype x latency to fall, 
[F(4,88)=0.673, p=0.613, repeated measures ANOVA]) (G). 
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Hippocampal MEK1 gain-of-function downregulates P-ERK1/2 expression levels in the 
dentate gyrus and CA3 regions but upregulates in hippocampal associated white 
matter tracts 
In addition to cortical glutamatergic neurons, NEX promoter activity is 
detected in dentate gyrus granule cells and mossy fibers that extend to the CA3 
region (Goebbels et al. 2006). Immunostaining for P-ERK1/2 showed a distinct 
downregulation in the cell bodies and the processes associated with them in the 
NexCre/caMek1 when compared to controls (N=3) (Figure 27A - D). However, the 
fimbria of the hippocampus and the stria terminalis show a substantial amount of P-
ERK1/2 labeling (Figure 27A - D). Due to the P-ERK1/2 localization detected here, we 
wanted to determine if there would be any effects on spatial learning associated with 
the hippocampus. For this analysis we used the Morris water maze tests. 
 NexCre/caMek1 and control mice were first subjected to a visual cue test with 
a visible platform. No effects of genotype were found between the NexCre/caMek1 
and control mice. A total of 5 mice (3 NexCre/caMek1 and 2 controls) had poor 
performance in finding the visible platform and were excluded from the acquisition 
and reversal phases of the water maze. In the acquisition phase, the NexCre/caMek1 
and control mice showed similar spatial learning in the hidden platform test (Figure 
28E). In the reversal phase, no effect of genotype was detected between the 
NexCre/caMek1 and control mice (Figure 28G). Although no effect of genotype was 
detected between the two groups, the NexCre/caMek1 mice failed to reach the 
criteria for learning while the control group reached that criteria from days 3 to 5 
(Figure 28G). Furthermore, the NexCre/caMek1 mice had significantly longer swim 
paths than the control mice (main effect of genotype, [F(1,16)=5.31], p=0.0349] 
(Figure 28G). This indicated a decreased ability to locate the new position of the 
hidden platform in the reversal phase.  
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In the probe trial following acquisition, a significant effect of quadrant was 
detected between NexCre/caMek1 and control mice (effect of quadrant, 
[F(1,16)=8.91], p=0.0088] repeated measures ANOVA) (Figure 28F). No effect of 
genotype was detected (Figure 28F). Significant quadrant preference was observed 
in the control mice (quadrant preference, [F(1,9)=8.83], p=0.0156) but not in the 
NexCre/caMek1 mice (Figure 28F). During the reversal probe trial, the control mice 
showed a shift in quadrant preference to the new location (quadrant preference, 
[F(1,9)=14.39], p=0.0043) (Figure 28H). In contrast, NexCre/caMek1 mice failed to 
show quadrant selectivity (Figure 28H). A significant effect of genotype was detected 
between the NexCre/caMek1 and control mice in quadrant selectivity (genotype x 
quadrant interaction, [F(1,16)=4.63], p=0.047, repeated measures ANOVA) (Figure 
28H). 
Swimming distance to the escape platform is dependent upon swimming 
velocity during the timed water maze test. Both the NexCre/caMek1 and control mice 
performed comparably in the visual cue test, for the acquisition, reversal and 
acquisition probe trial, the NexCre/caMek1 mice displayed significantly increased 
swim speeds (overall effect of genotype, [F(1,15)=4.56], p=0.0497, post-hoc tests 
following repeated measures ANOVA) (effect of phase of testing, [F(4,60)=21.06], 
p<0.0001, post-hoc tests following repeated measures ANOVA) (Figure 28I).  
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Figure 27.  
 
 
 
Subcortical recombination of caMEK1 selectively affects P-ERK1/2 detection 
in the NexCre/caMek1 mice. Immunostaining of NexCre/caMek1 and control mice 
revealed a lack of P-ERK detection in the granule layer of the dentate gyrus and 
axonal extension into the CA3 region of the hippocampus (n=3) (A-D). Additionally, 
a substantial increase in P-ERK1/2 detection was noted in the fimbria and the stria 
terminalis that contain white matter tracts originating in MEK1 hyperactivating 
regions (n=3) (A-D). (scale bars = 500µm, DG = dentate gyrus, fi = fimbria, 
st=stria terminalis). 
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 Figure 28.  
 
 
 
Subcortical recombination of caMEK1 selectively affects P-ERK1/2 detection 
in the NexCre/caMek1 mice. Hidden platform test in the Morris water maze 
indicated similar spatial learning in the NexCre/caMek1 and control mice with no 
genotype differences detected (controls n=10, NexCre/caMek1 n=8) (E). In the 
probe trial following acquisition, no effect of genotype was found controls n=10, 
NexCre/caMek1 n=8). However, only the control mice showed a higher percent of 
time in the target quadrant (within genotype analysis [F(1,9)=8.83, p=0.016], 
n=10) while the NexCre/caMek1 mice showed no significant preference, n=8) (F). In 
the reversal phase, only the control mice reached the criterion for learning (controls 
n=10, NexCre/caMek1 = n=8). During this phase, the NexCre/caMek1 mice had 
significantly longer swim paths than the control mice (controls n=10, NexCre/caMek1 
n=8) (G). In the probe trial following reversal, the control mice displayed a shift in 
quadrant preference to the new location (within genotype analysis [F(1,9)=14.39, 
p=0.004], repeated measures ANOVA, n=10). The NexCre/caMek1 mice however 
failed to show any quadrant preference (H). NexCre/caMek1 mice displayed 
significantly increased swim speeds on the first days of acquisition and reversal 
training, and during the acquisition probe trial (main effect of genotype, 
F(1,15)=4.56, p=0.0497, and phase of testing, F(4,60)=21.06, p<0.0001], post-hoc 
tests following repeated measures ANOVA, controls n=10, NexCre/caMek1 n=8) (I). 
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Discussion 
The ERK/MAPK signaling pathway is perhaps the most studied cellular 
signaling pathway to date. The majority of this research however has been 
performed in the context of cancers and specific cell types in culture. In the field of 
neurodevelopment and neurodevelopmental syndromes however, there is a lack of 
knowledge regarding the effects of aberrant ERK/MAPK signaling within a biological 
system. This absence is particularly noticeable concerning the formation and 
maintenance of cell-type specific connectivity under normal and syndromic 
conditions. In this study, we have identified the effects of hyperactivating MEK1 in 
the ERK/MAPK signaling pathway on the development of cortical glutamatergic 
axonal outgrowth and plasticity associated genes and its effect on motor learning 
acquisition.  
 
caMEK1 hyper-phosphorylates axonal but not somal ERK 
The classic RAS/MAPK signaling pathway ends with the dual phosphorylation 
of ERK1/2 at tyrosine and threonine residues. Phosphorylated ERK (P-ERK1/2) then 
acts upon several substrates within the cytosol, the nuclear membrane, and in the 
case of neurons, axons, dendrites and synaptic boutons. Substrates that are affected 
by P-ERK1/2 include cytoskeletal elements, cytoplasmic kinases, nuclear substrates, 
membrane proteins, and even upstream components of its own signaling chain. In 
the cytosol and nucleus, P-ERK1/2 is dephosphorylated or sequestered by dual 
specificity phosphatases (DUSPs). It is currently unclear whether this same method 
of deactivation is present in the axonal or dendritic compartments of the neuron. 
This current investigation involves the use of Cre-Loxp recombination to 
conditionally activate a constitutively active MEK1 construct (caMEK1) to hyper 
phosphorylate ERK1/2 specifically in cortical glutamatergic neurons. Transcription of 
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caMEK1 is controlled by the NEUROD6 promoter which initially begins being 
transcribed in post-mitotic glutamatergic neurons at approximately E11.5. We began 
by testing for production of the caMEK1 construct at E14.5 by immunohistochemical 
(IHC) analysis of the cortex and Western Blotting of whole cortical lysates. Western 
Blot results indicated a robust production of caMEK1 accompanied by a significant 
upregulation of P-ERK1/2 at this embryonic stage. IHC analysis of the embryonic 
cortices showed a high level of P-ERK1/2 localized to the trailing processes of the 
nascent glutamatergic neurons but no clear evidence of enrichment in the somal 
bodies. In Western Blots of adult mouse whole cortical lysates however, caMEK1 
detection remained at significantly increased levels and P-ERK1/2 surprisingly 
showed no differences in detected levels. IHC examination of the adult caMEK1 mice 
however revealed an extremely high level of P-ERK1/2 detection in the axonal 
compartments coupled with very little P-ERK1/2 detection in the somas. This finding 
was surprising and contrary to our expectations of hyper-phosphorylation of ERK1/2 
being detectable in all areas of the affected glutamatergic neurons. At this point we 
speculated that the early hyper-phosphorylation of ERK may have led to an 
upregulation of DUSP6 which is a P-ERK1/2 specific phosphatase. Western Blots and 
immunostaining however showed no evidence of upregulated DUSP6. There are 
several more phosphatases, pathway feedback mechanisms, and cellular transport 
systems specific to the regulation of P-ERK1/2 to investigate in future investigations.  
In our previous investigations, we found that the loss of MEK1/2 signaling in 
cortical glutamatergic neurons led to early cell death in the mutated neurons and the 
mice were not viable past approximately P21. The MEK1/2 loss-of-function (LoF) cell 
death was most notably evident in layer V CTIP2+ sub-cerebral projection neurons 
(SCPNs) and temporally followed disruption of cortico-spinal tract axonal extension. 
Here, in comparison, we found that the hyperactivation of MEK1 disrupts the 
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phosphorylation of ERK1/2 in the somas, greatly enhances P-ERK1/2 detection in 
axons, disrupts the elongation of the cortico-spinal tract, but does not lead to cell 
death. Most importantly though, these mice are viable long term thus allowing for 
further connectivity analysis and behavioral testing as adults. The comparison 
between our previous LoF MEK mice and the apparent down-regulation of somal 
expression of P-ERK1/2 in the caMEK1 mice leads to some interesting questions. Is 
there a basal level of P-ERK1/2 operating or necessary in the glutamatergic neuron 
necessary to support cell survival? Does the upregulation of P-ERK1/2 in the axon 
regulate or conduct survival cues independent of the RAS/MAPK pathway to the 
soma and nucleus? Further work with the Nex:CRE/caMEK1 model will be necessary 
to elucidate the specific nuances in this surprising compartmentalization effect of P-
ERK1/2. 
 
Key synaptic plasticity and immediate early gene ARC is downregulated 
In addition to the somal down-regulation of P-ERK1/2 in the caMEK1 mice, 
Western Blots of whole cortical lysates also revealed a significant reduction in 
activity-regulated cytoskeleton-associated protein (ARC). IHC analysis of basal state 
adult mouse cortices showed that this reduction is primarily detected in the soma 
with the dendritic compartment showing robust levels in both the control and 
caMEK1 mice. When stimulated with physical activity on the rotarod, ARC detection 
by IHC in the cortex becomes more pronounced in the caMEK1 mice yet still does not 
reach the level of ARC expression in activity stimulated control mice or even the 
basal state control mice. IHC detection of P-ERK1/2 in the activity induced mice 
revealed no changes in expression levels over basal caMEK1 mice.  
The amount of ARC detected in the soma and dendrites of the glutamatergic 
neurons in the caMEK1 mice reveals that a basal level of Arc is both transcribed and 
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translated. However, it is unknown what level of either Arc mRNA or ARC protein in 
our mutants can be attributed to P-ERK1/2 in either the somal or dendritic 
compartment. Several reports of the transcriptional dependence of Arc transcription 
on P-ERK1/2 in cultures and in hippocampal in vivo studies suggest that P-ERK1/2 is 
required for Arc transcription in general or Arc transcription above a basal level. Due 
to extensive pathway convergence and cross-talk, it is unclear if our data would 
suggest that Arc is transcribed at a basal level or that the caMEK1 affected neurons 
contain a basal level of P-ERK1/2 to activate transcription of Arc. Further detailed 
studies would need to be performed to describe fully ARCs dependence on this 
caMEK1 mutation. 
 
Long range axonal connectivity is disrupted 
We previously found deficits in axonal elongation of the cortico-spinal tract 
and arborization in the gray matter of the spinal cord and the hindbrain in the 
Nex:CRE/caMEK1 mice (Xing et al. 2016). In this current study, we describe a 
surprising change in the levels of P-ERK1/2 in the soma and the axons of the cortical 
glutamatergic neurons of the Nex:CRE/caMEK1 mice as well as reduced expression of 
select immediate early genes. Additionally, in this current study, we further analyzed 
axonal innervation deficits by analyzing corticocortical and corticostriatal axonal 
innervation and branching patterns.  
The analysis of corticocortical and corticostriatal innervation was performed 
by injecting an AAV virus that expresses a CRE dependent tdTomato construct in a 
single hemisphere of the primary motor cortex. The AAV injections were performed 
at P1 and all analysis was performed at P30. Analysis of the contralateral cortex and 
dorsal striatum allowed the precise quantitation of axonal innervation and branching 
in the Nex:CRE/caMEK1 mice. Our analysis found a significant reduction of axonal 
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innervation in both the contralateral motor cortex and the dorsal striatum. A 
significant reduction of tubulin beta 3 class III (TUBB3) in Western Blots of whole 
cortical lysates in the adult Nex:CRE/caMEK1 mice was also detected which supports 
the finding of reduced axonal innervation. Unlike the loss-of-function mice in our 
previous paper, we detected no loss of cortical glutamatergic neurons in the 
Nex:CRE/caMEK1 mice (Xing et al. 2016). While we can attribute the axonal deficits 
to the mis-regulation of P-ERK1/2 in general, it is unclear at this point whether it is 
the apparent low levels of P-ERK1/2 in the soma, or the high levels of P-ERK1/2 
within the axons that is the main element of these deficits. Considering the high 
complexity of ERKs involvement in the axonal growth program; neurotrophin induced 
axon assembly (Atwal et al. 2000), ERKs links to microtubule associated proteins 1 
and 2 (MAP1 and MAP2) (Ray and Sturgill 1987; Goold and Gordon-Weeks 2005), 
ERK regulation of actin filaments (Atwal et al. 2003), growth cone local protein 
regulation by ERK (Campbell and Holt 2003), and not least of all ERKs influence on 
gene transcription, further work will be needed to elucidate the exact cause or 
causes of these findings. 
 
Motor learning acquisition is disrupted 
With the discovery of these specific axonal extension, innervation, and 
branching deficits and the findings of the IEG ARC disruptions, we next subjected the 
mutant and control mice to motor learning acquisition testing. We began with the 
open field test to determine if overall motor function was impaired. The 
Nex:CRE/caMEK1 mice showed no difference from control mice for voluntary motor 
function in total distance traveled or in center time in the open field. This finding 
indicated that the Nex:CRE/caMEK1 mice did not have any physical impediments to 
voluntary motor function.  
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The Nex:CRE/caMEK1 mice were also subjected to an elevated plus maze test 
to test for any anxiolytic-like phenotypes. In general, it is reported that individuals 
with a RASopathy, especially NF1 and CS patients, are at a higher risk for anxiety 
disorders. This anxiety type may not be due to a personality shift or driven by 
neuroticism, but is suggested that it may be a distinct subtype of anxiety (Bizaoui et 
al. 2018). Our results indicated that the Nex:CRE/caMEK1 showed no anxiolytic-type 
behavior and actually made significantly more entries into the open arms and spent 
significantly more time on the open arms of the maze. To make any determination 
concerning an anxiety-like phenotype of any kind in this mouse model, much more 
specific behavioral tests should be performed.    
Accelerating rotarod testing for motor testing acquisition showed a surprising 
set of results for the Nex:CRE/caMEK1 mice. The mice were significantly better at 
performing on the rotarod than the control mice in initial performance. We theorized 
that this result was caused by the smaller size of the Nex:CRE/caMEK1 mice allowing 
them to better balance on the rotating rod than the larger control mice. In order to 
negate any effects of size differences between the mutant and control mice, we 
subjected the mice to a skilled reaching and grasping task. In this task, the 
Nex:CRE/caMEK1 mice showed no ability to improve over the course of the trial. In 
fact, their ability to succeed in this task actually dropped over the course of the trial. 
These results for the Nex:CRE/caMEK1 mice indicate deficits in motor learning 
acquisition such as seen in the RASopathies. 
ChAT:Cre/caMEK1 mice (Rossi et al. 2011) were also subjected to the open 
field and accelerating rotarod. This allowed for the analysis of motor learning 
acquisition due to the hyperactivating mutation on lower motor neurons. Within 
some of the RASopathies, common neurological issues include motor development 
delays and deficits and motor skill deficits associated with learning and cognition. 
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Open field analysis of the ChAT:Cre/caMEK1 mice revealed a significant deficit in 
total distance traveled when compared to control mice with no difference in center 
time. However, testing on the accelerating rotarod revealed no difference between 
mutant and control mice indicating the open field results to be a voluntary motor 
issue. Both the mutants and controls significantly improved their performance over 
the course of the test indicating no impairments in motor skill acquisition. These 
tests indicated that caMEK1 mutations in cholinergic lower motor neurons have little 
to no effect on motor behaviors.  
Recombination of the caMEK1 construct in the Nex:CRE/caMEK1 mice also 
affected regions of the hippocampus. This allowed us to test the Nex:CRE/caMEK1 
mice for associative and spatial learning in the Morris water maze. No significant 
differences were found between the mutants and controls in the acquisition phase as 
measured by swimming distance. However, in the probe trial following acquisition, 
the Nex:CRE/caMEK1 mice failed to establish a quadrant preference with the 
platform removed. In the reversal phase, there was also a significant difference 
between the Nex:CRE/caMEK1 and control mice in learning the new placement of the 
hidden platform. In the probe trial following reversal learning, the Nex:CRE/caMEK1 
mice again failed to establish a quadrant preference. It is interesting to note that 
again the Nex:CRE/caMEK1 mice outperformed the control mice in swimming speed. 
These results indicate a deficit in associative and spatial learning in the 
Nex:CRE/caMEK1 mice due to the caMEK1 mutation.   
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Conclusion 
Our results here are the first to detect a compartmentalization effect of P-
ERK1/2 by a hyperactivating MEK1 mutation in a mammalian system. This work 
further defines that the axonal extension aberrations as well as the learning 
phenotypes described here, stem from within a single cell type indicating a cell-
autonomous effect. 
 These results provide a basis for further examination of current clinical 
treatments of RAS/MAPK activating mutations. Furthermore, the down-regulating 
effect on detectable P-ERK1/2 within the somas questions a crucial aspect of clinical 
treatment of RASopathic genetic mutations. Is the treatment of an activating 
RAS/MAPK mutation by administering MEK inhibitors to ameliorate physical 
symptoms of the disease worsening the symptoms of the neurodevelopmental 
aspects of the disease? Can the neurodevelopmental symptoms be treated 
separately or even shielded in some way from the physiological treatments 
available? Is it possible or feasible to treat separate compartments of a single cell 
(i.e. cell body versus the axon versus the dendrite)? Further in vivo testing is needed 
to address these issues and to help develop effective strategies in treatment for the 
ongoing neurological symptoms of the RASopathies. 
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CHAPTER 4 
 
CORTICAL LAYER SPECIFICITY IN A GAIN-OF-FUNCTION  
CAMEK MOUSE MODEL 
 
 
 
 
Hyperactivation of MEK1 in cortical glutamatergic neurons results in 
projection axon deficits and aberrant motor learning 
in a layer autonomous manner 
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Abstract         
Germline mutations within the components of the RAS-RAF-MEK-ERK 
(RAS/MAPK) pathway form a group of neurodevelopmental disorders collectively 
known as RASopathies. A large portion of these mutations result in an upregulation 
of signaling. Previously we have described that a cell-type specific MEK1 
hyperactivating mutation leads to significant axonal connectivity issues and deficits 
in motor learning acquisition in a biological system. Here, we used cre-loxp 
technologies to hyperactivate the RAS/MAPK pathway in cortical glutamatergic 
neurons in a layer specific manner to affect only cortical layer 5. We have identified 
significant deficits in corticocortical, and corticostriatal axonal innervation and 
branching and a significant reduction in the expression of the immediate early gene 
ARC in a cell and layer autonomous manner. Unlike MEK1 hyperactivation of 
glutamatergic neurons across all cortical layers, layer 5 specific hyperactivation does 
not lead to motor learning deficits. These data reveal specific cortical layer 
requirements for RAS/MAPK signaling during development for axonal innervation and 
connectivity and further indicate that behavioral plasticity depends upon RAS/MAPK 
expression in cortical projection neurons other than layer 5. 
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Introduction 
Previously, we reported a critical requirement for RAS/MAPK signaling in loss- 
and gain-of-function as it applies specifically to cortical pyramidal neurons (Xing et 
al., 2016). Deletion of Map2k1/2 (Mek1/2) in cortical glutamatergic neurons resulted 
in the absence of large CTIP2+ neurons in cortical layer 5 and the impairment of 
corticospinal tract (CST) axonal extension in the dorsal funiculus of the cervical and 
lumbar spinal cord (Xing et al., 2016). Up-regulation of ERK/MAPK signaling in 
cortical glutamatergic neurons also decreased CST axonal elongation but markedly 
increased axonal branching in the gray matter of the spinal cord and the gray matter 
of the hind brain (Xing et al., 2016). The hyperactivating mutations also created a 
paradoxical change in the expression patterns of cellular P-ERK1/2. In the axonal 
compartment of the cortical glutamatergic neurons we detected a high level of P-
ERK1/2 while the somas contained a highly reduced expression level. Furthermore, 
corticocortical and corticostriatal axonal innervation was significantly reduced and 
indications of motor learning acquisition deficits were found upon hyperactivation of 
MEK1.  
In this study we have employed an Rbp4:Cre mouse crossed with the caMek1 
mouse to restrict Mek1 over-expression to layer 5 glutamatergic neurons. The layer 
5 specific hyperactivation will address specifically any layer autonomous effects with 
CST extension and further delineate the previous cell-type autonomous effect that 
was detected in the Nex:CRE/caMEK1 mice. An NF1 conditional knock-out mouse 
model was also used to further assess CST elongation phenotypes. The NF1 
conditional knock-out mouse is thought to more closely replicate the human 
condition in a cell-specific manner (Gutmann and Giovannini 2002). The use of these 
conditional genetic tools will allow the analysis of cell specific effects and 
contributions to the pathologies reported in RASopathy patients. 
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Analysis of contralateral cortical projections and cortico-striatal projections 
revealed a significant decrease in axonal innervation and branching while 
corticobulbar projections showed little change in the hindbrain. Much like the 
Nex:Cre/caMek1 mouse however, there was a significant decrease in CST elongation 
in the cervical and lumbar spinal cord and a significant increase in axonal branching 
in the spinal cord gray matter. Behavioral testing of the Rbp4:Cre/caMEK1 mice 
showed no gross motor defects but did display an apparent deficit in voluntary 
locomotor function. However, unlike the Nex:Cre/caMek1 mice, the 
Rbp4:Cre/caMEK1 mice showed no deficits in motor learning and acquisition. 
Furthermore, reduction of activity regulated gene expression appeared localized to 
layer V with no apparent effect on other regions. These results indicate that layer V 
hyperactivation of MEK1 is sufficient to cause the deficits detected in long range 
glutamatergic axonal projections. However, layer V hyperactivation is not sufficient 
to cause the motor learning acquisition disruptions as detected in the 
Nex:Cre/caMek1 mice indicating behavioral plasticity depends upon RAS/MAPK 
expression in cortical projection neurons other than layer 5. 
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Materials and Methods 
Transgenic Mice 
All animal experiments were performed in accordance with established 
procedures approved by the Institutional Animal Care and Use Committee of Arizona 
State University and NIH guidelines for the use and care of laboratory animals. Mice 
used in this work were of a mixed genetic background and housed in standard 
conditions. The mice were kept on a 12-hour light/dark cycle with food and water 
provided ad libitum. Each experiment was replicated a minimum of three times using 
littermates or mice from independent litters. No detectable effects on the phenotypes 
described in this manuscript were observed from Cre expression alone. Therefore, 
Cre-expressing or Cre-negative mice were used as controls. Map2k1s217/222 mice were 
furnished by Dr. Maike Krenz and Dr. Jeffrey Robbins (Krenz et al., 2008). Rbp4:Cre 
mice were purchased from the Mutant Mouse Resource & Research Centers 
(RRID:MMRRC_036400-UCD).   
 
Tissue Preparation 
Transcardial perfusions were performed on mice using a 4% 
paraformaldehyde/PBS solution with dissected brains being post-fixed in the same 
solution overnight at 4°C. Dissected brains were then serially incubated in 15% and 
30% sucrose/PBS solutions prior to embedding in Tissue-Tek O.C.T. (Tissue-Tek 
4583) and freezing. Cryostat sectioning was performed with sections being collected 
on Fisherbrand Superfrost/Plus slides (Fisher Scientific 12-550-15) and air-dried 
prior to staining. Alternatively, cryostat sections were collected in well plates with 
cold PBS for free-floating staining as appropriate. For some experiments, brains were 
mounted in agarose after post-fixation in preparation for vibratome sectioning. 
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Viral Injections 
P1 pups were removed from their home cage as a group and were individually 
cryo-anesthetized on ice for 4-6 minutes. Viral injections were then performed 
immediately with 50-80nl of solution using a 32-gauge beveled needle fitted to a 
Hamilton 5µl neuros syringe mounted on a stereotaxic arm. After injections, pups 
were placed on a 37°C heated surface for recovery and returned to their home cage 
as a group. Adeno Associated Viral vectors, RAAV9/AAV-Flex-tdTomato and 
RAAV8/CAG-Flex-tdTomato were purchased from the UNC Viral Vector Core and used 
for all viral tracing experiments. 
 
Behavioral Assays 
A single-pellet reaching and grasping task test was performed using male 
RBP4:Cre/caMek1 mice. Mice were mildly food restricted throughout training to 
maintain at least 90% of their baseline weight which amounted to free feeding 
between 2 and 6 hours daily. Sucrose pellets (TestDiet 1811555) were used for this 
test and the mice were acclimated to the pellets in their home cages. After pellet 
acclimation, mice were then placed in an acrylic chamber 15cm X 10cm X 20cm, with 
pellets either singly or in pairs depending on their housing for further acclimation. 
After acclimation, forelimb dominance was determined by placing a single pellet on 
the food platform (10cm high) outside a single slit (5cm wide) in one end of the test 
chamber. Once a mouse has conducted at least 20 reaching attempts within 20 mins 
with at least 70% of those reaches made with one hand, that mouse was moved on 
to testing. Testing consisted of placing a single pellet on the food platform in front of 
the slit, right or left, corresponding with the preferred paw. Testing was performed 
for 10 minutes daily for 5 days. Scoring was performed as follows; Success: if the 
mouse reached with its preferred paw, retrieved the pellet, and fed the pellet into its 
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mouth. Drop: If the mouse grasped the pellet but drops it before reaching its mouth. 
Fail: If the mouse reached for the pellet but failed to grasp it or knocked it out of 
position. Mice were scored on the rate (metric/attempts) for each of these metrics. 
Open field testing was performed in an open top opaque plexiglass box 
measuring 38cm X 38cm X 30cm. The area within the box is illuminated by a single 
40-watt spotlight approximately 2 meters overhead and centered within the area. 
Recording of mouse movements is done using a Microsoft LifeCam or Logitech HD 
Webcam and VirtualDub video capture software. Open field quantitation was 
performed using the MouseMove (Samson et al. 2015) plugin for ImageJ (Schindelin 
et al. 2012). 
Rotarod analysis for the RBP4:Cre/caMEK1 mice was performed using a San 
Diego Instruments Rotor-Rod. Prior to testing, mice were habituated by being placed 
on an approximately 5.0cm diameter foam roller followed by the standard 3.175cm 
diameter knurled plastic rollers. The mice were allowed three attempts on each rod 
to reach 180 seconds on the foam rollers and 90 seconds on the plastic rollers. All 
habituation is performed at a constant 4 RPMs. Rotarod testing is performed starting 
the first day following habituation. The mice are placed on the plastic rollers and the 
machine measures the latency to fall under accelerating conditions from 4 RPMs to 
40 RPMs for a maximum of 5 minutes. The testing period consisted of three trials per 
day for 5 consecutive days. Mice were allowed 5-10 minutes between trials for rest.  
 
Immunohistochemistry 
Tissue sections were rinsed with PBS/0.1% Triton X-100 (PBST) and blocked 
with 5% normal donkey serum in PBST at room temperature for ~1 hour. Primary 
antibodies were diluted in PBST/5%NDS and incubated overnight at 4°C with gentle 
shaking. Primary antibodies used were; rabbit anti-MEK1 (Abcam ab32091), rabbit 
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anti-phosph-p44/42 MAPK (ERK1/2) (Thr202/Tyr204) (Cell Signalling 4370), rabbit 
anti-ERK2 (Abcam ab32081), rabbit anti-ARC (Synaptic Systems 156 003), mouse 
anti-β 3 Tubulin (TUBB3) (Bioloegend 801202), rabbit anti-RFP (Rockland 600-901-
379), chicken anti-RFP (Rockland 600-401-379), mouse anti-neun (Millipore Sigma 
MAB377), and DAPI (Sigma Aldrich 10236276001). After rinsing in PBST 3X, 
secondary antibodies diluted in PBST/5%NDS were added and incubated overnight at 
4°C with gentle shaking. Secondary antibodies included Alexa Fluor 488, 546 or 568, 
and 647 conjugated anti-rabbit, anti-mouse, or anti-goat IgG (Invitrogen). Imaging 
was performed using a Zeiss LSM 800 laser scanning confocal microscope (LSCM), or 
a Leica SP5 LSCM.  
 
Western Blotting 
Cortices were collected from mutant and control mice and lysed in a buffer 
containing 50mM Tris-CL, 150mM NaCl, 0.1%triton x-100, Protease Inhibitor 
(Sigma-Aldrich P2714), and Phosphatase Inhibitor (Sigma-Aldrich P5726) either by 
sonication or with a syringe. Lysates were then cleared by centrifugation and total 
soluble protein concentrations determined by Bradford Assay using a Peirce Protein 
Assay Kit (Thermo Scientific 23200). Proteins were denatured in equal amounts of 
2X Laemmli sample buffer (BioRad 161-0737), separated by SDS-PAGE using either 
10% or 4-20% Mini-PROTEAN TGX precast gels (BioRad 456-1035 and 456-8095), 
then transferred to PVDF membranes (BioRad 162-0177). Membranes were blocked 
with 5% non-fat dry milk (NFDM) in TBS with 0.5% Tween (TBST) for 1 hour at room 
temperature followed by overnight incubation at 4°C with primary antibodies in 5% 
bovine serum albumin. Primary antibodies used were; rabbit anti-MEK1 (Abcam 
ab32091), rabbit anti-phosph-p44/42 MAPK (ERK1/2) (Thr202/Tyr204) (Cell 
Signalling 4370), rabbit anti-ERK2 (Abcam ab32081), rabbit anti-ARC (Synaptic 
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Systems 156 003), rabbit anti-GAPDH (Cell Signalling 2118), goat anti β-Actin (Cell 
Signaling 8457), and rabbit anti-β actin (Cell Signalling 8457). Secondary antibodies 
used were anti-rabbit HRP and anti-goat HRP (Jackson Immunoresearch 711-035-
152 and 705-035-147). Membranes were then washed in TBST and incubated with 
HRP-conjugated secondary antibodies in 5% NFDM/PBST for 1 hour at room 
temperature. Membranes were washed in TBST, developed with Pierce ECL Western 
Blotting Substrate (Thermo Scientific 32106), and exposed to radiographic film 
(Thermo Scientific 34089). 
 Quantification of Western Blots was performed using a high-resolution 
scanned image of the exposed radiographic film in a grayscale TIFF file format. The 
file was then transferred to Imagej were a region of interest was created to 
encompass individual bands for all mutant, control and loading control samples. The 
mean gray value of each band was then recorded along with a background 
measurement for each band. All values were inverted (subtracted from 255) and the 
background values were subtracted from the band values. The net band values were 
then reported as a ratio of net band value over net loading control value.  
 
Image Analysis and Quantitation 
For quantitation of axonal innervation and branching in the cortex and 
striatum, a radial section of the cortex encompassing all layers within the primary 
motor cortex was used. A minimum of 4 sections from each mutant and control 
animal centered about the rostral-caudal area of the injection site was analyzed. The 
area in µm2 of this region was measured in Photoshop and the image was then 
transferred to Imagej. Once in Imagej, pixel intensities were adjusted using the Otsu 
Auto Threshold component, total pixels counted, and multiplied by the images pixel 
size to obtain the total µm2 of pixels in the ROI. The total µm2 was then divided by 
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the number of transfected cells that were manually counted in an identical ROI in the 
ipsilateral (RFP injected) cortical hemisphere to obtain the axonal labeling per 
transduced cell. Spinal cord arborization was measured in the same manner except 
the µm2 of pixels was normalized to the CST to obtain a spinal cord arborization 
ratio. 
The CBT was measured using at least three anatomically matched hind brain 
sections from each mutant and control animal. The CBT was outlined using the 
difference of appearance in NEUN or DAPI and the image was transferred to Imagej. 
A pixel intensity threshold was manually set by an observer blinded to the genotype. 
The number of labeled pixels was then measured and multiplied by the images pixel 
size to obtain the µm2 of pixels in the CBT. The µm2 of pixels was then normalized to 
the number of transfected cells in the injection site ROI to obtain the CBT axonal 
labeling per transduced cell. The CST in the dorsal funiculus was measured in the 
same manner except the µm2 of pixels was normalized to the CBT to obtain the CST 
elongation ratio. 
Representative images have been cropped and adjusted for brightness and 
contrast in Photoshop for presentation. All images used for comparison analysis 
where collected using the same microscope settings and all adjustments made were 
done equally between images. 
 
Statistical Analysis 
Data analysis was performed using SPSS software (IBM Analytics). Statistical 
methods used included Student’s t-test (unpaired, two-tailed), ANOVA, repeated 
measures ANOVA, and multivariate ANOVA. F-test results, p-values, and tests used 
are reported where appropriate.  
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Results 
ERK/MAPK gain-of-function in layer V excitatory neurons reduces CST elongation and 
increases spinal cord axonal innervation but does not affect CBT elongation or hind 
brain axonal innervation  
In our previous study, we found that both MEK1 loss-of function mice, 
Map2k1;Neurod6-Cre, and MEK1 gain-of-function mice, NexCre/caMek1, exhibited 
CST elongation deficiencies. The MEK1 loss-of-function mutation was lethal at ~P21 
and prevented further characterization. However, the the gain-of-function 
NexCre/caMek1 mouse was viable and exhibited additional deficiencies in CBT 
elongation and enhanced innervation and branching of the spinal cord and hindbrain 
(Xing et al. 2016). Our current work further defines deficits in corticocortical and 
corticostriatal axonal innervation and branching in the NexCre/caMek1 mouse. At this 
point we wanted to further explore layer specific contributions to the abnormalities 
that we have documented.  
Generally, callosal projection neurons (CPNs) residing in cortical layers II/III, 
and to a lesser extent in layers V and VI, project to mirrored areas in the 
contralateral cortex. Subcerebral projection neurons (SCPN) from M1 project to the 
brainstem motor nuclei and spinal cord motor neurons (Greig et al. 2013). With our 
NexCre/caMek1 deficits in mind, we wanted to test the possibility of a layer 
autonomous role when MEK1 is hyperactivated in layer V glutamatergic neurons 
only. A loss-of-function mouse designed by crossing an Erk1-/-,Erk2fl/fl mouse with an 
Erk1-/-,Erk2wt/fl;RBP:Cre mouse that would specifically knock-out Erk1/2 function in 
cortical layer V. Unfortunately, this appeared to be an embryonic lethal mutation 
even though we restricted the knock-out of ERK1/2 function to layer V glutamatergic 
neurons only. Over the course of ~85 live births, no mice were born with Erk1-
/-,Erk2fl/fl;RBP:Cre genotype when we should have expected   
  124 
~21 by Mendelian ratios (1 in 4). For the gain-of-function mouse we used an 
RBP4:Cre mouse crossed with the caMEK1 mouse (RBP4:Cre/caMEK1), to produce a 
mouse that will hyperactivate ERK/MAPK primarily in cortical layer V glutamatergic 
neurons. With this mouse, we employed the previously described method of using 
the AAV:CAG-FLEX-tdTomato viral vector to trace and quantify the developed axons. 
As previously performed on the NexCre/caMek1 mice, the RBP4:Cre/caMEK1 mice 
were injected in the primary motor cortex at P1 with a CRE dependent AAV-tdTomato 
with axonal extension and innervation analyzed at P30. 
Analysis of the CBT in the RBP4:Cre/caMEK1 mice was performed by 
measuring the amount of RFP labeling in the tract and normalizing to the number of 
tdTomato labeled glutamatergic neurons in the primary motor cortex injection site. 
Cell counts between the RBP4:Cre/caMEK1 and control mice revealed no significant 
differences (labeled cells, RBP4Cre/caMEK1 = 96.30 ± 10.38 SEM, n=5, control = 
85.60 ± 6.12 SEM, n=5, p=0.400, Student’s t-test) (Figures 32A-C). In contrast to 
our previous findings when hyperactivating all cortical glutamatergic neurons in the 
NexCre/caMek1 mice, layer V specific hyperactivation in the RBP4:Cre/caMEK1 mice 
showed no significant differences in CBT elongation when compared to control mice 
(CBT labeling per tdTomato labeled neuron, RBP4Cre/caMek1 = 319.38 ± 77.74 
SEM, n=4, control = 298.46 ± 38.95 SEM, n=4, p=0.818, Student’s t-test) 
(Supplemental Figure 31D - E, H). Additionally, analysis of axonal innervation in the 
contralateral side of matched sections of the hindbrain in RBP4:Cre/caMEK1 and 
control mice also revealed no significant differences (innervation factor, 
RBP4Cre/caMek1 = 4366.57 ± 742.36 SEM, n=4, control = 5061.28 ± 1103.85 SEM, 
n=4, p=0.620, Student’s t-test) (Supplemental Figures 31C - D, F, I). 
CST elongation was determined by measuring the area and extent of labeling 
of the CST in the dorsal funiculus between C5 and T1 (Figures 29A, C - D, F). The 
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RBP4:Cre/caMEK1 mice were found to have a significantly lower amount of labeling 
in the CST as a percentage of labeling in the CBT (Figures 29I, L) (labeling/%CBT, 
RBP4:Cre/caMEK1 26.23 +/- 1.69 SEM, n=4, controls = 45.62 +/- 7.01 SEM, n=4, 
p=0.036, Student’s t-test) (Figure 29G). We next measured the amount of axonal 
labeling in the spinal cord gray matter in relation to the white matter of the CST in 
the RBP4:Cre/caMEK1 mice (Figures 29A - C, E). We found that the 
RBP4:Cre/caMEK1 mice had a significant increase  in the amount of axonal 
innervation in the ipsilateral grey matter in relation to CST elongation 
(arborization/CST, control = 100.00% +/- 0.00 SEM, n=4, RBP4:Cre/caMEK1 = 
206.83 +/- 24.59 SEM, n=4, p=0.015, Student’s t-test) (Figure 29H). These findings 
show that layer 5 specific hyperactivation of MEK1 leads to a reduction in the number 
of axons extending down the CST yet enhances the extent of innervation (per axon) 
in the grey matter of the spinal cord. 
 Having determined a layer V specific effect on CST elongation in the 
RBP4:Cre/caMEK1 mice, we next wanted to determine if a direct mutation in the 
RAS/MAPK pathway would phenocopy those results. For this we used the layer V 
glutamatergic specific RBP4:Cre mouse crossed with an NF1 mouse. The NF1 mouse 
produces a mutation in the NF1 gene that encodes neurofibromin which is a RasGAP 
upstream of MEK and ERK in the RAS/MAPK pathway. Neurofibromin is a GTPase-
activating protein that is a negative regulator of Ras ultimately causing an 
upregulation in ERK/MAPK signaling. CST elongation in the RBP4:Cre/NF1 mouse was 
also significantly reduced as measured in the lumbar spinal cord (Figures 30J - K, M - 
O). These results indicate a substantial reduction in the elongation of the CST due to 
the hyperactivation of MEK1 or the knock-out of NF1 selectively in cortical layer V 
glutamatergic neurons.  
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Figure 29.  
 
 
 
 
Corticospinal tract elongation is decreased but corticospinal axonal 
innervation is increased in layer V specific MEK1 hyperactivation. Axonal 
innervation of corticospinal tract elongation and innervation analysis was performed 
on cross sections of RBP4Cre/caMEK1 (D-F) and control mice (A-C) cervical spinal 
cords. High resolution confocal microscopy shows a reduction of corticospinal axonal 
elongation in the dorsal funiculus of the RBP4Cre/caMEK1 (F)  when compared to 
control mice (C). Increased axonal innervation of spinal cord gray matter was 
detected RBP4Cre/caMEK1 mice when compared control mice (B, E) (scale bars = 
A,D=200µm, B,E=50µm, D,F=20µm n=4, dh = dorsal horn, df = dorsal funiculus, iz 
= intermediate zone, vh = ventral horn). Quantification of corticospinal tract 
elongation revealed a significant reduction in the RBP4Cre/caMEK1 mice when 
compared to control mice (labeling/%CBT, RBP4:Cre/caMEK1 26.23% +/- 1.69% 
SEM, n=4, controls = 45.62% +/- 7.01% SEM, n=4, p=0.036, Student’s t-test) (G). 
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Figure 30.  
 
 
 
Corticospinal tract elongation is decreased but corticospinal axonal 
innervation is increased in layer V specific MEK1 hyperactivation. Axonal 
innervation of spinal cord gray matter revealed an increase in the RBP4Cre/caMEK1 
mice when compared to control mice (axonal arborization/CST, % of control, 
RBP4Cre/caMEK1 = 206.83% +/- 24.59% SEM, n=4, control = 100.00% +/- 0.00% 
SEM, n=4, p-value ≤ 0.0148) (H). Axonal innervation of RBP4:Cre/NF1loxp/loxp 
revealed a similar reduction in CST innervation in the CBT in the hind brain (I and L), 
and the dorsal funiculus of the cervical spinal cord (J and M). Additionally, the dorsal 
funiculus of the lumbar spinal cord also showed a reduction of elongation (K and N) 
(LEI - n=?). CST labeling of the lumbar spinal cord was significantly reduced when 
measured as a % of the CBT (O). 
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Figure 31.  
 
 
 
 
Corticobulbar tract axonal extension and hindbrain innervation not affected 
in the RBP4Cre/caMek1 mice. Confocal imaging of the corticobulbar tract and 
axonal innervation of the hind brain revealed little to no differences between the 
RBP4Cre/caMek1 (D-F) and control mice (A-C) (scale bars, A,D=500µm, 
B,E=100µm, C,F=50µm).  Quantification of tdTomato labeled axons in the 
corticobulbar tract revealed no significant differences between the RBP4Cre/caMek1 
and control mice (CBT labeling/tdTomato labeled neuron, RBP4Cre/caMek1 = 319.38 
± 77.74 SEM, n=4, control = 298.46 ± 38.95 SEM, n=4, p=0.818, Student’s t-test) 
(H). Axonal innervation of the hind brain also revealed no significant differences 
between the RBP4Cre/caMek1 and control mice (innervation factor, RBP4Cre/caMek1 
= 4366.57 ± 742.36 SEM, control = 5061.28 ± 1103.85 SEM, n=4, p=0.620, 
Student’s t-test) (I). 
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Hyper-activation of ERK/MAPK in layer V excitatory neurons significantly reduces 
contralateral axonal innervation and contralateral striatal innervation 
By using a layer V specific mouse model to hyperactivate MEK1, we expected 
to find little to no change in the axonal projections and branching patterns in the 
contralateral primary motor cortex and contralateral dorsal striatum. To test this, we 
analyzed high resolution confocal images of serial sections of the forebrains of the 
AAV:CAG-Flex-tdTomato injected P30 RBP4:Cre/caMEK1 and control mice. Axonal 
labeling was measured in the primary motor cortex and the dorsal ventral to medial 
ventral area of the striatum. These measurements were normalized to the area 
measured and the number of transfected cells in the contralateral injection site.  
As in the NexCre/caMek1 mice, we controlled the injection area in both the 
rostral-caudal and medial-lateral position (Figure 32A-B). Labeled cell counts in the 
primary motor cortex of the injected hemisphere showed no significant differences 
between the RBP4Cre/caMEK1 and control mice (labeled cells, RBP4Cre/caMEK1 = 
96.30 ± 10.38 SEM, n=5, control = 85.60 ± 6.12 SEM, n=5, p=0.400, Student’s t-
test) (scale bars = 500µm) (Figure 32C). Contralateral cortical innervation labeling in 
the RBP4:Cre/caMEK1 mice was significantly reduced when compared to control mice 
(axonal labeling/transduced cell, RBP4Cre/caMEK1 = 173.21 ± 15.20 SEM, n=5, 
control = 234.83 ± 14.69 SEM, n=5, p=0.019, Student’s t-test) (Figures 33D, G, H, 
K, M). Contralateral dorsal striatum labeling was also significantly reduced in the 
RBP4:Cre/caMEK1 mice when compared to controls (axonal labeling/transduced cell, 
RBP4Cre/caMEK1 = 89.54 ± 18.69 SEM, n=5, control = 189.82 ± 20.67 SEM, n=5, 
p=0.007, Student’s t-test) (Figures 33 - F, I, J, N). These results indicate that 
ERK/MAPK is necessary for corticocortical and corticostriatal innervation by cortical 
layer V glutamatergic axonal extensions irrespective of all other cortical layers. 
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Figure 32.  
 
 
Corticocortical and corticostriatal innervation and branching is reduced in a 
layer V autonomous manner. To analyze corticocortical and corticostriatal 
innervation and branching, RBP4Cre/caMEK1 and control mice were injected at P1 in 
the primary motor cortex with an AAV:CAG-Flex-tdTomato.   Contralateral primary 
motor cortex and dorsal striatum were analyzed at P30 to determine the amount of 
labeling in axonal innervation and branching. Injection locations were controlled in 
both the medial-lateral and rostral-caudal positions (A-B) (scale bars = 500µm). 
Labeled cell counts in the primary cortex region showed no significant differences 
between the RBP4Cre/caMEK1 and control mice (labeled cells, RBP4Cre/caMEK1 = 
96.30 ± 10.38 SEM, n=5, control = 85.60 ± 6.12 SEM, n=5, p=0.400, Student’s t-
test) (scale bars = 500µm) (C).  
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Figure 33. 
  
Corticocortical and corticostriatal innervation and branching is reduced in a 
layer V autonomous manner. Representative samples of diminished tdTomato 
labeling in the contralateral cortex and dorsal striatum of the RBP4Cre/caMEK1 mice 
(H-K) compared to control mice (D-G) (scale bars = D,E,H,I = 500µm, 
F,G,J,K=150µm, n=5, M1 = primary motor cortex, st = striatum).  A significant 
reduction of tdTomato labeled axons from contralateral layer V glutamatergic 
neurons was detected in the cortex of the RBP4Cre/caMEK1 mice when compared to 
controls (axonal labeling/transduced cell, RBP4Cre/caMEK1 = 173 ± 15.20 SEM, 
control = 235.00 ± 14.69 SEM, n=5, p=0.019, Student’s t-test) (M). A significant 
reduction was also detected in the dorsal striatum of the RBP4Cre/caMEK1 (axonal 
labeling/transduced cell, RBP4Cre/caMEK1 = 90.00 ± 18.69 SEM, control = 190.00 ± 
20.67 SEM, n=5, p=0.007, Student’s t-test) (N). 
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ARC protein levels are selectively affected by MEK1 hyperactivation in layer V cortical 
glutamatergic neurons 
Having detected reduced levels of ARC in all glutamatergic neurons in the 
NexCre/caMek1 mice cortices, we wanted to see if the effects of hyperactivating 
MEK1 solely in layer V or if there is an effect on other layers also. 
 IHC analysis of basal state RBP4:Cre/caMEK1 mice revealed a localized down-
regulation of ARC protein detected in layer V when compared to control mice (Figure 
34A-F). These data show that hyperactivating MEK1 solely in layer V glutamatergic 
neurons has little to no effect on ARC detection in other layers. 
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Figure 34.  
 
  
 
 
ARC levels reduced specifically in layer V glutamatergic neurons in the 
RBP4Cre/caMEK1 mice. Immunostaining of adult cortex revealed a specific and 
marked reduction of ARC levels in layer V glutamatergic neurons in the 
RBP4Cre/caMEK1 mice (D-F) when compared to controls (A-C) (scale bars = 
200µm).  
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MEK1 hyperactivation in layer V cortical glutamatergic neurons is not sufficient to 
disrupt skilled motor learning 
 In the behavioral analysis of the NexCre/caMek1 mice, we found that 
hyperactivation of MEK1 in all glutamatergic neurons of the cortex led to disruption 
of motor skill learning and acquisition. Here we wished to determine if the 
RBP4:Cre/caMEK1 mice would exhibit the same deficits in motor learning acquisition 
as the NexCre/caMek1 mice did. 
Like the NexCre/caMek1 mice, the RBP4:Cre/caMEK1 mice also displayed no 
overt physical defects other than a smaller size than wild-type mice. However, since 
the RBP4 Cre recombinase is active in liver hepatocytes and adipose tissue 
(Thompson et al. 2017), the RBP4:Cre/caMEK1 mice were in some cases much more 
sensitive to the standard food restriction paradigm. In the case of the 
RBP4:Cre/caMEK1 and their control mice, food restriction was changed to allow free-
feeding for 6 hours per day approximately 3-4 hours after behavioral testing. This 
allowed the mice to maintain a healthy body weight and helped prevent any health 
issues arising. 
Open field testing of the RBP4:Cre/caMEK1 mice showed a significant 
decrease in overall distance traveled when compared to control mice (cm traveled, 
controls = 2818.77cm +/- 132.28 SEM, n=19, RBP4:Cre/caMEK1 = 2069.23cm +/- 
228.61 SEM, n=12, p=0.005, Student’s t-test) and a significant difference in percent 
center time (control = 26.46% ± 22.50% SEM, n=19, RBP4Cre/caMEK1 = 14.36% ± 
1.68% SEM, n=, p=0.001 Student’s t-test) (Figure 35G). In the accelerating rotarod 
test however, the RBP4:Cre/caMEK1 mice displayed no significant difference from 
the control mice in either overall performance or motor skill acquisition and learning 
in the five-day trial (genotype x latency to fall, [F(1,38)=0.237, p=0.629], repeated 
measures ANOVA) (Figure 35H). Over the course of the trial, both the 
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BP4Cre/caMek1 and control groups made significant improvements 
(RBP4Cre/caMek1 45.02secs ± 8.58 SEM to 75.80secs ± 8.29 SEM, 
[F(1,11)=12.501, p=0.005, n=12, controls = 40.85secs ± 6.51 SEM to 70.59secs ± 
6.73 SEM, [F(1,27)=19.943, p<0.005, n=18, repeated measures ANOVA) (Figure 
35H). 
In the skilled reaching and grasping task, the RBP4:Cre/caMEK1 mice also 
performed as well as the control mice as measured by the increase in successful 
attempts over the course of the trial (retrievals/overall attempts, RBP4Cre/caMek1 = 
17.44% ± 4.43 SEM to 35.94% ± 5.50 SEM, [F(1,11)=5.275, p=0.042], n=12, 
controls = 20.67% ± 3.69 SEM to 32.33% ± 5.51 SEM, [F(1,13)=8.641, p=0.011], 
n=14, ANOVA) (Figure 35I). In measurements of drop rate and miss rate however, 
only the RBP4Cre/caMek1 made a significant improvement in reducing the rate of 
dropped pellets (drop/overall attempts, RBP4Cre/caMek1 = 12.21% ± 3.79 SEM to 
3.13% ± 1.43 SEM, [F(1,11)=9.607, p=0.010], n=12, ANOVA) (Figure 35J). 
These results indicate that layer V specific hyperactivation of MEK1 in 
glutamatergic neurons is insufficient to disrupt motor skill learning and acquisition. 
However, open field testing alone indicates a deficit in voluntary locomotor activity 
and the possibility of an anxiety-like phenotype. 
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Figure 35.  
 
  
 
ARC levels reduced specifically in layer V glutamatergic neurons in the 
RBP4Cre/caMEK1 mice. Open field testing revealed a significant difference in total 
distance traveled between RBP4Cre/caMEK1 and control (controls = 2818.77cms ± 
132.28 SEM, n=19, RBP4Cre/caMek1 = 2069.23cm ± 228.61 SEM, n=12, p=0.005, 
Student’s t-test) and a significant difference in percent center time (control = 
26.46% ± 22.50% SEM, n=19, RBP4Cre/caMEK1 = 14.36% ± 1.68% SEM, n=, 
p=0.001 Student’s t-test) (G). Rotarod performance revealed no significant 
differences between the RBP4Cre/caMek1 and control groups (genotype x latency to 
fall, [F(1,38)=0.237, p=0.629], repeated measures ANOVA). Both the 
RBP4Cre/caMek1 and control groups made significant improvements over the course 
of the trial (latency to fall, RBP4Cre/caMek1 45.02secs ± 8.58 SEM to 75.80secs ± 
8.29 SEM, [F(1,11)=12.501, p=0.005, n=12, control = 40.85secs ± 6.51 SEM to 
70.59secs ± 6.73 SEM, [F(1,27)=19.943, p<0.005, n=18, ANOVA) (H). In the skilled 
reaching and grasping task, no significant differences were found between the 
RBP4Cre/caMek1 and control groups (genotype X success rate, [F(1,24)=0.050, 
p=0.825] ) (I). Both the RBP4Cre/caMek1 and control groups made significant 
improvements in their success rates over the course of the trial (success rate, 
RBP4Cre/caMek1 = 17.44% ± 4.43 SEM to 35.94% ± 5.50 SEM, [F(1,11)=5.275, 
p=0.042], n=12, controls = 20.67% ± 3.69 SEM to 32.33% ± 5.51 SEM, 
[F(1,13)=8.641, p=0.011], n=14, ANOVA) (I – J). In measurements of drop rate 
and miss rate, only the RBP4Cre/caMek1 made a significant improvement in reducing 
the rate of dropped pellets (RBP4Cre/caMek1 = 12.21% ± 3.79 SEM to 3.13% ± 
1.43 SEM, [F(1,11)=9.607, p=0.010], n=12, ANOVA) (J). 
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Discussion 
The ERK/MAPK signaling pathway is perhaps the most studied cellular 
signaling pathway to date. The majority of this research however has been 
performed in the context of cancers and specific cell types in culture. In the field of 
neurodevelopment and neurodevelopmental syndromes however, there is a lack of 
knowledge regarding the effects of aberrant ERK/MAPK signaling. This absence is 
particularly noticeable concerning the formation and maintenance of cell-type specific 
connectivity under normal and syndromic conditions. In this study, we have 
identified the effects of hyperactivating MEK1 in the ERK/MAPK signaling pathway on 
the development of cortical glutamatergic axonal outgrowth and plasticity associated 
genes and its effect on motor learning. Furthermore, we have also identified a 
cortical layer autonomous effect on cortical axonal projections and innervation 
patterns, ARC expression, and motor learning acquisition. Interestingly, when MEK1 
is hyperactivated in glutamatergic neurons across all layers of the cortex, we detect 
similar deficits with corticocortical, corticostriatal, and corticospinal axonal 
projections and innervation as when MEK1 hyperactivation is restricted to only layer 
V cortical glutamatergic neurons. In contrast to these projection deficits, we find a 
deficit in motor learning acquisition with cortex wide MEK1 glutamatergic 
hyperactivation whereas no motor learning deficit was detected in layer V specific 
MEK1 hyperactivation.   
 
Key synaptic plasticity and immediate early gene ARC is downregulated 
Interestingly, when MEK1 was hyperactivated in layer V glutamatergic 
neurons in the RBP4:CRE/caMEK1 mice, the reduction of ARC expression was 
isolated to only those glutamatergic neurons located in cortical layer V. This cell and 
layer autonomous effect shows that the reduction of ARC levels is a direct 
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consequence of the reduction of P-ERK1/2 levels and the RBP4:CRE/caMEK1 cell 
specific mutation.  
 
Long range axonal connectivity is disrupted 
We previously found deficits in axonal elongation of the cortico-spinal tract 
and arborization in the gray matter of the spinal cord and the hindbrain in the 
Nex:CRE/caMEK1 mice (Xing et al. 2016). Additionally, we found significant deficits 
with corticocortical and corticostriatal innervation, deficits in motor learning 
acquisition, and a cell-autonomous effect in the down-regulation of ARC. Due to this 
cell-autonomous effect, we began address a layer specific hyperactivating mutation 
on axonal projections of cortical layer 5 glutamatergic neurons independent of any 
other cortical layers excitatory or inhibitory effects. The RBP4:CRE/caMEK1 mice 
were subjected to the same AAV injection scheme and analysis controls as the 
Nex:CRE/caMEK1 with the CRE-dependent tdTomato expressing AAV injected at P1 
in one hemisphere of the primary motor cortex and analysis performed at P30. 
Analysis of CST extension and innervation of the cervical spinal cord showed a very 
similar and significant deficit in axonal elongation coupled with an increased amount 
of innervation in the spinal cord gray matter. Interestingly, a mouse model of NF1 
also expressed a significant deficit in CST axonal extension as measured in the 
lumbar spinal cord. As NF1 is an activating mutation resulting in an overall increase 
in GTP bound RAS (Katherine A. Rauen 2013), this finding served to reinforce the 
results of both the Nex:CRE/caMEK1 and RBP4:CRE/caMEK1 mouse models.  
We next investigated the contralateral axonal innervation of the contralateral 
cortex and dorsal striatum and the gray matter axonal innervation in the hind brain 
of the RBP4:CRE/caMEK1 mice. Unlike the Nex:CRE/caMEK1, the RBP4:CRE/caMEK1 
mice displayed no changes in either cortico-bulbar tract extension or axonal gray 
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matter innervation when compared to control mice as had been previously found. 
Axonal innervation of the contralateral cortex though revealed a significant reduction 
of axonal innervation and branching as did the dorsal striatum. These results again 
showed that the caMEK1 mutation expressed in a single layer, layer 5 in this 
instance, acts in an autonomous fashion in regard to axonal extension, innervation, 
and branching. Nevertheless, in order to determine a probable cause of the hind 
brain innervation differences between the Nex:CRE/caMEK1 and the 
RBP4:CRE/caMEK1 mice, more work will be necessary. 
 
Motor learning acquisition is disrupted 
Unlike the Nex:CRE/caMEK1 mice, the RBP4:CRE/caMEK1 showed a 
significant deficit in voluntary movement over the course of the test as measured by 
total distance traveled. While the Nex:CRE/caMEK1 appeared unhindered in 
locomotor function, the RBP4:CRE/caMEK1 appeared to lack either motivation or 
perhaps had an unknown impairment. However, much unlike the Nex:CRE/caMEK1 
mice, the RBP4:CRE/caMEK1 revealed no differences from control mice over the 
course of the accelerating rotarod test. This indicated that the performance of the 
RBP4:CRE/caMEK1 mice in the open field test was not due to a motor or physical 
impairment.  Both groups, the RBP4:CRE/caMEK1 and control mice, also showed a 
significant level of improvement over the course of the test indicating the ability to 
acquire the motor skills needed to perform this task.  
In the skilled reaching and grasping task, the RBP4:CRE/caMEK1 mice again 
revealed no differences from control mice. The RBP4:CRE/caMEK1 and control mice 
both showed significant increases in their success rates and the RBP4:CRE/caMEK1 
mice also significantly decreased their drop rate. These results indicated that a layer 
5 specific MEK1 hyperactivation had no effect on motor learning acquisition.  
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The combined results from the Nex:CRE/caMEK1 and the RBP4:CRE/caMEK1 
shows that RAS/MAPK signaling plays an important bi-directional and cortical 
projection neuron autonomous role in axonal outgrowth and motor learning in vivo. 
Furthermore, cortical layer 5 specific RAS/MAPK mutants exhibit no change in motor 
learning, indicating behavioral plasticity depends upon RAS/MAPK expression in 
cortical projection neurons other than layer 5. Overall, our research suggests that 
the pathogenesis of cognitive deficits in RASopathies involves changes in the 
development of neuronal connectivity and the expression of plasticity associated 
genes at an early stage of cortical formation and subsequent developmental stages.  
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CHAPTER 5 
CONCLUSION 
 
Recent findings of diffusion tensor imaging (DTI) of major white matter (WM) 
tracts as well as functional magnetic resonance imaging (fMRI) in neurofibromatosis 
(NF-1) patients has highlighted connectivity issues within the RASopathies. These 
studies have allowed a non-invasive look into the composition, construction, and 
integrity of connectivity in normal and diseased brains. While these studies have 
shown major areas of connectivity disorganization in the brains of NF1 patients, they 
have not addressed the molecular causes at the root of these problems. Birchmeier 
and colleagues studied the effects of a constitutively active form of MEK1 in the 
myelinating cells of the peripheral nervous system, Schwann cells. They found that 
continuous MEK1 signaling was able to overcome the termination of myelin growth 
during development by protein synthesis stimulation (Sheean et al. 2014). The 
failure to terminate myelin growth in turn created a significantly increased amount of 
WM. Bansal and colleagues found similar results in the oligodendrocytes of the 
central nervous system by hyperactivation of MEK1 (Ishii et al. 2016). While this 
may explain the WM aberrations in DTI studies of NF-1 patients, either in part or in 
whole, it does not address connectivity issues or pathologies associated with the 
underlying axons themselves. In our studies, we have sought to address the cell-
type specific contributions to the reported connectivity issues as well as the 
pathophysiology of the axons themselves within the WM tracts.  
The RASopathies contain both loss- and gain-of function (LoF and GoF) 
mutations within the Ras/MAPK intracellular signaling pathway. In these in vivo 
mouse studies, we used both a MEK1/2 conditional knockout or a constitutively 
active MEK1 (caMEK1) construct activated in cortical glutamatergic neurons. As these 
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neurons provide long-range connectivity both within the cortex and sub-cortically, 
we were able to determine the effects of both LoF and GoF RAS/MAPK signaling in a 
cell-autonomous manner. In addition to cell-autonomous effects, we also analyzed 
cortical layer autonomous effects by inducing the GoF caMEK1 mutation solely in 
layer 5 glutamatergic neurons. We further moved to address behavioral and 
cognitive issues, particularly motor learning acquisition, as reported within the 
RASopathies with these mouse models.  
Much like the referenced DTI and fMRI studies in NF1 patients, we found 
widespread aberrations in cortical and subcortical connectivity in addition to cell 
survival and behavioral deficits. In the LoF model, we found a significant cell-death 
phenotype most notably in cortical layer 5 CTIP2+ neurons as well as significant 
deficits in corticospinal tract (CST) elongation. In the cortex wide GoF in cortical 
glutamatergic neurons model, we found a surprising down-regulation of 
phosphorylated ERK1/2 (P-ERK1/2) in the soma and a high amount of P-ERK1/2 in 
the axons compared to controls. We additionally found significant deficits in 
corticocortical and corticostriatal axonal innervation, a significant deficit in CST 
elongation with hyperactivated innervation in spinal cord and hind brain gray matter, 
a reduction in the expression of immediate early gene (IEG) ARC, and a deficit in 
motor learning acquisition. When the GoF mutation was restricted to layer 5 
glutamatergic neurons we also found significant deficits in corticocortical and 
corticostriatal axonal innervation, and a significant deficit in CST elongation with 
hyperactivated innervation in the spinal cord, However, we did not detect any 
changes in hind brain gray matter and the reduction in the expression of immediate 
early gene (IEG) ARC was restricted to layer 5 glutamatergic neurons. Furthermore, 
we detected no deficits in motor learning acquisition of the layer 5 specific GoF 
mutation mice. 
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Overall, this research shows that RAS/MAPK signaling plays an important bi-
directional and cortical projection neuron autonomous role in axonal outgrowth and 
motor learning in vivo. These data suggest that the pathogenesis of cognitive deficits 
in RASopathies involves changes in the development of neuronal connectivity, but 
not neuronal number, at an early stage of cortical formation and the expression of 
plasticity associated genes during subsequent developmental stages.  
 Our LoF model used a CRE activated conditional knockout of MEK1/2 that was 
activated in post-mitotic neurons at approximately E11.5 due to embryonic lethality 
of germline mutations. In our study, we found that the initial complement of cortical 
glutamatergic neurons was fully intact at P1. At P3 we found a significant deficit in 
CST elongation. By P14 we found a significant amount of cell death most notably in 
layer 5 glutamatergic neurons. Analyzing the cell death at earlier time points we 
found a peak at approximately P5. This mutation however was lethal at about P21 so 
we were unable to further investigate connectivity, behavioral, or the cell death 
phenotypes in this model.  
 Our early discovery concerning deficits in CST elongation addressed partially 
the involvement of RAS/MAPK in axonal extension during this early developmental 
period. However, we were unable to observe RAS/MAPK signaling requirements or 
consequences in the period after development. To address this issue, we have 
designed experiments that creates a MEK1/2 LoF mutation in the primary motor 
cortex (M1) of one cortical hemisphere. With this model, we will be able to analyze 
axonal elongation of the CST as well as corticocortical and corticostriatal axonal 
projections and innervation. IEG expression will also be analyzed in dual expression 
labeling experiments of the affected neurons. Motor learning acquisition may not be 
able to be addressed due to the mono-hemisphere and single structure mutation, 
however, motor function will be assessed by analyzing the lateralization of motor 
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skills. Insights gained form these experiments will further add to our knowledge of 
RAS/MAPK LoF beyond early development.  
Our GoF mouse model relied on the same post-mitotic activation of CRE to 
transcribe the caMEK1 construct. Unlike the LoF mice however, the GoF mice were 
viable and vital with the exception of a smaller size. This model allowed not only the 
identification of CST elongation deficits early in development but also the post-
developmental P-ERK1/2 localization/expression phenotype, corticocortical and 
corticostriatal innervation deficits, and motor learning deficits.  
One of the most surprising findings of the GoF analysis proved to be the 
apparent down-regulation of P-ERK1/2 in the bodies of the caMEK1 mutated neurons 
accompanied by an accumulation in the axons. This phenotype has not appeared in 
the known literature and the cause of it is a very interesting area for further research 
and possible therapeutic targets in the RASopathies. Two areas that would be of 
immediate promise to focus on for this phenotype would be axonal transportation 
mechanisms and P-ERK1/2 regulation. Retrograde transport of P-ERK1/2 from the 
distal axon to the nucleus is critical to evoke transcriptional programs and changes in 
development. Several phosphatases have been identified to deactivate P-ERK1/2 and 
their activities are thought to be compartment specific. We tested for one of the 
most commonly reported neuronal phosphatases but found no evidence of changes. 
This leaves the question of additional phosphatases that may be active and their 
compartmental specificity as well as transcriptional programs that control their 
expression. 
Our in vivo connectivity analysis also confirmed the widespread WM 
aberrations and functional disorganization detected in DTI and fMRI studies in NF1 
patients. Furthermore, these deficits were detected in a cell-autonomous manner 
within a biological system and may solely be a function of axonal dynamics. Much 
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further analysis however is needed to pinpoint the cause or causes of these 
connectivity issues. Due the many functions and cross-talk characteristics of the 
RAS/MAPK signaling pathway, there are many areas to be analyzed. A major area to 
address would be transcription programs affected by the apparent loss of somal P-
ERK1/2. It is thought that the disorganization seen in the DTI studies may be a 
function of loosely packed or non-fasciculated axons. This may indicate the loss of 
cellular adhesion and-or pathfinding molecules needed by the axons during 
elongation and growth. Additionally, the build-up of P-ERK1/2 in the axonal 
compartment is also a major consideration in axonal elongation and innervation 
during development. P-ERK1/2 interactions with MAP1B and TAU serve to stabilize 
microtubules and neurofilaments. However, axonal elongation and branching rely on 
the dynamic actions of de-stabilization and stabilization. Therefore, the accumulation 
of P-ERK1/2 in the axons may in fact be causing a scenario of over stabilization 
interfering with growth cone and axonal branching dynamics. There are several 
different aspects within these identified phenotypes that need further investigation to 
identify. 
The cortex-wide expression of the caMEK1 mutation in glutamatergic neurons 
also affected motor learning acquisition. We also detected a significant down-
regulation of ARC which is known to play an important role in synaptic plasticity. 
Whether the deficits in motor learning are a consequence of ARC down-regulation or 
due to a loss in axonal innervation is unknown at this point. Western Blot results of 
whole cortical lysates show a significant reduction of ARC in the Nex:Cre/caMEK1. 
Immunostaining for ARC confirms this reduction and it appears that the majority of 
ARC loss is in the neuronal bodies of glutamatergic neurons. Additionally, while ARC 
expression is still detected in the dendritic compartments, it is unclear at this point if 
those are the dendrites of the mutated glutamatergic neurons. Glutamate activation 
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of NMDA and AMPA receptors in the post-synaptic density are required for Arc 
induction and Arc regulation respectively. NMDAR activation leads to Arc 
transcription through several signaling pathways including the RAS/MAPK pathway. 
Arc transcription can be further accelerated through BDNF/TRKB activation. Nuclear 
transportation of ERK-phosphorylated ARC however acts in the down-regulation of 
Arc transcription by inhibiting GluA1 transcription and in turn AMPAR activation. This 
NMDAR activating and AMPAR inhibition is required to mediate changes in synaptic 
competence and regulate homeostatic scaling required for learning and memory 
(Epstein and Finkbeiner 2018). Here we have detected a decreased level of both P-
ERK1/2 and the IEG ARC in the soma and nuclear spaces. The lack of both these of 
these proteins could lead to a drastic down-regulation not only of Arc induction, but 
all other immediate early genes that rely on the same transcriptional program. Our 
previous study analyzed differential gene expression of the Nex:Cre/caMEK1 and 
control mice (Xing et al. 2016). In that study, we found no evidence of differential 
RNA expression (greater than +/-1.5 fold change in mutants vs controls) in 
neurotrophins or their receptors (Appendix D, Table 2) (Xing et al. 2016). This 
however does account for post-translation modifications or actual protein levels for 
each transcript. Further work is necessary to determine the cellular mechanisms 
responsible for the lack of nuclear and cytosolic ARC as well as neurotrophins and 
their receptors. 
In addition to the cell-autonomous deficits that we identified in the GoF 
model, we also identified a cortical layer autonomous effect. When the caMEK1 
mutation was applied solely to layer 5 glutamatergic neurons we found similar 
deficits in long-range connectivity. Significant deficits were identified in 
corticocortical and corticostriatal axonal innervation, CST elongation deficits, and 
hyperinnervation of the spinal cord gray matter but no changes of axonal innervation 
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in the hind brain. ARC expression levels were also reduced but the reduction was 
isolated to solely glutamatergic neurons in cortical layer 5. No deficits in motor 
learning acquisition in the layer 5 GoF mice were detected indicating behavioral 
plasticity depends upon RAS/MAPK signaling in cortical projection neurons other than 
layer 5.  
These combined data show the cell-type specific and layer specific phenotypes 
associated with the RASopathies. Future studies to analyze cell-cell interactions 
would also help to identify the effects of RAS/MAPK signaling in connectivity and 
system communications. This would entail adding the GoF MEK1 mutation to 
additional cell types. For example, introducing the hyperactivating MEK1 mutation in 
inhibitory neurons would affect the excitatory-inhibitory balance of the cortex. 
However, how this would affect connectivity or plasticity is unknown. The same could 
be said of oligodendrocytes. Would the hyperactivating mutation in glutamatergic 
cells and oligodendrocytes change the conclusions of these current studies? Would 
these interactions afford the opportunity for RASopathy targeted interventions? 
A major question that arises in the RASopathies is: What are the differences 
in RAS/MAPK signaling requirements in and after development? To take that even 
further: What points in development are more or are less dependent on RAS/MAPK 
signaling functions? Currently the spatial and temporal dynamics of the 
consequences of RAS/MAPK signaling are not fully understood in the development of 
a biological system. Another very important question for the RASopathies is not only 
at what point in development should we intervene, but at what point can we 
intervene? The developmental trajectory of the mouse models we use and that of a 
human are very different. These problems that we have identified in post-natal 
mouse development are mostly completed in human development during the second 
trimester of pregnancy. This leads to a very important question of how to treat the 
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disease after development. As we have identified an apparent down-regulation effect 
of P-ERK1/2 in neuronal cell bodies, is it still wise to treat a heart condition with MEK 
inhibitors in a RASopathy patient? While there is much further work to do to pinpoint 
causes of the molecular phenotypes we have shown here, there is also that many 
more areas of intervention to explore. For example, instead of a MEK1 inhibitor for a 
GoF mutation, is there a target that can be manipulated to fix axonal transport to 
release P-ERK1/2 to the soma? Or can MAP1B and TAU be intermittently de-
stabilized to promote axonal branching or improve synaptic plasticity? Currently, 
management of the RASopathy diseases are to treat their manifestations. These 
studies have presented on the cellular level several possible manifestations to treat.  
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• Taught basic laboratory techniques and applications used in molecular biology 
labs 
• Aided and assessed students in scientific report writing. 
• Administered and graded weekly quizzes. 
 
 
General Manager/Owner  
 
AZ-Tech Manufacturing Inc., Phoenix AZ                                 Mar 1993 - Mar 2005 
                
• Started and incorporated an aerospace manufacturing facility in March of 
1993. Operated until sale in March of 2005. 
• Initiated and ran all aspects of the business including manufacturing 
engineering, quality control to ISO, AS, and customer specific specifications. 
• Grew business from the ground-up to a multi-million-dollar entity employing 
up to 43 people running three shifts to service customers. 
• Specialized in manufacturing complex aerospace hardware for OEMs such as 
Honeywell Aerospace, Allied Signal Aerospace, and TRW aerospace. 
• Specialized in the manufacture of a variety of aerospace components used in 
aircraft, satellites, rockets, Space Shuttles, defense systems, and the 
International Space Station. 
 
Previous work history can be provided upon request 
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Publications 
 
Journal Articles: 
 
Holter M*, Bjorklund GR*, Nishimura K, Hewitt L, Nichols J, Shah S, Martinez J, 
Marsh S, Treiman D, Snider WD, Anderson T, Newbern JM. (2018) ERK/MAPK 
hyperactivation in embryonic GABAergic neurons reduces cortical Parvalbumin 
neuron number and increases cortical excitability. In Preparation 
 
Bjorklund GR, Hewitt L, Moy S, Nikolova V, Nishimura K, Smith C, Xing L, Snider WD, 
Newbern JM. (2018) Hyperactivation of ERK/MAPK in cortical glutamatergic neurons 
results in projection axon deficits and aberrant motor learning in a layer autonomous 
manner In Preparation 
 
Nichols J, Bjorklund GR, Newbern JM, Anderson T. “Parvalbumin Fast-Spiking 
Interneurons are Selectively Altered by Pediatric Traumatic Brain Injury”. The Journal 
of Physiology. PMID:29333742 (2018). 
 
Sinakevitch IT, Bjorklund GR, Newbern JM, Gerkin RC, and Smith BH. Comparative 
study of chemical neuroanatomy of the olfactory neuropil in mouse, honey bee and 
human. Biological Cybernetics. PMID:28852854 (2017). 
 
Xing Lei, Rylan S. Larsen, George Reed Bjorklund, Xiaoyan Li, Yaohong Wu, 
Benjamin D. Philpot, William D. Snider, and Jason M. Newbern. "Layer Specific and 
General Requirements for ERK/MAPK Signaling in the Developing Neocortex." ELife. 
PMID:26848828 (2016). 
 
 
Conference Abstracts and Poster Sessions: 
 
Holter, M., Bjorklund, G., Shah, S., Nishimura, K., Newbern, J. Constitutively active 
MEK1 signaling drives selective death of cortical parvalbumin-expressing GABAergic 
interneurons in mouse embryonic brain development. Abstract and poster session 
presented at: Neuroscience 2018. 48th annual conference of the Society for 
Neuroscience; 2018 Nov 3-7; San Diego, CA. 
 
Bjorklund GR, Hewitt LT, Nishimura K, Newbern JM. Hyperactivation of ERK/MAPK 
leads to altered cortical projection neuron outgrowth, reduced activity dependent gene 
expression, and motor learning deficits. Abstract and poster session presented at: 
Neuroscience 2017. 47th annual conference of the Society for Neuroscience; 2017 Nov 
11-15; Washington, D.C. 
 
Holter M, Bjorklund GR, Shah SA, Nichols JD, Martinez JS, Anderson TR, Newbern 
JM.  Functions of ERK/MAPK signaling in GABAergic neuron development and identity. 
Abstract and poster session presented at: Neuroscience 2017. 47th annual conference 
of the Society for Neuroscience; 2017 Nov 11-15; Washington, D.C. 
 
Bjorklund GR, Hewitt LT, Xing L, Nikolova V, Moy SS, Snider WD, Newbern JM. 
ERK/MAPK hyperactivation leads to altered corticospinal neuron connectivity and 
motor learning deficits. Abstract and poster session presented at: Neuroscience 2016. 
46th annual conference of the Society for Neuroscience; 2016 Nov 12-16; San Diego, 
CA. 
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Irina S, Bjorklund GR, Newbern JM, Smith BH. Comparative study of chemical 
neuroanatomy of the olfactory neuropil in mouse, honey bee and human. Paper and 
poster session presented at: Neural Coding 2016: 12th International Workshop, 
University of Cologne; 2016 Aug 29 – Sep 2; Cologne, Germany. 
 
Bjorklund GR, Newbern JM. ERK/MAPK signaling is critical for corticospinal axon 
morphology. Poster session presented at: Barrow Neurological Institute 2016 
Neuroscience Symposium; 7 Jan 2016; Phoenix, AZ. 
 
Xing L, Larsen RS, Bjorklund GR, Li X, Wu Y, Philpot BD, Snider WD, Newbern JM. A 
bidirectional threshold of ERK/MAPK signaling regulates axonal outgrowth in 
developing corticospinal neurons. Abstract and poster session presented at: 
Neuroscience 2015. 45th annual conference of the Society for Neuroscience; 2015 
Oct 17-21; Chicago, Il. 
 
Moreno MA, Hewitt LT, Bjorklund GR, Daniels CW, Olive MF, Sanabria F, Marsh S, 
Treiman DM, Snider WD, Newbern JM. Hyperactivation of ERK1/2 signaling in 
developing GABAergic circuits reduces parvalbumin interneuron number and 
increases cortical excitability. Abstract and poster session presented at: 
Neuroscience 2015. 45th annual conference of the Society for Neuroscience; 2015 
Oct 17-21; Chicago, Il. 
 
Irina S, Bjorklund GR, Baluch DP, Newbern JM, Smith BH. Comparative study of 
chemical neuroanatomy of the olfactory neuropil in mouse, honey bee and human. 
Paper and poster session presented at: Olfaction 2015. Kavli Institute for Theoretical 
Physics Conference: Olfaction; 2015 Jul 7-10; Santa Barbara, CA. 
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Service: 
 
• School of Life Sciences New Grad Mentor - Assisted new students in getting 
their bearings in SoLS. 2017-2018 
 
• Ask a Biologist – Community outreach answering biological questions posed 
by pre-K-12 students and teachers. 2011 – 2018 
 
• Invited speaker for the Molecular and Cellular Biology and Microbiology annual 
graduate student retreat. Oct. 2017 
 
• Neuroscience and Molecular and Cellular Biology Program Representative for 
SoLS Septennial Review. Apr. 2017 
 
• ASU Graduate and Professional Student Association - Volunteer for grant 
reviews and teacher awards reviews. Sept. 2015 - 2017  
 
• Graduate Association of Interdisciplinary Neuroscience Students (GAINS) 
Community outreach volunteer. 2017 
 
• Night of the Open Door – Volunteered, set-up, ran displays for the annual 
ASU open house. 2013, 2014, 2015 
 
• Annual MCC Biotechnology Symposium – Panelist for College to University 
transfer forum. 2010, 2011, 2012, 2013 
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APPENDIX C 
Animal Subjects 
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 Research involving the use of animals conducted under the auspices of Arizona State 
University is reviewed by the University Institutional Animal Care & Use Committee 
(IACUC, approval #17-1521R), Institutional Biosafety Committee (IBC, approval 
#16-696), and in compliance with federal regulations. Documents containing any 
data collection from animal research require that applications be submitted to the 
University Animal Care& Use Committee for approval. For further information, 
contact the IACUC secretary in the IACUC Office at 480-965-4387 or visit 
https://www.researchintegrity.asu.edu/animals. 
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Appendix D 
Table 2 
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Table 2 
Gene 
Symbol 
Fold-
Change 
(Mut vs. Ctl) 
p-value  
(Mut vs. 
Ctl) 
Fold-Change  
(Mut vs. Ctl) 
(Description) 
Gene Name 
Neurotrophins and growth factors 
Ntf3 -1.0051 0.9550 Mut down vs Ctl neurotrophin 3  
Ntf5 1.0771 0.4970 Mut up vs Ctl neurotrophin 5 
Bdnf 1.0773 0.3826 Mut up vs Ctl brain derived neurotrophic factor 
Ngf 1.3762 0.0202 Mut up vs Ctl nerve growth factor 
Egf 1.0485 0.2787 Mut up vs Ctl epidermal growth factor 
Fgf1 -1.0805 0.1479 Mut down vs Ctl fibroblast growth factor 1  
Fgf8 1.0268 0.2164 Mut up vs Ctl fibroblast growth factor 8 
Neurotrophin receptors  
Ngfr 1.0629 0.3378 Mut up vs Ctl nerve growth factor receptor (TNFR superfamily, member 16) 
Ntrk1 1.0872 0.4857 Mut up vs Ctl neurotrophic tyrosine kinase, receptor, type 1 
Ntrk2 1.0020 0.9480 Mut up vs Ctl neurotrophic tyrosine kinase, receptor, type 2 
Ntrk3 -1.0812 0.0777 Mut down vs Ctl neurotrophic tyrosine kinase, receptor, type 3 
Egfr -1.0495 0.4289 Mut down vs Ctl epidermal growth factor receptor 
Fgfr1 1.0260 0.3259 Mut up vs Ctl fibroblast growth factor receptor 1 
Fgfr2 -1.0840 0.1611 Mut down vs Ctl fibroblast growth factor receptor  
Ionotropic glutamate receptor subunits (AMPARs, NMDARs, KainateRs) 
Gria1 1.0266 0.5541 Mut up vs Ctl glutamate receptor, ionotropic, AMPA1 
Gria2 -1.0454 0.0961 Mut down vs Ctl glutamate receptor, ionotropic, AMPA2  
Gria3 -1.0276 0.2202 Mut down vs Ctl glutamate receptor, ionotropic, AMPA3  
Gria4 -1.1496 0.0015 Mut down vs Ctl glutamate receptor, ionotropic, AMPA4  
Grid1 1.0426 0.4885 Mut up vs Ctl glutamate receptor, ionotropic, delta 1  
Grid2 1.0586 0.4474 Mut up vs Ctl glutamate receptor, ionotropic, delta 2 
Grik1 1.0099 0.8779 Mut up vs Ctl glutamate receptor, ionotropic, kainate 1  
Grik2 1.0444 0.4132 Mut up vs Ctl glutamate receptor, ionotropic, kainate 2 (beta 2)  
Grik3 -1.0411 0.7017 Mut down vs Ctl glutamate receptor, ionotropic, kainate 3  
Grik4 -1.2210 0.0318 Mut down vs Ctl glutamate receptor, ionotropic, kainate 4  
Grik5 -1.0454 0.4093 Mut down vs Ctl glutamate receptor, ionotropic, kainate 5 (gamma 2) 
Grin1 1.0051 0.9682 Mut up vs Ctl glutamate receptor, ionotropic, NMDA1 (zeta 1) 
Grin1 -1.0321 0.4421 Mut down vs Ctl glutamate receptor, ionotropic, NMDA1 (zeta 1)  
Grin2a -1.1401 0.0948 Mut down vs Ctl glutamate receptor, ionotropic, NMDA2A (epsilon 1) 
Grin2b -1.0189 0.5716 Mut down vs Ctl glutamate receptor, ionotropic, NMDA2B (epsilon 2)  
Grin2b -1.0806 0.6816 Mut down vs Ctl glutamate receptor, ionotropic, NMDA2B (epsilon 2) 
Grin2c 1.1999 0.1812 Mut up vs Ctl glutamate receptor, ionotropic, NMDA2C (epsilon 3) 
Grin2c 1.0105 0.8669 Mut up vs Ctl glutamate receptor, ionotropic, NMDA2C (epsilon 3)  
Grin2d 1.0443 0.1135 Mut up vs Ctl glutamate receptor, ionotropic, NMDA2D (epsilon 4)  
Grin2d 1.0393 0.6052 Mut up vs Ctl glutamate receptor, ionotropic, NMDA2D (epsilon 4) 
Grin3a 1.1201 0.1397 Mut up vs Ctl glutamate receptor ionotropic, NMDA3A  
Grin3b 1.1243 0.0786 Mut up vs Ctl glutamate receptor, ionotropic, NMDA3B  
Metabatropic glutamate receptors (MGLURs) 
Grm1 1.1858 0.0822 Mut up vs Ctl glutamate receptor, metabotropic 1  
Grm2 -1.0565 0.5959 Mut down vs Ctl glutamate receptor, metabotropic 2  
Grm3 -1.1767 0.0287 Mut down vs Ctl glutamate receptor, metabotropic 3  
Grm4 -1.1794 0.0469 Mut down vs Ctl glutamate receptor, metabotropic 4  
Grm5 1.0417 0.0875 Mut up vs Ctl glutamate receptor, metabotropic 5  
Grm6 1.0437 0.3602 Mut up vs Ctl glutamate receptor, metabotropic 6  
Grm7 1.0819 0.0353 Mut up vs Ctl glutamate receptor, metabotropic 7  
Grm8 1.2054 0.0925 Mut up vs Ctl glutamate receptor, metabotropic 8  
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